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ABSTRACT
Adult adipose derived mesenchymal stromal cells (ASCs) have been characterized in various
species. Many factors may affect ASC fate and ASCs from different species may have different
response to these factors. The first study was to identify the differences of the canine ASCs
isolated from subcutaneous and infrapatellar adipose tissues, and evaluate the impact of
cryopreservation on the cells. Based on paired comparisons of fresh and cryopreserved ASCs,
cryopreserved ASCs had lower CD29 and CD44 protein expression and lower proliferation rates.
The cryopreserved ASCs had relative lower mitochondria in the cytoplasm compared to the fresh
ASCs regardless of tissue sources. The second study was to apply human ASCs for bone
regeneration. The spinner flask bioreactor system was employed to load human ASCs onto three
commercial scaffolds and the cell-scaffold constructs were cultured in stromal, osteogenic, or
osteogenic for 48 hours followed by stromal medium for up to 28 days. The distinct scaffold upregulated different osteogenic signaling pathways, suggesting distinct osteogenic cell signaling
pathways were selectively upregulated by scaffold composition. The third study was designed to
quantify in vivo equine multipotent stromal cell (MSC) osteogenesis on synthetic polymer
scaffolds with distinct mineral combinations 9 weeks after implantation in a murine model.
Addition of mineral to polymer scaffolds enhanced equine MSC osteogenesis over polymer alone,
and contributions by both exo- and endogenous MSCs were confirmed. The fourth study was
designed to evaluate the effects of collagenase digestion and cryopreservation on equine ASCs.
Higher collagenase concentration yielded more nucleated cells, and the percentages of MHCII-,
CD44+, CD105+ cells in freshly isolated and cryopreserved cells were similar. The embryonic
gene expression was enhanced and the essential gene expression decreased after cryopreservation.
The fifth study was to demonstrate the endodermal transdifferentiation capability in feline ASCs.

xii

Feline-specific pancreatic β cell induction medium was developed in the study, and islet-like cell
clusters that secrete insulin in response to glucose stimulation were created.

Overall, the

investigations in this dissertation provide critical information for canine, feline, equine and human
MSC based tissue engineering therapies and may contribute to better efficiency and efficacy of
cell preservation techniques.

xiii

CHAPTER 1. THE EFFECTS OF CRYOPRESERVATION, CHEMICAL REAGENTS,
AND PHYSICAL ENVIRONMENT ON ADULT MULTIPOTENT STROMAL CELLS
1.1. Adult Multipotent Stromal Cell Cryopreservation: Pluses and Pitfalls
1.1.1. Introduction
Adult multipotent stromal cells (MSCs) are increasing as standard therapy for a multitude of
pathologic conditions as diverse as cancer, renal disease and musculoskeletal and cardiac tissue
injury [1-5]. Isolation of adequate cell numbers for several therapeutic doses with minimally
invasive tissue harvest is a perpetual struggle [6]. Based on current knowledge, distinct MSC
immunophenotype subpopulations are most effective for specific clinical applications [7].
Extensive in vitro culture expansion of low frequency MSC immunophenotypes is necessary to
achieve sufficient cell numbers, and potential for genetic alterations and contamination increases
with culture time [8-11]. In addition to immunogenicity concerns of allogeneic donors,[12] MSC
quality varies with age and health status [13]. Thermally dependent metabolic processes do not
occur below -120oC, so MSCs are in metabolic stasis at liquid nitrogen temperature, around -196oC
[14]. Multiple cell aliquots collected over time from an individual or set of donors can be
maintained for later administration immediately upon revitalization or after short-term expansion
of pooled or individual isolates [15, 16]. Cryopreservation also increases MSC availability since
frozen cells can be delivered to patients over long distances using standard transportation [17].
Despite prevalent MSC cryopreservation, relatively little focus has been directed toward the effects
cryopreservation on cell morphology and behavior.
There is a growing awareness of differences between fresh and cryopreserved MSCs [6,
18-22], though cryopreservation effects on retention of MSC characteristics vary widely [18-21,
23, 24]. Most veterinary MSC cryopreservation techniques are derived from human and murine
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protocols[18, 25] for cell aliquots of 1-4 × 106 cells in cryopreservation medium that contains
cryoprotectants (CP) and exogenous serum (Fig. 1) [26]. A cooling process is used to reduce the
temperature to about -80oC prior to transfer to liquid nitrogen [25-27]. For revitalization, cells are
thawed and then washed with buffer or medium to remove cryopreservation medium ingredients
[14]. Each step, as well as cryopreservation duration can impact MSC survival and attributes [14].

Figure 1. Schematic of domestic animals (cat, dog and horse) adult multipotent stromal cell (MSC)
cryopreservation process
1.1.2. Cooling Process
Cryopreservation maintains unfrozen cells at a supercool temperature within frozen
medium [28]. The freezing point of the medium surrounding the cells is reduced by CPs to around
-5 to -15oC. During the cooling process, fluid moves from the lower solute concentrations in the
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unfrozen cells into partially frozen medium while the plasma membrane prevents extracellular ice
crystals from entering them. Slow cooling permits fluid loss from the cells at a rate that results in
a balanced osmotic pressure between cells and medium by the time the medium freezes. If the
cooling rate is too slow, cells are fatally dehydrated or the plasma membranes irreversibly damaged
before solutes crystallize at the eutectic temperature [14]. Excessively rapid cooling results in
insufficient extracellular fluid migration to maintain the high solute concentration to prevent fatal
cell freezing [29].
As described above, cell cooling rate is a delicate balance of fast enough to avoid solute
and electrolyte imbalances that result in cell dehydration and uneven sample freezing and slow
enough to prevent lethal extra- and intracellular ice crystal formation [14]. Unique membrane
permeability among cell types influences fluid movement rate as well [14]. Conventional slow
freezing at a rate of -1oC/min [30] with microprocessor-controlled freezers or freezing containers
with a heat transfer interface (isopropyl alcohol or insulation) between the samples and an ultralow temperature environment [31, 32] reportedly has minimal effect on MSC immunophenotype,
proliferation or lineage differentiation [31, 32]. Slow freezing of sterile specimens within sealed
vials also minimizes contamination risk [33]. Limitations of this cooling mechanism include cell
dehydration and membrane damage, intracellular ice formation (IIF) and exposure to CPs [14].
Another form of cooling used for MSC cryopreservation, vitrification, involves extremely
rapid cooling (>-1,000oC/s) of cells immersed in CPs within open storage vessels [34, 35]. While
the process prevents fluid crystallization, potentially cytotoxic concentrations of CPs are necessary
to facilitate the freezing process and protect the cells [34]. Additionally, samples must be
maintained at cryogenic temperatures, and open containers are a potential source of contamination
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[36, 37]. Largely due to technical challenges, vitrification is not used as frequently as slow freezing
for veterinary MSC cryopreservation, so the focus of this review is on the latter.
1.1.3. Thawing Process
Cells pass through the critical temperature range for ice crystal formation, -15 to -60oC,
during the freezing and thawing processes [14]. Rapid thawing, 90-100oC/min, is often employed
to prevent fluid crystallization by immersing samples in a 37oC water bath until all ice melts [38].
When murine hematopoietic progenitor cells are cooled at -1.5oC/min, survival is higher when
they are thawed rapidly at 900oC/min versus slowly at 2oC/min [39]. Recovery rates of human
erythroid progenitor cells are reported to be the same when they are thawed rapidly at 37oC versus
more slowly at 20oC [40]. It is likely that the best thawing mechanism varies between both cells
and CPs with the ideal rate a balance of preventing ice formation versus prolonged exposure to
CPs at temperatures when cells are metabolically active. Both freezing and thawing processes
should be customized and then consistently utilized for a given species and MSC harvest tissue.
1.1.4. Cryoprotectants
The primary function of CPs is to prevent cell damage during freezing and thawing [37,
41-43]. Cryoprotectant formulation and concentration varies among species, MSC type, and
cooling technique, among other considerations [30, 37, 43]. Even relatively low concentrations of
CPs used for slow freezing, 1-2M, are associated with toxicity that differs among cell types and
increases with time, temperature, concentration and metabolic activity [37, 43]. There are two
major CP categories based cell membrane permeability, permeable and impermeable [37, 43].
Those with high permeability tend to be the most cytotoxic [14]. Combinations of permeable CPs
like dimethyl sulfoxide (DMSO), ethylene glycol, methanol, propylene glycol, dimethylacetamide,
and less permeable CPs like polyvinypyrrolidone, hydroxyethylstarch, polyethylene glycol and
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dexamethasonetran, reduces permeable CP concentrations and associated problems [14, 37, 43].
Dimethyl sulfoxide and fetal bovine serum (FBS) are among the most common CPs used for
companion animal MSC cryopreservation [1, 25]. The carcinogenic properties of DMSO [4] and
xenogeneic proteins in FBS may alter the cells and impact post implantation behavior [18, 44].
Some of the functions and limitations of these as well as alternative CPs follow.
Dimethyl Sulfoxide
One of the most popular CPs, DMSO, stabilizes cell proteins [45], and penetrates cells to
displace fluid and equilibrate electrolyte concentrations between the intra- and extracellular fluid
to maintain cell volume [46, 47]. Protein stabilization is mediated via hydrophobic interactions
between DMSO and positively charged proteins, including those in the cell membrane
phospholipid bilayer [45]. Additionally, DMSO forms high energy hydrogen bonds with water
molecules, interfering with interactions among them to prevent ice formation [48, 49].
Dimethyl sulfoxide can cause MSC chemical toxicity and osmotic shock [44, 46, 47]. The
same hydrophobic interactions that protect vital proteins during cryopreservation can also denature
and deactivate them [50]. Increasing DMSO concentrations (5 – 20%) in the freezing medium is
associated with lower survival and increased apoptotic gene expression (Bak and Bcl2) in porcine
bone marrow derived stromal cells (BMSCs) [19-21, 51-53]. In vivo, neurotoxicity can occur
from 10% DMSO solutions, a typical concentration in cryopreservation medium [54]. Sedation,
headache, nausea, vomiting, hypertension, bradycardia, hypotension, central nervous system
depression, and anaphylactic shock have been attributed to DMSO in cell suspensions
administered intravenously to humans [54]. Washing cells to reduce DMSO concentration after
thawing results in cell loss and lower colony forming units [55], and complete DMSO removal can
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be complex and time consuming [56, 57]. These points, among others, support continued efforts
to identify replacements for DMSO in cryopreservation medium [37, 43].
Fetal Bovine Serum
Fetal bovine serum collected at different gestational stages [58] is a common culture
medium ingredient that provides growth factors, nutrients and hormones for cell proliferation and
adhesion [46, 47]. It is also thought to act as a CP through protection of cell proteins and
stabilization of osmotic pressure, though the mechanisms have not been completely defined [46,
47, 59]. In addition to ethical, zoonosis, and xenogeneic protein concerns, compositional variation
of FBS lots contributes to inconsistent cell culture performance [58]. A recent finding that
cryopreserved canine ASCs have increased CD44 expression compared to fresh cells was
attributed to FBS in the freezing medium [18]. The US Food and Drug Administration (FDA)
does not permit use of FBS in products intended for humans or animals owing to potential
immunogenicity [60]. Autologous and allogeneic serum in MSC freezing media reportedly
compare favorably to FBS in terms of MSC viability, morphology, and plasticity [41, 42, 61]. A
study to assess different media effects on equine BMSCs included two freezing media composed
of 20% serum, 10% DMSO, 70% DMEM or 95% serum and 5% DMSO, both with autologous
serum, commercial pooled equine serum or FBS added [61]. There was no difference in post-thaw
cell viability, morphology or growth kinetics among different freezing media, and 95% autologous
serum with 5% DMSO was recommended for short-term (2-3 days) cryopreservation [61]. Serum
free MSC cryopreservation medium has been shown to have similar or superior postcryopreservation outcomes compared to FBS-containing media [59, 62]. Increasing availability
of FBS-free freezing media may be important to improving consistency in MSC pre- and postcryopreservation characteristics.
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Impermeable Cryoprotectants
Methylcellulose (MC) is a high-molecular weight polymer in MSC freezing medium,
including serum-free [30, 62]. Human ASC post-thaw cell viability with freezing medium
containing MC in Dulbecco’s Modified Eagle’s medium (DMEM) is greater than DMEM alone,
but lower than that containing 80% serum, 10% DMSO and 10% DMEM [41, 42]. Another
nontoxic, impermeable, high molecular weight polymer, polyvinylpyrrolidone (PVP), is also a
fairly popular MSC CP [56, 57, 63]. As extracellular fluid ice forms at -10 to -20oC, the
concentration of dissolved PVP in the unfrozen fluid increases and creates an osmotic gradient that
drives fluid out of cells to prevent IIF [64]. Despite lower intracellular fluid, IFF may occur at low
PVP levels, and high concentrations of 20-40% can cause excessive cellular dehydration, cell
necrosis and membrane damage [56, 57, 63]. Human ASC viability and plasticity appears to be
maintained with 10% PVP as the CP [56, 57]. Carboxylated ε-poly-L-lysine polyampholytes are
effective CPs in MSC freezing medium without exogenous protein, but it has had little use in
companion animals [65]. Hydroxyethyl starch (HES) is a synthetic polymer CP that absorbs water
molecules (0.5g water per 1g HES) and maintains them in a glassy state, solid without
crystallization, during the cooling process [66, 67]. The polymer, widely used as a plasma volume
substitute, is metabolized by glycolytic enzymes in vivo, so it does not have to be removed from
thawed cells [66, 67]. A “6&5 solution” composed of physiologic saline, 6% HES, 5% DMSO and
4% human serum albumin appears to maintain better cell viability, recovery rates and plasticity of
human peripheral blood progenitors, cord blood stem cells, peripheral blood cells and BMSCs
compared to 10% DMSO in Roswell Park Memorial Institute (RPMI) 1640 medium [66, 67].
Similar findings are reported for canine CD34+ BMSCs cryopreserved in the same “6&5” solution
[68-72]. Novel cryopreservation solutions that support cell stasis without impacting inherent
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characteristics will continue to promote availability and standardization of cell therapies across
species.
1.1.5. Cryopreservation of Mesenchymal Stem Cells from different species (Fig. 2, 3, & 4)

Figure 2. Schematic diagram of domestic animals (cat, dog and horse) adult multipotent stromal
cell (MSC) processing for clinical applications. A. Photomicrographs of MSCs culture in stromal
medium, 5×; B. Fluorescent photomicrographs of MSCs with cytoskeleton (actin, green) and
nuclear (DNA, blue) staining.
Some of the earliest descriptions of cryopreservation were for spermatozoa, ova, and
embryos in the field of theriogenology [73, 74]. Cell cryopreservation has vastly expanded with
the rapidly evolving field of cell-based regenerative medicine [75]. It is increasingly apparent that
cryopreservation should be customized for species and cell type, especially with established
differences among immunophenotypes in primary cell isolates [18-21, 26]. Despite numerous
variables, conflicting outcomes and inconsistent cryopreservation effects across and within species,
consistent findings have emerged and are summarized below.
Comparisons among fresh and cryopreserved cells provide important information about
storage and behavior to guide therapeutic and research applications and assessments, respectively.
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Much of the existing literature documents similar, though not identical changes in cell plasticity
and expansion potential across species. Canine ASCs from subcutaneous and intra-articular
adipose tissues have lower sex determining region Y-box2 (SOX2) protein expression and distinct
ultrastructure and immunophenotype compared to fresh ASCs following 30 days of
cryopreservation in 80% FBS, 10% DMSO and 10% DMEM [18]. Two reports indicate that while
canine ASCs and BMSCs maintain their fibroblast-like morphology, alkaline phosphatase (ALP)
activity and plasticity following cryopreservation, there are significant differences from fresh cells
[26, 82]. Specifically, after 12 months of cryopreservation in freezing medium composed of 90%
FBS and 10% DMSO, canine MSCs have lower proliferation and telomerase activity than fresh
cells [26], and, separately, canine BMSCS have lower viability and proliferative capacity
following seven days of cryopreservation in freezing medium with 10% DMSO and 10% FBS [82].
In contrast to these studies, another found lower ALP activity and plastic adhesion in canine
BSMCs cryopreserved for one month [68, 83]. Equine peripheral blood MSCs cryopreserved in
90% FBS and 10% DMSO have faster proliferation but lower telomerase activity and myogenic
plasticity compared to unfrozen cells [25]. The in vitro osteogenic differentiation of fresh and
cryopreserved rat, lapin and porcine ASCs are reportedly similar on direct comparison [84].
Human ASCs have lower proliferation and adipocytic and osteoblastic plasticity following
cryopreservation in 90% FBS and 10% DMSO, and cryopreserved cells less effectively enhance
calvarial healing in an athymic mouse model compared to fresh [23, 24]. These findings support
the need to definitively characterize cell isolates before and after cryopreservation and to establish
and maintain cryopreservation procedures for consistent cell characteristics.
Another common finding among species is more rapid loss of progenitor cell expansion
and multipotentiality with passage following cryopreservation. Canine BMSCs cryopreserved in
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80% FBS, 10% DMSO and 10% DMEM for one month had lower fibroblastic and osteoblastic
colony forming unit frequencies than fresh cells with increasing passage [77]. Feline ASCs
cryopreserved in identical freezing medium for one month had lower CD9 and CD105 expression
compared to fresh cells, and the proliferation rate and osteoblastic capability decreased to a greater
extent with increasing passage in cryopreserved versus fresh cells [6, 22, 85]. The cell proliferation
rate of equine ASCs frozen in 20% FBS, 70% DMEM-high glucose and 10% DMSO significantly
declined at P12 while fresh cells did not show a similar decline until P15 [86]. The potential aging
effects of cryopreservation on MSCs that contribute to more rapid waning of cell expansion and
plasticity compared to fresh cells is an important area of continued discovery to anticipate both in
vitro and in vivo cell potential.
Harvest
Tissue

Pass
age

0

Cell Aliquot
(cells/ml)

~ 2 × 106

Adipose

Freezing Medium

DMEM, 10% FBS,
10% DMSO

0

1 × 106

Serum-free
medium, 80% FBS,
10% DMSO

0

N/A

Low glucose
DMEM, 30% FBS,
5% DMSO

1

3 × 106

Freezing
Rate

-1oC/min

Cooling Process
Cryovials were in
an insulated
container for 24
hours at -80oC and
then moved to
liquid nitrogen

-1oC/min

Cryovials were in
an insulated
container at -80oC
overnight and then
moved to liquid
nitrogen

N/A

N/A

Thawing
Process

Effects

Ref

N/A

N/A

[76]

Cryovials
removed
from
liquid
nitrogen
and
immersed
in a 37oC
water bath
for 2-3
min

None

[77-79]

N/A

N/A

[80,
81]
[26]
[82]

Figure 3. Adult Canine MSC Freezing Medium Components, Cryopreservation Conditions and
Behaviors
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1.1.6. Cell Passage Number and Cryopreservation Duration
The amount of cell expansion prior to and duration of cryopreservation is an established factor in
post-cryopreservation cell characteristics [30, 87, 88]. There is a direct relationship between equine
umbilical cord blood MSC viability and pre-cryopreservation passage number following
cryopreservation in 20% DMEM, 70% FBS and 10% DMSO for 8 weeks. Specifically, cell
viability decreases from about 80.4% for P1 to 51.2% for P10 [87, 88]. Similarly, a comprehensive
study of human ASCs to assess cooling rate, end temperature, hold time and thawing rate on cell
membrane integrity showed that a significant effect of thawing rate was limited to P3 and P4 cells
while the interaction between cooling rate and end temperature was significant for cell passages
P0-P4 [30]. The impact of cryopreservation duration may be most detectable following short term
storage. Human BMSCs reportedly maintain tri-lineage differentiation capacity after 7 years of
cryopreservation [38]. However, total cell recovery is reportedly significantly lower after 5 (80%)
versus 1 (90%) months of cryopreservation in 10% fetal calf serum, 10% DMSO and 30% bovine
serum albumin [89]. These findings convey the importance of consistent cell expansion and
consideration of the length of cryopreservation when preparing MSCs for potential clinical
application.
1.1.7. Cell Transportation
Cell delivery from current Good Manufacturing Processes (cGMP) facilities to patient
administration sites requires maintenance of frozen cells for variable time periods despite external
temperature fluctuations [17, 35, 90]. Vitrified cells are transported at cryogenic temperatures in
dry shippers with liquid nitrogen in absorbent materials to avoid sample contact with liquid [56,
57]. Slow cooled samples can be shipped frozen in approved, polystyrene containers without the
need for dry shippers [35, 90]. Cryovials are often wrapped with precooled, absorbent material
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and placed in a leak-proof, biohazard grade container to prevent direct contact of samples with dry
ice placed on top of the container within the polystyrene shipping box. Sample transportation
responsibilities extend beyond sample preparation and packaging, however. A detailed inventory
should be included with the shipment, all samples permanently labeled, signage applied to shipping
containers and all necessary shipping manifests filed. Shipping should be tracked and clear
guidelines provided to the recipient surrounding sample handling and administration [56, 57].
Contemporary travel mechanisms makes it possible to transport cryopreserved samples globally.
It is imperative, however, that national and international laws and regulations are observed.
Harvest
Tissue

Passage

Cell
Aliquot
(cells/ml)

Adipose

N/A

~ 5 × 105

Freezing Medium
20% FBS, 10%
DMSO, DMEM

Freezing
Rate

Effects

-1oC/min

Decreased
proliferati
on rate

[86]

Ref

~1 × 106

10% FBS, 10%
DMSO, DMEM

-1oC/min

N/A

[27]

~ 10 × 106

20% serum, 10%
DMSO, α-MEM
or 95% serum, 5%
DMSO

-1oC/min

Lower
MSC
numbers

[61]

Lower
proliferati
on rate

[25]

Bone
Marrow

N/A

Peripheral
Blood

2-3

2 × 106

90% FBS, 10%
DMSO

-1oC/min

Umbilical
cord
blood

N/A

1 × 106

10% DMSO, 70%
FBS, DMEM

N/A

[87, 88]

Figure 4. Adult Equine MSC Freezing Medium Components, Cryopreservation Conditions and
Behaviors
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1.1.8. Regulation of Cryopreserved Regenerative Cells for Veterinary Use
Regulation of veterinary medicine in the United States has a complicated history with some
products regulated by the United States Department of Agriculture (USDA) and others by the Food
and Drug Administration Center for Veterinary Medicine (CVM). The Federal Food, Drug, and
Cosmetic (FDC) Act of 1938 established federal government’s responsibility to regulate animal
health products. Since then, a number of additional laws surrounding veterinary medicine product
approval and use have gone into effect. In the mid-1990’s, Congress passed two major Animal
Health Acts. The Animal Medicinal Drug Use Clarification Act of 1994 allowed veterinarians to
prescribe human drugs and extra-label use of veterinary drugs for animals under specific
circumstances. The Animal Drug Availability Act of 1996 added moderation to the animal drug
approval process, including flexible labelling and more direct communication between drug
sponsors and the FDA. During the infancy of adult stem cell therapy discovery and development
in 2002, the FDA announced a current good manufacturing practice (cGMP) initiative to enhance
and update regulation of manufacturing processes and end-product quality of animal and human
drugs and biological medicines. The goals of the initiative were to drive focus on the greatest to
public health risks of manufacturing procedures and ensure that process and product quality
standards did not impede innovation. In 2004, passage of the Minor Use and Minor Species Animal
Health Act encouraged development of treatments for species that may otherwise attract little
interest. Collectively, these laws provided veterinarians reasonable discretion and freedom to use
emergent drugs and medical devices within their practices. There was no specific guidance
surrounding development and use of regenerative cell therapies for industry or practicing
veterinarians prior to 2015.
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The Guidance for Industry Publication #218 – Cell-Based Products for Animal Use was
published by the CVM in June of 2015, to clarify Agency regulation of cell therapies. Non-primary
cells that are culture expanded and intended to treat patients other than the donor are considered
to be “drugs” and must go through FDA drug licensing and approval processes [91]. Autologous
cryopreserved cells to treat injury or disease in the donor are classified as either type I or type II
cell based products (Table 1). Both are regulated as drugs and must undergo all indicated safety
and efficacy testing and receive CVM authorization for use similar to allogeneic cell therapies. For
type II classification, autologous cells must be: 1) minimally manipulated, 2) for homologous use
and 3) for non-food-producing animals. They cannot be combined with anything other than water,
crystalloids or a sterilizing, preserving or storage agent that do not raise additional safety concerns.
Additionally, cells may not be combined with or modified by adding them with a drug or a device.
Prior to the advent of stem cell based products, the term “type II autologous cells” was generally
understood to mean whole or fractionated peripheral[2, 92], umbilical cord [93-96] or marrowderived blood cells [97] intended for transplantation, cells within cryopreserved mesenchymal
tissues like fat, bone, ligament and tendon, cartilage grafts [1, 3, 15, 16, 98], or β cell pancreatic
islets for diabetes therapy [99].
Improved methods of cell preservation with ingredients beyond serum and DMSO
complicate cell classification since commercial cryopreservation solution components may be
considered drugs in some circumstances. Use of cryopreserved cells in combination with popular
blood derivatives like platelet rich plasma occupies a nebulous area in the classification scheme
that requires further clarification. The speed of discovery in the stem cell arena exceeds
development of regulations governing their use. Similarly, definitions of “homologous use” and
“minimally manipulated” do not entirely capture current knowledge of stem cell functionality.
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Academic and industrial scientists continue to work with the regulatory authorities to achieve and
maintain contemporary language that is consistent with intended and practical use.
In summary, CMV consultation should be sought prior to manufacture and use of
cryopreserved cells as a commercial treatment, especially since cells transported across state lines
are automatically within federal regulatory jurisdiction. Additionally, state requirements for
reporting and licensing GTP Cell Bank facility must be abided by. Use of cell processing and
banking services provided by veterinary regenerative medicine companies appears to be acceptable
as the long the provider has implemented appropriate quality and safety standards.
Table 1. Autologous Cell-based Therapy Classification
Autologous Type I Cell Therapy Criteria

Autologous Type II Cell Therapy Criteria

(One must be true)

(All must be true)

More than minimally manipulated
(Example: Cells cultured in vitro for an
extended period of time)

Minimally manipulated
(Example: Cells are only centrifuged)

For non-homologous use

For homologous use

For use in a food-producing animal

For use in nonfood-producing animals

Effects are dependent on metabolic activity of
living cells

No statement regarding metabolic activity

Manufacture of the ASCP involves
combination of the cells with another article
(Except water, crystalloids, or a sterilizing,
preserving, or storage agent that does not
raise new product safety concerns)

Manufacture does not involve combination of
cells with another article
(Except water, crystalloids, or a sterilizing,
preserving, or storage agent, provided that the
addition of water, crystalloids, or the
sterilizing, preserving, or storage agent that
does not raise new product safety concerns)
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1.1.9. Conclusion
Cryopreservation of adult MSCs is central to their development, availability and use. The practice
is relatively new in veterinary medical disciplines compared to human counterparts, and its
importance and use will only continue to grow in concert with regenerative medicine [41, 42, 63].
It is readily clear that fresh and frozen MSCs are not identical. However, mechanisms, extent and
full implication of distinctions between them is uncharted and complicated by numerous variables
before, during and after cryopreservation. Efforts to discover and standardize cryopreservation
protocols based on species, tissue and, potentially, cryostasis duration will continue to advance
therapeutic efficacy and safety of cryopreserved cells.
Table 2. Differentiation media components and β cell induction of MSCs from different tissue
sources[123]
Species

Cell Type

Differentiation Factors

References

Activin-A, conophyline, nicotinamide,
L-glutamine, betacellulin-delta4;
Mouse

BMSC

fibronectin (FN), laminin (LAM),

[100]

hepatocyte growth factor (HGF),
extendin-4,
Glucose, nicotinamide, activin-A,
Human

ASC

exendin-4, HGF, pentagastrin,

[103]

betacellulin
Glucose, retinoic acid, nicotinamide,
Umbilical cord blood derived
Human

exendin-4, epidermal growth factor,
MSCs
B27
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[102]

1.2. Transdifferentiation of Multipotent Stromal Cells into Insulin Producing Clusters
A series of transition steps are required to induce the differentiation of MSCs to β cells in vitro.
Currently numerous studies reported that several stem cell types have the capability to form insulin
producing β cells [100-103] and different factors are used for specific cell type (Table 2).
Currently, there is no standard protocol for pancreatic differentiation. However, most
reports use B27 and N2 rather than FBS to support prolonged self-renewal of MSCs [104, 105].
Nicotinamide is another additive that is widely used to induce human BMSCs [105], human ASCs
[104], and other MSC types [106-112]. In previous studies, nicotinamide has been shown to have
the ability to promote the islet-like cell cluster formation and increase the rate of proinsulin
biosynthesis [70, 113-121].

Pentagastrin is an artificially synthesized polypeptide that can

stimulate β cell neogenesis and increase the β cell mass [122]. Besides these supplements, there
are several growth factors and extrinsic proteins used to promote β cell proliferation and
differentiation (Table 3).
1.3. The Effects of the Physical Environment on Multipotent Stromal Cell Osteogenesis
1.3.1. Bioreactor Systems for Bone Tissue Engineering
The general definition of bioreactor is a device that can closely monitor and tightly control
environmental conditions (e.g. pH, oxygen concentration, pressure, nutrient supply, flow rate, and
waste removal) to achieve desired biological and/or biochemical results [124]. Since the reliability,
reproducibility, control and automation introduced by bioreactors for specific tissue engineering
approaches have been established, they are widely used in many fields, such as bone [125],
cartilage [126], vascular tissue [127], cardiac tissue [128], liver [129], and so on [124]. In this
section, several common bioreactor systems, including spinner flasks, rotating wall and perfusion
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bioreactors as well as the effects of hydrodynamic shear stress on osteoblastic differentiation will
also be discussed.
Table 3. Extrinsic growth factors for β cell proliferation and/or differentiation [123]
Extrinsic growth
Function

Ref

factors
Enhance the effect of insulin secretion from β cells; increase
Glucagon like
the β-cell mass; enhance fetal pig β-cell differentiation and

[130-133]

peptide
initiate their functional maturation
Promote the differentiation, regeneration and proliferation of

[70, 113-

pancreatic β cells

115]

Activin-A

Regulate neogenesis of β cells

[134]

Hepatocyte

Promote β cell proliferation and regeneration of islets;

[109, 135,

growth factor

Increase insulin content and islet cell growth

136]

Enhance the nestin-positive cell growth

[137]

Enhance the nestin-positive cell growth

[137]

Betacellulin

Endothelial
growth factor
Basic fibroblast
growth factor
Enhance differentiation of MSCs into insulin producing cells
Laminin

[101]
and insulin secretion
Enhance differentiation of MSCs into insulin producing cells

Fibronectin

[101]
and insulin secretion

Extendin-4

Promote β-cell proliferation and maturation
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[36]

Spinner flask bioreactor
A spinner flask is a simple and inexpensive bioreactor [125]. Normally a spinner flask is
composed of a glass media reservoir with side arms, a stir bar or another stirring mechanism [125].
Scaffolds can be attached to a needle connected to the lid of the flask and the side arms fitted with
porous covers to allow oxygen and CO2 exchange [125]. Numerous studies demonstrate that the
spinner flask can enhance the early osteogenic marker alkaline phosphatase (ALP), late
osteoblastic marker osteocalcin (OCN), calcium deposition, and cell proliferation in various cell
types compared to static controls (Table 6) [138-143].

Besides the advantages of cellular

proliferation and differentiation from the transportation of nutrients and oxygen throughout the
scaffold, another advantage is its low cost [144]. In static culture, because of nutrient and oxygen
concentration gradients, cells in the center of the scaffold do not receive the same nutrition and
oxygenation as cells on the periphery [144]. In a spinner flask bioreactor system, nutrients and
oxygen are delivered throughout the scaffold [145]. However, there are several drawbacks of the
system that should be considered. The possible formation of a dense superficial cell layer can
hamper nutrient and oxygen supply, leading to cell death in the center of the scaffolds [140]. The
spinner flask bioreactor system may not adequately transport nutrients and oxygen in large
scaffolds [125].

Additionally, the shear stress from medium flow around the cell-scaffold

constructs is not applied homogenously throughout the scaffold as the highest shear forces occur
on the construct surfaces closest to the stirring mechanism [125].
Rotating bioreactor systems
The rotating wall bioreactor contains two concentric cylinders with culture media and cellscaffold constructs in the space between them [144]. The inner cylinder is stationary and provides
gas exchange [144]. Typically the outer cylinder one of two designs: 1) a free-fall design where
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scaffolds freely moving in the space; or 2) rotating bed bioreactor (RBB) design where scaffolds
are fixed to the outer cylinder rather. Using the first bioreactor system design, the expression of
osteogenic genes (ALP, OCN, and OPN) was upregulated while the proliferation was not affected
in rat calvarial osteoblastic cells on poly (lactide-co-glycolide) (PLGA) scaffolds [146]. However,
in another study the ALP activity decreased and the OCN activity did not change in osteoblastic
cells [147]. Meanwhile, the rotating wall bioreactor cannot enhance ALP activity and OCN
secretion in rat BMSCs [138]. In this design, scaffolds may collide with the bioreactor wall and
damage scaffolds and disrupt attached cells [144]. The RBB system was developed to avoid this
problem [148-151]. Using this system, affixed human bio-derived bone scaffolds had enhanced
cell proliferation, ALP expression, mineralized nodule formation compared to the spinner flask
and static culture [148]. Other studies demonstrated that the RBB system has positive effects on
cell proliferation, extracellular matrix (ECM) deposition, and osteogenic differentiation in various
cell types (human MSCs and MC3T3-E1 cells) [149-151]. One major potential disadvantage of
the rotating wall bioreactor systems is that nutrients, oxygen transportation, mineralization and
cell distribution are limited to the outside of the scaffolds [138, 144].
Perfusion-based bioreactor systems
Many different perfusion bioreactor systems have been

developed to meet distinct

requirements, but most systems consist of a media reservoir, a pump, a tubing circuit, and a
chamber or cassette [152]. In a flow perfusion bioreactor system, medium is pumped through cellscaffold constructs at a controlled rate [152]. Perfusion bioreactor are divided into indirect and
direct perfusion bioreactors based on the cassette where the cell-scaffold constructs maintained
during perfusion [144, 152]. In an indirect perfusion system, medium flows through the space
between the constructs and the cassette. Therefore, the medium flow can follow the path of least
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resistance around the constructs and flow-derived shear stress may not reach the cells in the center
of the constructs [144]. The ALP activity and OCN secretion were increased in rat osteoblasts on
β-tricalcium phosphate (β-TCP) scaffolds using this system compared to static culture [153]. Bone
formation was also enhanced by perfusion bioreactor constructs were implanted into rats.

Reference
[139]
[140]

[138]
[143]
[146]
[142]

Figure 5. Studies utilizing spinner flask bioreactor for bone tissue engineering. ALP: alkaline
phosphatase; PLGA: Poly (D, L-lactic-co-glycolic acid); PLG: poly (lactide-co-glycolide); BSP:
bone sialoprotein; Col1α1: collagen 1α1; OCN: osteocalcin; TERT: telomerase reverse
transcriptase; OPN: osteopontin; RUNX2: Runt-related transcription factor-2; ↑: positive effect
In a direct perfusion system, the scaffolds are fixedin cassettes in a press-fit manner so that
the medium cannot flow around the scaffold [144]. Because of this characteristic, this system
enhances biophysical forces and medium delivery to the cells throughout the scaffold [152]. This
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system design has been used with numerous scaffold materials including titanium, starch-based,
and calcium phosphate ceramics [154-160]. In this system, the center cell distribution in the
scaffold center is improved and cell proliferation and osteogenesis, and mineralized ECM
deposition are enhanced compared to static culture [156, 161, 162].
Table 4. Comparison among spinner flask, rotating wall, and direct perfusion bioreactor systems
for bone tissue engineering
Bioreactor

Advantage

Disadvantage

Shear Stress

Reference

Spinner
flask

Low cost; Enhance
cell proliferation
and expression of
osteogenic marker
genes; Benefit
mineralization

Internal nutrient and
oxygen transport
limitations; Shear
stress distribution is
not homogenous.

The degree of shear
stress depends on the
stirring speed

[144]

Low cost; Enhance
the expression of
osteogenic marker

Internal nutrient and
oxygen transport
limitations;
Limitations of
mineralization and
culturing benefits;
Scaffolds may be
damaged and cell
attachment may be
disrupted.

The degree of shear
stress depends on the
centrifugal forces of
the cylinder balance
with the force of
gravity

[138,
144]

Need more devices to
build the system

In vivo studies to
prove the
effectiveness of the
systems are
necessary; The
maintenance of the
system is timeconsuming; The
difficulty of perfusing
media directly
through a scaffold

[125]

Rotating
wall vessel

Direct
perfusion
bioreactor

Enhance cell
proliferation,
distribution,
differentiation, and
viability in the
interior of
scaffolds;
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In a rat cranial defect model, rat BMSCs were seeded onto the titanium scaffolds overnight
and then followed cultured in the flow perfusion bioreactor system at a flow rate of 1 ml/min for
8 days before implanted into the cranial defects sites in rats [163]. After 30 days implantation,
there were no significant differences between the groups of perfusion versus static culture [163].
Currently, there are few in vivo studies that prove the effectiveness of the flow perfusion systems.
Additionally, to develop a successful flow perfusion bioreactor, it is necessary to customize the
cassette to direct the medium flow through a scaffold design. The maintenance of these systems
can be time-consuming [125].
1.3.2. Effect of Shear Stress and Mass Transfer on Proliferation and Osteoblastic
Differentiation
Table 5. Comparison of shear stresses reported in different perfusion bioreactor systems [125]
Shear stress
(dyn/cm2)

Cell Type

Effects

Ref

Increasing perfusion rate improved proliferation rate,
Human
0.007 ~ 0.1

cell distributions and the osteogenic specific protein [170]
BMSC
and mineralization.
Human

<0.05

More calcium content and higher ALP activity

[142]

BMSC
Higher amounts of calcified matrix deposition; More
Rat
0.05

homogeneous ECM distribution; Enhanced cellular [171]
BMSC
proliferation and differentiation.
Human

Increasing shear stress accelerated the osteogenic

BMSC

differentiation and enhanced the ECM mineralization

0.05 ~ 0.15

[168]
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(Table 5 Continued)
Shear stress
(dyn/cm2)

Cell Type Effects
Human

Ref

Improve the cell distribution and bone matrix

0.1

[172]
ASC

deposition

Rat

Enhance the expression of the osteoblastic phenotype

BMSC

and the mineralized ECM production and distribution

0.1 ~ 0.3

[169]
Rat

0.2 ~ 0.3

Increase calcium deposition

[159]

BMSC
Rat

Increasing shear stress increase mineralized matrix

< 1.0

[154]
BMSC

production

Rat

Repeated application of shear stress stimulate late

1.6

[166]
BMSC

osteogenic marker expression

The positive effects of fluid shear on osteogenic signal expression and osteoblastic
differentiation of MSCs have been reported numerous times [164-167]. Most long-term, three
dimensional bioreactor studies use continuous flow at a set rate [125]. In a bioreactor system, the
shear forces from fluid flow in scaffold pores are determined by flow rate and difficult to calculate
correctly for long term culture because cell growth and ECM deposition can alter local velocity
and shear stress[125]. As discussed above, bioreactor systems improve mass transport which can
be expressed by flow rate and the increasing mass transport could result in the change in cell
proliferation [125, 142, 168]. When the mass transport is sufficient for the cell proliferation, the
shear stress would be the main effectors on the osteogenic signal expression and cell osteogenesis
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[168]. Shear stresses are reported to range from 0.05 to 1.0 dyn/cm2 (Table 5) in different perfusion
bioreactor systems. One report indicates that calcium deposition increased with increasing
viscosity [169]. All bioreactor systems require a fluid rate necessary for optimal nutrient and gas
transport that does not generate shear forces that interfere with cell attachment and function [168].
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CHAPTER 2. EFFECTS OF CRYOPRESERVATION ON CANINE MULTIPOTENT
STROMAL CELLS FROM SUBCUTANEOUS AND INFRAPATELLAR ADIPOSE
TISSUE *
2.1. Introduction
Tissue engineering with adult multipotent stromal cells (MSCs) harvested from adipose
tissue, adipose derived multipotent stromal cells (ASCs), is rapidly emerging as a therapeutic
reality in human and veterinary medicine [75, 173]. Higher MSC tissue density and comparable
cell plasticity to bone marrow derived multipotent stromal cells are some of the characteristics that
establish adipose tissue as a viable MSC source [77]. Existing knowledge supports potential
differences in ASC behavior among adipose depots in numerous species [174, 175]. One rationale
for observed differences is varying proportions of brown and white adipose tissue among harvest
sites [176]. Intra-articular and visceral adipose tissue are predominantly white while subcutaneous
adipose tissues are mostly brown [177]. Distinctions between cells isolated from brown versus
white adipose tissue like lower plasticity of brown adipose tissue cells, have been attributed to
epigenetic factors and functional differences, endocrine versus thermogenic of white and brown,
respectively [178, 179]. Distinct features of cells isolated from brown and white adipose tissues
contribute to efforts to optimize isolation procedures and culture conditions for cells from each
[180].
Canine infrapatellar adipose tissue ASCs reportedly have similar in vitro properties as bone
marrow derived multipotent stromal cells and higher expansion capacity and plasticity than
undifferentiated cells from joint capsular and cranial cruciate ligament synovium [181]. This
makes them appealing for intra-articular tissue regeneration. Subcutaneous adipose tissue harvest
*This chapter previously appeared as [Wei Duan, and Mandi Lopez. “Effects of Cryopreservation
on Canine Multipotent Stromal Cells from Subcutaneous and Infrapatellar Adipose Tissue.” Stem
Cells Reviews and Report 12 (2016): 257-268]. It is reprinted by permission of [Springer and
BioMed Center]
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is less invasive and more abundant than intra-articular [96, 182]. Hence, use of subcutaneous
adipose tissue ASCs may reduce morbidity and augment tissue resources for generation of intraarticular structures.
A recent study highlighted differences between ASCs from intraarticular and subcutaneous
adipose tissues in and around the human knee [182]. Published reports of canine subcutaneous and
infrapatellar ASCs suggest similarities between cells from the two harvest sites [180, 183], but a
side by side in vitro characterization is necessary to anticipate the ability of each cell type to
support complex tissue generation. This study was designed to determine in vitro expansion
capabilities and plasticity of paired canine ASCs harvested from subcutaneous (SUB) and
infrapatellar (IFP) adipose tissues before and after cryopreservation to test the hypothesis that IFP
ASCs have the highest in vitro expansion rates, plasticity and MSC immunophenotypes that are
sustained over multiple cell passages.
2.2. Materials and Methods
2.2.1. Ethics Statement
All animal procedures were approved by the Institutional Animal Care and Use Committee.
2.2.2. Study Design
Subcutaneous and infrapatellar IFP adipose tissues were collected from 6 adult, mixed-breed dogs
(3.5 ± 0.8 years of age, mean ± standard error of the mean (SEM)). Adipocyte and ASC
ultrastructure were evaluated with transmission electron microscopy (TEM). Cell doublings (CDs)
and doubling time (DT) were determined for fresh and cryopreserved ASC passages (fresh, P;
cryopreserved, tP) 0-3 from both tissues of each dog. For P0, 1, 3 and tP1 and 3, CD29+, CD34+,
CD44+, and CD90+ cell percentages were quantified. Fibroblastic (CFU-F), osteoblastic (CFUOb), and adipocytic (CFU-Ad) colony-forming unit frequency percentages and lineage-specific
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target gene mRNA expression levels were determined (peroxisome proliferator-activated receptor
γ (PPAR-γ) and leptin - adipogenesis; osteoprotegerin (OPG) and collagen type 1α1 (Col1α1) osteogenesis) after culture in lineage-specific induction or stromal media. Similarly, P3 and tP3
chondrogenic pellet alcian blue (proteoglycan) staining, CD29, CD34, CD44 and CD90 protein
expression and target protein expression (PPAR-γ - adipogenesis; osteopontin (OPN) osteogenesis; sex determining region Y-box 2 (SOX2) – progenitor) were also quantified
following standard induction procedures. A seeding density of 5 ×103 cells/cm2 and humidified
culture conditions (37oC, 5% CO2) were used for all cell culture experiments. Materials were from
Sigma-Aldrich, St. Louis, MO unless otherwise noted.
2.2.3. Cell Isolation
Cells from SUB and IFP adipose tissues were isolated according to published procedures with
minor modifications [181]. Briefly, tissue was rinsed with phosphate buffered saline (PBS,
Hyclone, Logan, UT) and minced, followed by digestion in an equal volume of Dulbecco’s
modified Eagle’s medium: F-12 (DMEM/F-12, Hyclone, Logan, UT), 0.1% collagenase type I
(Worthington Biochemical Corporation, Lakewood, NJ) and 1% bovine serum albumin (BSA) for
90 minutes with agitation. The tissue suspension was then filtered (100 μm, BD Falcon, Bedford,
MA). Subsequently, the digest was centrifuged (260×g, 5 minutes), and the pellet was suspended
in stromal medium (DMEM/F-12 medium, 10% (v/v) fetal bovine serum (FBS, Hyclone), 1% (v/v)
antibiotic/antimycotic solution). An equal volume of red cell lysis buffer (0.16 mol/L NH4Cl, 0.01
mol/L KHCO3, 0.01% ethylenediaminetetraacetic acid (EDTA)) was added, and the mixture was
maintained at room temperature for 30 minutes. The solution was centrifuged, and the resulting
stromal vascular fraction (SVF) pellet resuspended in stromal medium followed by culture in T75
flasks (CellStar, Greiner, NC). Medium was refreshed after 24 hours to remove unattached cells,
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and then every 3 days [181]. Subsequent passages were performed at 80-90% cell confluence. For
purposes of this study, the primary cell isolate was the SVF and the first cell passage of primary
cells was P0. Aliquots of each SVF were suspended in freezing medium (10% DMEM/F-12, 10%
dimethyl sulfoxide (DMSO, Fisher Scientific, Fair Lawn, NJ), 80% FBS) during the first cell
passage and cryopreserved in the cryopreserved medium composed of 10% DMSO and 80% FBS
in DMEM in CoolCell® (BioCision, LLC) overnight. The cryopreserved cells were then moved
in liquid nitrogen for a minimum of 30 days. Cells were revitalized and seeded in T75 flasks as
tP0 after the cryopreservation period.
2.2.4. Adipocyte and ASC Ultrastructure (adipocytes, P1, tP1) - Transmission Electron
Microscopy
Harvested SUB and IFP adipose tissues, P1 and tP1 ASCs were rinsed with PBS and then fixed in
2% paraformaldehyde and 1.25% glutaraldehyde in 0.1 M sodium cacodylate (CAC) buffer (pH
7.4). Samples were rinsed in 0.1M CAC buffer with 5% sucrose and incubated with 1% osmium
tetroxide in 0.1M CAC buffer. The tissues were dehydrated in a series of ethanol-distilled water
solutions and embedded in Epon (Plano, Marburg, FRG). Ultrathin sections were evaluated with
a transmission electron microscope (JEM-1011, JEOL, Japan).
2.2.5. Cell Expansion (P0-3, tP1- 3)
Cells were cultured in 12-well plates (Thermal Fischer Scientific, Denmark) to calculate CD and
DT after 2, 4 and 6 days of culture using standard formulae (CD= ln(Nf/Ni)/ln(2) and DT=CT/CD;
Ni: initial cell number; Nf: final cell number; CT: culture time) [184]. Cell counts were performed
with a hemocytometer. Day 2 and 4 cell numbers were used as the Ni for days 4 and 6, respectively.
2.2.6. Multipotentiality (P0, 1, 3, tP1, 3) - Limiting Dilution Assays and Pellet Chondrogenesis
Limiting dilution assays were used to determine fibroblastic (CFU-F), adipocytic (CFU-Ad), and
osteoblastic (CFU-Ob) colony-forming unit frequencies [77]. A total of 5000, 2500, 1250, 625,
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312 or 156 cells were seeded in each well of one row in a 96-well plate for 8 replicates of each cell
number/well. Fibroblastic (CFU-F) colonies were fixed with 2% formalin (Anapath, Mckinney,
TX) and stained with 0.1% toluidine blue after 7 days of culture in stromal medium. For CFU-Ob,
cells were cultured in stromal medium for 7 days followed by culture in osteogenic medium
(DMEM/F-12, 10% FBS, 10 mmol/L β-glycerophosphate, 10 nmol/L dexamethasone, 50 μg/ml
sodium 2-phosphate ascorbate) for 21 additional days. Cells were fixed in ice cold 70% ethanol
and then alkaline phosphatase (ALP) was stained with 5-bromo-4chloro-3indolyl phosphate/nitro
blue tetrazolium (BCIP/NBT, 0.15mg/ml BCIP, 0.30 mg/ml NBT). To determine CFU-Ad, cells
were cultured in stromal medium for 7 days followed by culture in adipogenic medium
(DMEM/F12, 3% FBS, 1% antibiotic/antimycotic solution, 33 µmol/L biotin, 17 µmol/L
pantothenate, 1 µmol/L dexamethasone, 100 µmol/L indomethacin, 1 µmol/L insulin, 0.5 mmol/L
isobutylmethylxanthine (IBMX), 5 µmol/L rosiglitazone (TZD, AK Scientific, Union City, CA))
for 21 additional days. Cells were fixed in 4% formalin and stained with 0.3% oil red O. Wells
with 10 or more toluidine blue-stained, oil red O-stained, or BCIP/NBT-stained colonies were
considered positive for fibroblastic, adipocytic or osteoblastic colonies, respectively. The ratio of
negative to total wells per row was used to estimate the CFU frequencies according to Poisson’s
ratio (F=e-x; F: ratio of negative to total wells; e: natural logarithm constant 2.71; x: CFU) [77, 181,
184]. CFU frequency was expressed as a percentage percentage (1/CFU frequency × 100).
For chondrogenesis, 2.5×105 cells were centrifuged (200×g, 5 minutes) to form a pellet
after 7 days of culture in stromal medium. Pellets were cultured in stromal or chondrogenic
medium (DMEM/F-12, 3% FBS, 1% antibiotic/antimycotic solution, 50 μg/ml ascorbate
phosphate, 100nmol/L dexamethasone, 40 μg/mL proline, 2 mmol/L sodium pyruvate (Invitrogen,
Carlsbad, CA), 1% insulin-transferrin-selenium (ITS, Invitrogen), 10 ng/mL recombinant human
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transforming growth factor-β3 (rTGF-β3, R&D systems, Minneapolis, MN)) for 21 days. They
were then fixed with 10% neutral buffered formalin, embedded in paraffin, sectioned (5 μm) and
stained with 1% alcian blue (Acros Organics, Belgium) and 3% nuclear fast red.
2.2.7. Immunophenotype - Flow Cytometry (P0, 1, 3, tP1, 3)
Cell aliquots (105 cells) were suspended in 200 μl PBS containing 0.1 μl (200 μg/ml) of labeled or
unlabeled antibody (CD34-PE, CD44-FITC, CD90-PE, CD29) specific for canine antigens or
validated for canine cross reactivity for 30 minutes at room temperature (Table 6). Cells were then
washed with PBS and fixed with 4% neutral buffered formalin. For CD29, cells were incubated
with labeled anti-immunoglobulin (IgG-FITC) for 30 minutes at room temperature, washed with
PBS and then fixed with 4% neutral buffer formalin. For the autoflourescence control, cells were
not incubated with antibodies. Cell fluorescence was quantified by flow cytometry using a
FACSCalibur flow cytometer and Cell Quest Pro software (BD Biosciences, San Jose, CA).
2.2.8. Gene Expression – RT-PCR (P0, 1, 3, tP1, 3)
Total RNA was isolated from cells (RNeasy Plus Mini Kit, Qiagen) and the concentration
determined spectrophotometrically (NanoDrop ND-1000; NanoDrop Technologies, Montchanin,
DE, USA). A QuantiTect Reverse Transcription Kit (Qiagen, GmbH, Germany) was used to
generate cDNA. Target gene levels, glyceraldehyde 3-phosphate dehydrogenase (GAPDH),
PPAR-γ, leptin, Col1α1 and OPG (Table 7) were quantified with real-time RT-PCR using SYBR
Green (Qiagen) technology and an MJ Research Chromo 4 Detector (Bio-Rad Laboratories,
Hercules, CA). The 2

–ΔΔCt

values were determined relative to the reference gene GAPDH and

target gene expression in cells cultured in stromal medium.
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2.2.9. Protein Expression – Immunocytochemistry, western blot (P3, tP3)
Immunocytochemistry. Cells were cultured in stromal medium in 4-well chamber slides for 3 days
and then fixed with 10% neutral buffered formalin for 24 hours. Antigen retrieval was performed
with SDS/TBS antigen retrieval buffer (1% SDS, 100 mM Tris, 138 mM NaCl, 27 mM KCl,
pH=7.4) for 5 minutes at room temperature. Cell preparations were blocked with goat serum (1:10
in TBS) overnight at 4oC and then incubated with antibodies against CD34-PE (1:200), CD44FITC (1:500) or CD90-PE (1:500) (Table 6) for 2 hours at room temperature. Cells were washed
with TBS buffer and nuclei were stained with DAPI (1μg/ml). For CD29 labeling, cells were
incubated with antibodies against CD29 (1:500) for 2 hours at 37oC followed by IgG-FITC (1:800)
and DAPI nuclear stain. Photomicrographs were obtained for all labeled cells (Leica DM 4500b).
Western blot. Total protein was extracted from cells cultured in stromal and induction medium
using RIPA buffer (150 mM NaCl, 1.0% Triton X-100 (Thermo Scientific, Rockford, IL), 0.5%
sodium deoxycholate, 0.1% SDS, 50 mM Tris (pH=8.0), protease inhibitor (Thermo Scientific)).
Protein concentrations were determined with the Bicinchoninic Acid (BCA) Protein Assay Kit
(Thermo Scientific). Protein aliquots (20 μg) were denatured for 10 minutes at 95oC in an equal
volume of 1x SDS loading buffer. Proteins were separated on a 12% SDS-PAGE gel and
transferred (300 mA, 90 minutes) to nitrocellulose membranes (Bio-Rad Laboratories, Hercules,
CA). Membranes were blocked (4% BSA, 0.05% sodium azide) for 1 hour at room temperature
and then incubated with primary antibodies directed against OPN (1:300), PPAR-γ (1:500) or
SOX2 (1:500) at 4o C overnight (Table 6). Tris buffer saline with Tween-20 (TBST, 0.1% Tween20, 0.24% Tris, 0.8% NaCl) washes were followed by incubation with horseradish-peroxidaseconjugated (HRP) IgG (1:3000) at room temperature for 2 hours. Labeled bands were imaged by
exposure to light sensitive film (GE Healthcare, Chalfont St. Giles, Buckinghamshire, UK)
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following color development with Amersham ECL prime western blotting detection reagents (GE
Healthcare). Target protein bands were to β-actin standards.
Table 6. Antibodies for flow cytometry and immunocytochemistry

Antibody Label

Marker
Expression

CD29

N/A

CD34

PE

CD44

FITC

CD90

PE

Goat
antimouse
IgG

FITC

β-actin

N/A

Sox-2

N/A

PPAR-γ

N/A

OPN

N/A

CD29

N/A

β1 integrin

CD44

N/A

Hyaluronic acid
receptor

HRP

Secondary
antibody

HRP

Secondary
antibody

Goat
antirabbit
IgG
Goat
antimouse
IgG

β1 integrin

Manufacturer

Cat No.

Species

Target
Species

Diluent

BD
Biosciences

610468

Mouse

Human

PBS

Hematopoietic
progenitor
(HSC)
Hyaluronic acid
receptor
Thy-1,
fibroblasts,
MSC, HSC

BD
Biosciences

559369

Mouse

Dog

PBS

eBiosciences

115440

Mouse

Dog

PBS

eBiosciences

125900

Mouse

Dog

PBS

Secondary
antibody

Sigma-Aldrich

F9006

Goat

Mouse

PBS

Thermo
Scientific
LifeSpan
BioSciences

RB-9421P0

Rabbit

Dog

TBS

LS-B4562

Rabbit

Dog

5% Skim
milk/PBS

LifeSpan
BioSciences

LS-B651

Rabbit

Dog

5%
BSA/TBS

LifeSpan
BioSciences

LS-B425

Rabbit

Dog

5%
BSA/TBS

610468

Mouse

Human

TBS

DGBOV2037

Mouse

Dog

TBS

Santa Cruz
Biotechnology

sc-2004

Goat

Rabbit

TBS

Santa Cruz
Biotechnology

sc-2005

Goat

Mouse

TBS

Cytoskeletal
protein
Transcription
factor
NHR/NR1
Thyroid
homone-like
Secreted
Phosphoprotein
1

BD
Biosciences
Monoclonal
Antibody
Center
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Table 7. Primer sequences
Lineage
Housekeeping

Primer
GAPDH

Sequence
F: TGGCAAAGTGGATATTGTCG
R: AGATGGACTTCCCGTTGATG

Accession No.
XM_003435649.2

F: TTCTCCAGCATTTCCACTCC
PPAR-γ
Adipogenic

R: AGGCTCCACTTTGATTGCAC

XM_005632014.1

F: TGTGTTGAAGCTGTGCCAAT
Leptin

R: CCCTCTGTTTGGAGGAGACA

XM_005628342.1

F: GGTGGTGGCTATGACTTTGG
Col1α1
Osteogenic

R: CAGTTCTTGGCTGGGATGTT

XM_005628344.1

F: TGTCTATACTGCAGGCCGGTG
OPG

R: TCAGGCAGAACTCAAGCTCCA

XM_003639448.2

For evaluation of surface marker protein expression, total protein was extracted with NP40 buffer (150 mM sodium chloride, 1.0% Triton X-100, 50 mM Tris, pH=8.0) from fresh and
cryopreserved P3 cells cultured in stromal media. Protein concentration determination and western
blot procedures were identical to above with the exception of incubation with primary antibodies
directed against CD29 (1:200) and CD44 (1:2000) at room temperature for 1 hour (Table 1)
followed by IgG-HRP (1:2000). Protein bands were quantified using ImageJ software (Rasband,
WS, ImageJ; National Institutes of Health, Bethesda, MD, http://rsb.info.nih.gov/ij).
2.2.10. Statistical Analysis
Statistical analyses were performed with commercially available software (SAS 9.2, Institute, Cary,
NC). Analysis of variance (ANOVA) models were used to evaluate cell surface marker
precentages, CD, DT, CFU frequency percentages and gene expression among tissue sources
within passages and among passages within tissue sources. Tukey’s post hoc tests were applied
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for multiple group comparisons (p<0.05). Normality and homogeneity of variance were assessed
with Shapiro-Wilk tests and residual plots.
2.3. Results
2.3.1. Adipocyte and ASC Ultrastructure (adipocytes, P1, tP1) - Transmission Electron
Microscopy
Adipocytes and ASCs had different morphologies from each other and between tissue sources.
There were large, unilocular lipid vacuoles that peripherally displaced cytoplasm and organelles
in adipocytes from both tissue sources. However, SUB adipocytes had numerous mitochondria
concentrated near the cell membrane compared to mitochondria distributed throughout the
cytoplasm in IFP adipocytes. Further, IFP adipocytes had abundant small lipid vacuoles (in
addition to the central vacuole) among mitochondria whereas SUB had fewer (Fig. 6). Cultured
ASCs were smaller than adipocytes, and they did not have central, large lipid vacuoles. Fresh IFP
and SUB ASCs had mitochondria clustered around the nucleus and small, cytoplasmic lipid
vacuoles, though IFP ASCs tended to have more vacuoles and fewer mitochondria. After
cryopreservation, IFP ASCs had many small lipid vacuoles and few mitochondria in the cytoplasm
compared to few lipid vacuoles in the cytoplasm and mitochondria clustered around the nucleus
in SUB ASCs (Fig. 6). Additionally, the relative number of mitochondria in cryopreserved SUB
ASCs appeared to be lower than in fresh ASCs based on subjective assessment.
2.3.2. Cell Expansion (P0-3, tP1-3)
The CDs of fresh and revitalized IFP and SUB ASCs decreased with passage, while the
corresponding DTs increased (Fig. 7). Significant differences were less incremental in fresh versus
cryopreserved cells with P0 and 1 tending to expand more quickly than P2 and 3. The CDs were
significantly lower for P0 SUB ASCs versus IFP ASCs. The CDs and DT were significantly lower
and higher, respectively, for cryopreserved P3 versus fresh ASCs from the same tissue source.
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Figure 6 Transmission electron microscopy (TEM) image of adipocytes and adipose derived
multipotent stromal cells (ASCs) from canine subcutaneous (SUB) and infrapatellar (IFP) adipose
tissues. Legend: 1 – nucleus, 2 – euchromatin, 3 – mitochondria, 4 – Golgi apparatus, 5 – lipid
droplet, 6 – lysosome. Scale bar = 2 μm.
2.3.3. Multipotentiality (P0, 1, 3, tP1, 3) – Limiting Dilution Assays and Pellet
Chondrogenesis
Based in histochemical staining, fresh and revitalized IFP and SUB ASCs showed robust
adipogenesis and osteogenesis for all passages evaluated. The CFU frequency percentage indicates
the percentage of cells capable of forming a colony of fibroblastic (CFU-F), osteoblastic (CFUOb) or adipogenic (CFU-Ad) lineage. Before and after cryopreservation, SUB and IFP ASCs
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showed similar CFU frequency percentages, and, though values tended decrease after
cryopreservation, they were not significantly different among fresh and cryopreserved cells from
the same tissues within passages (Fig. 8). In fresh and cryopreserved cells, the frequencies
decreased with passage and were significantly lower in P3 versus P0. For CFU-F, P0 and 1 were
significantly higher than P3, and for CFU-Ob, P0 was significantly higher than P1 which was
significantly higher than P3. The only difference in behavior between cell sources was that P1
SUB ASC CFU-Ad was significantly lower than P0 while IFP ASC CFU-Ad was significantly
higher in P0 and 1 than P3 in fresh cells. Fresh and cryopreserved SUB and IFP ASCs displayed
characteristic chondrogenic differentiation including glycosaminoglycan (GAG) deposition and
tissue organization, both of which were absent in the control group (Fig. 9).
2.2.4. Immunophenotype -Flow Cytometry (P0, 1, 3, tP1, 3)
The majority of fresh cells from both adipose tissue depots were CD29+, CD44+, CD90+ and
CD34- for all passages evaluated (Fig. 10). The percentage of CD29+ ASCs was significantly
higher in P0 compared to 1 and 3 for fresh SUB and IFP ASCs (Fig. 10a). There were significantly
higher percentages of CD29+ and CD44+ ASCs in cryopreserved P1 versus P3 for both tissue
sources (Fig. 10a, c). Fresh P1 SUB and P3 ASCS from both tissue sources had significantly higher
percentages of CD29+ cells than the same passages after cryopreservation (Fig. 10a). There were
significantly higher percentages in of CD44+ P1 ASCs after cryopreservation compared to fresh
cells within tissue source (Fig. 10c). However, cryopreserved P3 ASCs had significantly lower
percentages of CD44+ than fresh. There were significantly fewer fresh CD90+ P3 SUB ASCs
compared to cryopreserved (Fig. 10d).
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Figure 7. Cell doublings (CD) and doubling time (DT) (mean ± SEM) for fresh (a, b), revitalized
(c, d) and both fresh and revitalized canine ASCs (e, f) from SUB and IFP adipose tissues.
Columns with asterisks within passages are significantly different between cell tissue source (a),
columns with distinct superscripts within cell tissue source (a-d), and columns with distinct
superscripts within passage (e, f) are significantly different (P < .05).
2.2.5. Gene Expression - RT-PCR (P0, 1, 3 tP1, tP3)
With increasing passage, adipocytic and osteoblastic target gene expression decreased
significantly in both fresh and cryopreserved cells (Fig. 11). Both P1 and tP1 SUB and IFP ASCs
had significantly higher levels of PPAR-γ and leptin after adipogenic induction as well as OPG
and Col I after osteogenic induction compared to P3 and tP3 (Fig. 11a, b). Additionally, PPAR-γ
expression was significantly lower in P3 ASCs following induction after cryopreservation in cells
from both tissue sources.
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Figure 8. Colony forming unit (CFU) frequencies (mean ± SEM) for fresh (a, b, c) and revitalized
(d, e, f) canine ASCs from subcutaneous (SUB) or infrapatellar (IFP) adipose tissue after culture
in stromal (CFU-F), osteogenic (CFU-Ob), or adipogenic (CFU-Ad) medium. Columns with
different superscripts within cell source are significantly different among passages (P < .05).

Figure 9. Light photomicrographs of fresh P3 canine ASCs from SUB (a, b) and IFP (c) after
pellet culture in stromal (a) or chondrogenic (b, c) medium. Alcian blue staining of proteoglycans
with nuclear fast red counter stain. 63× magnification. Scale bar = 20 μm.
2.2.6. Protein Expression – Immunocytochemistry, western Blot (P3, tP3)
Immunocytochemistry. Cell surface marker expression (CD29+, CD44+, CD90+, and CD34-) was
confirmed with immunocytochemistry in all ASCs before and after cryopreservation (Fig. 12).
Western blot. The mean gray value for each band was measured to quantify protein bands. The
measured values for band increased with increasing protein expression. The PPAR-γ and OPN
protein expression increased in P3 and tP3 ASCs cultured in adipogenic or osteogenic induction
medium, respectively, while SOX2 decreased (Fig. 13b, c, e and f). Additionally, SOX2 protein
expression decreased after cryopreservation in cells from both tissues cultured in stromal medium
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(Fig. 13d). Cryopreserved P3 SUB and IFP ASCs had significantly lower protein expression of
CD29 and CD44 compared to fresh P3 ASCs (Fig. 14).

Figure 10 Percentages (mean ± SEM) of CD29+ (a), CD34- (b), CD44+ (c), and CD90+ (d) fresh
and revitalized (-R) ASCs from canine SUB and IFP adipose. Columns connected by lines with
asterisks are significantly different within passage and columns with distinct superscripts within
cell tissue source and treatment (fresh or cryopreserved) are significantly different among passages
(p<.05).
2.5. Discussion
Paired comparisons of fresh and cryopreserved ASCs from canine SUB and IFP adipose tissue in
this study showed comparable in vitro expansion and multipotentiality up to passage 3. Fresh and
cryopreserved canine ASC expansion metrics, CD and DT, and CFU frequency percentages had
similar values and cell passage changes to previous reports using the same techniques [77, 181].
However, detectable effects of cryopreservation on ultrastructure, immunophenotype, and both
surface marker and transcription factor expression indicates that cryopreserved canine ASCs may
not be directly interchangeable with fresh. In spite of the potential impact of cryopreservation on
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ASC potential, study results suggest that ASCs from either tissue source are promising candidates
for future studies to optimize cell isolation, cryopreservation, tissue regeneration strategies and
therapeutic applications.

Figure 11 Fold change (mean ± SEM) of adipogenic (a, b) and osteogenic (c, d) lineage target
genes in fresh and revitalized (t) canine ASCs from subcutaneous (SUB) and infrapatellar (IFP)
adipose tissue cultured in induction medium. Values are relative to the reference gene GAPDH
and to cells cultured in stromal medium. OPG = Osteoprotegerin, Col1α1 = Collagen Iα1.
Columns with different superscripts within cell tissue source are significantly different (P < .05).
The ultrastructure observed in this study was similar to those reported for other species
[185, 186] including abundant cytoplasmic mitochondria [185] and many small lipid vacuoles [186]
in brown and white adipocytes, respectively. The characteristics are consistent with lipid energy
storage [178, 187] and the role of the inner mitochondrial membrane in thermogenesis [188, 189].
Mature adipocytes are post-mitotic, so cell precursors rapidly differentiate in response to energy
demands [190, 191]. As such, immature cells at many stages of differentiation assume
characteristics of the mature cells as observed in the ASCs in study. This is also consistent with
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the current knowledge that white and brown adipocytes are derived from distinct precursor
populations [192-194].

Figure 12. Fluorescent photomicrographs of SUB and IFP fresh and revitalized canine P3 ASCs
from subcutaneous (SUB) and infrapatellar (IFP) adipose tissue labeled with cell surface markers
indicated. 40 × magnification. Scale bar = 50 μm.
Fewer mitochondria surrounding the nucleus after cryopreservation may indicate greater
maturity in revitalized cells. Mitochondrial localization is a characteristic of mammalian cleavagestage embryos that is strongly indicative of stem cell competence, and alterations may be
associated with diminished pluripotency [195, 196]. The percentage of cells with perinuclear
mitochondria decreased while that of cells with lipid droplets increased with cell passage in an
adult primate adipose derived stem cell line [195]. Reduced perinuclear mitochondria were
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associated with lower oxygen consumption and higher adenosine triphosphate consistent with
lower energy requirements of differentiated cells with slower metabolism. The decrease in
mitochondria after cryopreservation in this study was a subjective assessment, so the magnitude
of the change could not be quantified or directly compared between ASC tissue sources. A
consistent finding was that mitochondrial numbers were consistent within cells from specific tissue
sources and reduced following cryopreservation.

Figure 13. Western blot image of proteins from fresh and revitalized (-R) canine P3 ASCs from
subcutaneous (SUB) and infrapatellar (IFP) adipose tissue after culture in stromal (a), adipogenic
(b) or osteogenic (c) medium with corresponding graphs indicating relative density (d-f). PPARγ = Peroxisome proliferator-activated receptor-γ, SOX2 = Sex determining region Y box-2, OPN
= Osteopontin.

Figure 14. Western blot image (a) and corresponding relative density graph (b) of fresh and
revitalized (-R) P3 ASCs following culture in stromal medium.
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Current knowledge suggests that loss of mitochondria may be a result of organelle
disruption and/or cell selection by the cryopreservation process [37, 43, 197]. The potential for
cell selection is further supported by increased numbers of lipid vacuoles post-cryopreservation.
The cryoprotectant used in this study, DMSO, is a standard component of cryopreservation media
for cell protein and membrane stabilization [21, 37, 43] and to prevent intracellular ice formation
[37, 43]. At non-toxic DMSO levels, and despite a slow freezing process, intracellular ice
formation is not fully prevented [198-200]. Fewer mitochondria and more abundant lipid vacuoles
are associated with greater cell maturity as indicated above [195, 196]. Based on the these findings,
it is possible that the higher lipid content of more mature cells within the heterogeneous cell isolate
confers a higher transition temperature during freezing [201]. Together with the DMSO, the higher
lipid content may protect against ice formation and thereby select for greater cell maturity. Further
studies are required for confirmation of this finding.
Additional distinctions between fresh and cryopreserved ASCs were decreases in cell
percentages expressing CD29 and CD44, multipotent stromal cell phenotypic markers that are
stably expressed in ASCs [75]. Exceptions included variable CD90 expression and an initial
increase in the number of CD44+ cells in P1 cryopreserved cells. Previous studies identified
increased CD90 expression in revitalized cells versus fresh MSCs from human umbilical cord and
rat adipose and bone marrow tissues [202, 203]. It is generally accepted that due to the presence
of CD90 in the endothelial population, changes in expression are best interpreted in combination
with the expression of other surface markers [75]. The initial increase in CD44 expression in
revitalized cells that was not paralleled in CD29 expression could be due to an increase in CD44
expression by cells that do not express CD29, potentially due to high protein concentrations in
FBS. The principle ligand of CD44 is hyaluronic acid (HA) [204]. Murine cumulus cell-oocyte
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complexes retain HA in the extracellular matrix and expand in the presence of FBS [205]. In
contrast, HA is released into the culture medium in the absence of FBS, the cells dissociate and
attach to culture ware as individual cells [205]. Hence, high concentrations of FBS in the freezing
medium may increase local HA concentrations and stimulate upregulation of the receptor in cells
in the passage immediately post revitalization.
In general, there were fewer cells expressing CD29 and CD44 after cryopreservation within
passages, with the exceptions discussed above, and passage effect tended to be more profound in
cryopreserved cells.

Lower CD29 and CD44 expression was confirmed by western blot.

Upregulation of apoptotic genes and increased apoptosis is associated with cryoprotectants and the
cryopreservation process itself [19, 206]. Additionally, DMSO concentrations of 10% or higher
reduce the number of porcine ASC fibroblastic colony forming units and increase cell apoptotic
gene expression after cryopreservation [21]. A previous study confirmed that the expression of
adhesion molecule CD62L [207] was lost while CD57, an apoptosis protein [208], increased after
cryopreservation in CD4+ and CD8+ T cells [206]. Based on this established information,
decreases in CD44 and CD29 post cryopreservation suggests a similar and important effect on
canine SUB and IFP ASCs that should be considered for cell therapy and tissue regeneration
strategies.
Decreases in SOX2 protein expression and PPAR-γ gene expression observed in this study
further suggests that cryopreservation may impact ASC plasticity. Both are early transcription
factors, SOX2 is associated with the multipotent ASC phenotype [209, 210] and PPAR-γ is nuclear
receptor that controls energy metabolism and cell differentiation and is highly expressed in [211,
212]. It is further controls transcription of genes for radical oxygen species detoxification enzymes
[213]. Recently, mitochondria were shown to be central to oligodendrocyte differentiation and
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major targets of PPAR-γ agonist protection against inflammatory cytokine damage [211]. The fact
that PPAR-γ protein expression was not detectably lower in P3 ASCs after cryopreservation is
likely because gene and protein expression is not necessarily parallel, and changes in gene
expression typically precede alterations in protein levels. Lower expression of both SOX2 and
PPAR- γ in addition to the reduced presence of cellular mitochondria may indicate greater cell
vulnerability to inflammatory byproducts in addition to decreased differentiation capacity.
As a whole, these in vitro study results indicate that there are few differences between
canine SUB and IFP ASCs before and after cryopreservation. The impact of cryopreservation on
the cells is strongly supported at the genetic, protein and ultrastructural levels and appears to be
consistent with lower expansion capacity and plasticity associated with greater cell maturity.
Cryopreservation is vital to storage and transport of progenitor cells [41, 42, 214, 215]. It is
especially important given the growing recognition of the importance of cell phenotype for specific
therapeutic and tissue regeneration purposes [216-218]. Continued efforts to minimize the impact
of cryopreservation on ASC properties as well mechanisms to clearly delineate and anticipate the
effects will continue to improve cell-based therapies and tissue regeneration.
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CHAPTER 3. COLLAGEN AND HYDROXYAPATITE SCAFFOLDS ACTIVATE
DISTINCT OSTEOGENESIS SIGNALING PATHWAYS IN ADULT HUMAN
ADIPOSE-DERIVED MULTIPOTENT STROMAL CELLS

3.1. Introduction
Bone grafts are a standard therapy to augment osteogenesis, but autografts can be complicated by
limited graft material and donor site morbidity and allografts by potential disease transmission and
immunogenicity [219, 220]. Bone graft substitutes offer plentiful, risk free options that are not
influenced by donor condition [221]. ASCs enhance the osteoinductive and osteoconductive
properties of commercially available, bone graft substitutes [219, 222]. Advantages like a greater
number and volume of tissue harvest depots in addition to higher stromal cell density and
comparable plasticity to bone marrow derived multipotent stromal cells make ASCs an appealing
choice for MSC-scaffold constructs [223]. However, recipient factors like age, sex and health also
influence the ability of ASCs to promote bone formation [224, 225]. Customization of ASC-bone
graft constructs for individual morbidities will elevate current standards of care.
Osteogenesis is a dynamic, multifaceted process with intersecting cell signaling cascades
that direct cell recruitment, differentiation, maturation and behavior [226]. Bone forming capacity
is reduced by cell signaling pathway modifications from disease or age [226-228]. Osteoblastic
and osteoclastic activity is regulated by the ratio of osteoprotegerin (OPG) and receptor activator
of nuclear factor kappa β ligand (RANKL), and alterations are thought to contribute to abnormal
bone healing and maintenance in several bone diseases [226]. Activity levels of CB1 and CB2 are
implicated in age related changes in bone turn over and mass [227-230]. Notably, OPG stimulation
triggers Wnt/β catenin signaling while the cannabinoid receptors appear to work via adrenergic
signaling [226, 231, 232]. This knowledge provides an opportunity to explore targeted restoration
of specific osteogenic pathways with ASC-bone graft constructs. Specifically, the ability to
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confidently restore cell signaling most strongly associated with compromised bone formation of
individual patients will contribute to improved and customized treatment options.
Commercially available bone grafts are composed of inorganic and organic components to
direct cell differentiation and extracellular matrix (ECM) production [219, 221, 233-236]. The type
and amount of inorganic crystals as well as their ratios to each other and proteins stimulate distinct
gene expression [142, 234, 237-241]. Cells also behave differently on identical scaffolds when
cultured in environments designed to maintain a primordial state versus those to promote
differentiation and maturation [242, 243]. Mechanisms to “prime” cells by short term exposure to
induction reagents may accelerate differentiation stimulated by the scaffold [244].
We propose that it is possible to reproducibly select for specific ASC osteogenesis
signaling pathways with scaffold composition and/or culture medium. To evaluate this potential,
in vitro human adult ASC viability, gene expression and ECM deposition and organization was
determined on bone graft scaffolds composed of pure type I collagen, type I collagen and one
mineral, β tricalcium phosphate, and type I collagen with two minerals, β tricalcium phosphate and
hydroxyapatite. Cell-scaffold combinations were determined following culture in stromal (S),
osteogenic (O) or short term osteogenic followed by stromal medium (OS) for up to 28 days. The
following two-part hypothesis was tested: 1) Identical ASC isolates on distinct bone graft scaffolds
demonstrate unique viability, differentiation, ECM production and gene expression in the same
culture conditions; 2) Identical ASC-bone graft scaffold combinations have unique cell viability,
differentiation, ECM production, and gene expression when cultured in S, O or OS medium. The
overarching goal of this investigation was to identify ASC-scaffold combinations for local,
targeted restoration of genetic expression and ECM deposition to enhance bone healing in the
presence of specific bone pathology.
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3.2. Materials and Methods
3.2.1. Ethics Statement All procedures were approved by the Institutional Review Board
(Protocol #00006218) and informed consent was obtained prior to tissue use.
3.2.2. Study Design Commercially available human ASCs (LaCell LLC, New Orleans, LA) were
culture expanded to cell passage (P) 3. Cell viability was quantified with confocal laser microscopy
immediately after loading and 7 and 14 days of culture. Gene expression (alkaline phosphatase
(ALP), osteocalcin (OCN), cannabinoid receptors one and two (CB1, CB2), osteoprotegerin
(OPG), nuclear factor kappa β ligand (RANKL)) and ECM deposition (double stranded DNA
(dsDNA), total protein, sulfated glycosaminoglycan (sGAG), total collagen) in ASC-scaffold
constructs were quantified prior to and after 7, 14 and 28 days of culture in S, O and OS medium.
Scanning electron microscopy (SEM) was used to assess scaffolds without cells and extra-cellular
matrix on constructs after 7 and 14 days of culture. Specifically, the sample set consisted of ASCs
from 3 donors that were each loaded on three distinct scaffolds and immediately assessed or
evaluated after culture in three different media for 7, 14 or 28 days for all measures except cell
viability and SEM, which were each performed after the first two. A minimum of three replicates
of each assay were performed for all samples.
3.2.3. Scaffold Materials Bone graft scaffolds were composed of type I bovine collagen (C,
Avitenetm Ultrafoamtm, Davol, Inc., Warwick, RI), 15%

hydroxyapatite, 85% β-tricalcium

phosphate, type I bovine collagen (HT, MasterGrafttm Matrix, Medtronic Sofamor Danek, Inc.,
Minneapolis, MN) and 20% type I bovine collagen, 80% β-tricalcium phosphate (CT, Vitoss®
Scaffold Foamtm, Stryker Corp., Kalamazoo, MI). Scaffolds were aseptically cut into 5x5x3 mm
(C), 5x5x5 mm (HT), and 5x5x4 mm (CT) rectangular blocks for constructs.
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3.2.4. Cells Frozen ASC aliquots (LaCell, LLC, New Orleans, LA) from 1 male and 2 females
(47.3 ± 7.0 years (mean ± SEM), 28.3 ± 4.1 BMI) in cryopreservation medium (LaCryoM-100,
LaCell, LLC) were used for this study [41, 42]. Aliquots were thawed at 37oC with agitation for
2-3 min, combined with 5 ml of stromal medium (S, DMEM/F12 (Hyclone, Logan, UT), 10%
characterized fetal bovine serum (Hyclone), 1% antibiotic (MP Biochemicals, Solon, OH)) and
centrifuged (300xg, 5 min). Cells were culture expanded to P3 in S medium (37oC, 5% CO2) with
an initial seeding density of 5x103 cells/cm2, media changes every three days and passage at ~70%
confluence [181].
3.2.5. Cell Loading Passage 3 ASC suspensions (17.0 x 106 cells/120 mL corresponding to 57,000
cells/mm3 of total scaffold volume) from each donor were loaded onto 3 scaffolds of each
composition on 3, 4-inch-long, 22g spinal needles suspended from a rubber stopper in 100 ml
spinner flasks (Bellco® Biotechnology, Newark, NJ). The process was repeated 5 times for each
donor (15 samples/scaffold/donor). Scaffolds were oriented with the shortest dimension
perpendicular to the needle long axis. Spinner flasks were maintained in a humidified incubator
(37C, 5% CO2) for 2 h with a magnetic stir bar rotating at 70 rpm. Following cell loading, loading
efficiency was calculated from the number of cells remaining in each flask. Samples were
evaluated or transferred to 1 of 3 media in six well culture plates (Thermo Fisher Scientific,
Waltham, MA, USA): 1) stromal (S, DMEM/F12 (Hyclone, Logan, UT), 10% characterized fetal
bovine serum (Hyclone), 1% antibiotic (MP Biochemicals, Solon, OH)); 2) osteogenic (O, stromal
+ 10 mM β-glycerophosphate (Affymatrix, Santa Clara, CA), 20 nM dexamethasone (SigmaAldrich, St. Louis, MO), 0.05 mM ascorbic acid (Sigma-Aldrich)); or 3) osteogenic for 48 h
followed by stromal (OS).
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3.2.6. Cell Viability (Days 0, 7, 14) Cell viability was quantified on 20 digital photomicrographs
(TIFF,10x) of the construct surface, 250 µm apart, that were generated with a spectral confocal
laser scanning microscope digital imaging system (Leica TCS SP2, Leica Microsystems, Buffalo
Grove, IL, USA). Constructs were rinsed with phosphate buffered saline and incubated at room
termperature in darkness with assay reagents (Invitrogen LIVE/DEAD® Viability/Cytotoxicity kit,
Thermo Fisher Scientific) for 30 min [245]. The numbers of live (green) and dead (red) cells in
each section were quatified (Image-Pro, Media Cybernetics, Bethesda, MD) to calculate live cell
percentage (live cells/total cells x 100) for each construct.
3.2.7. Gene Expression (Days 7, 14, 28) Total RNA was extracted from cell-scaffold constructs
(RNeasy Plus Mini Kit, Qiagen, Germantown, MD) and cDNA synthesized (QuantiTect Reverse
Transcription Kit, Qiagen). Quantification of target gene levels (ALP, OCN, CB1, CB2, OPG
RANKL) was performed with a 384-well plate sequence detection system (ABI Prism 7900HT,
Applied Biosystems, Carlsbad, CA) using SYBR Green Supermix (Bio-Rad Laboratories,
Hercules, CA) and validated primer sequences (Table 8). The 2-ΔΔCt values were determined
relative to the reference gene glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and target
gene expression immediately after cell loading (Day 0). The OPG/RANKL ratio was determined
in individual samples by dividing the OPG fold change by the RANKL fold change.
3.2.8. Compositional Analysis (Days 7, 14, 28) Cell-scaffold constructs were lyophilized (-55o C,
0.2 mbar, 4 hr) and then incubated in a papain digest (2 mg papain (MP Biomedicals)/g lyophilized
sample, 20 mM L-cysteine (MP Biomedicals), 9 mM di-sodium EDTA (Sigma-Aldrich), 3.6 M
sodium acetate (Sigma-Aldrich)) at 60o C for 10 hrs. Following centrifugation of the solution (4000
× g, 10 min), the supernatant was collected and stored at -80oC. Samples were thawed for 1 min
in a 37°C water bath immediately prior to compositional analysis. All assays were performed
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according to manufacturer’s instructions or published methods for microtiter plate analysis,
performed in triplicate and fluorescence or absorbance quantified with a multiwell plate reader
(Synergy HT, BioTek Instruments, Winooski, VT). Composition fold change relative to Day 0 was
calculated as Cf/Ci (Ci: content immediately after cell loading; Cf: content after 7, 14, or 28 days
of culture).
Table 8. RT-PCR primer sequences
Gene Name

Sequence

Accession No.

F: CGGGATTTGGTCGTATTG
GAPDH

NM_001289746.1
R: CTGGAAGATGGTGATGGG
F: TTCTTCTTGCTGGTGGAG

ALP

XM_017000903.1
R: GGCTTCTTGTCTGTGTCA
F: AGAGCATGACCGATGGATTC

ColIαI

XM_005257059.4
R: CCTTCTTGAGGTTGCCAGTC
F: GCAGAGTCCAGCAAAGGT

OCN

NM_199173.5
R: CCCAGCCATTGATACAGG
F: CGATACACTTGGCATTGACG

CB1

XM_006715330.3
R: AACCACGAGCAAAGGAGAGA
F: ATTGGCAGCGTGACTATG

CB2

XM_011540629.2
R: GAAGGCGATGAACAGGAG
F: AACCCCAGAGCGAAATAC

OPG

NM_002546.3
R: AAGAATGCCTCCTCACAC
F: ATCGTTGGATCACAGCACATCA

RANKL

XM_017020803.1
R: TGAGCAAAAGGCTGAGCTTCA
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GAPDH: glyceraldehyde 3-phosphate dehydrogenase; ALP: alkaline phosphatase; ColIαI:
collagen 1α1; OCN: osteocalcin; CB1: cannabinoid receptor type I; CB2: cannabinoid receptor
type II; OPG: osteoprotegerin; RANKL: receptor activator of nuclear factor kappa-B ligand.
Double stranded DNA (dsDNA) – PicoGreen: Total dsDNA was quantified using a
commercially available kit (Quant-iT PicoGreen dsDNA Assay Kit, Thermo Fisher Scientific).
Fluorescence was measured at 480 and 520 nm and dsDNA quantified on a lambda DNA standard
curve.
Total Collagen – Hydroxyproline [246]: An equal volume of 6N HCl was added to samples
or serial dilutions of trans-4-hydroxy-L-proline (ACROS OrganicsTM, Morris Plains, NJ) and
incubated overnight at 110oC. Samples were incubated for 5 min at room temperature following
addition of 500 µl of oxidant solution (0.178g Chloramines T in 15 ml of isopropanol and 10 ml
of ddH2O) and then 25 ml of acetate citrate buffer (120 g sodium acetate trihydrate, 12 ml acetic
acid, 50 g citric acid monohydrate, 34g NaOH in 1L ddH2O, pH 6.0). Subsequently 500 µl of
Ehrlich’s reagent (1g p-dimethylaminobenzaldehyde (Sigma-Aldrich) in 20 ml isopropanol with
6.6 ml perchloric acid and 15.6 ml ddH2O) was added and samples incubated at 60oC for 12 min.
Following 4 min of cooling on ice, samples were transferred to a 96 well microtiter plate and
absorbance read at 550 nm.
Sulfated Glycosaminoglycan (sGAG) - Dimethylmethylene Blue (DMMB) [247]: Sodium
formate was added to 1, 9- DMMB in ethanol and the pH adjusted to 3.0 with formic acid to create
the sGAG assay buffer. Samples were combined with buffer in a microtiter plate, and the sGAG
concentration determined from absorbance at 520 nm and a chondroitin sulfate standard curve.
Total Protein – Lowry Assay [248]: Samples were mixed with Biuret’s reagent (SigmaAldrich) and maintained at room temperature for 12 min. The absorbance at 650 nm was measured
after 30 min at room temperature following addition of Folin-Ciocalteu’s reagent (Sigma-Aldrich).
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Total protein concentration was determined on a bovine serum albumin (Sigma-Aldrich) standard
curve.
3.2.9. Ultrastructure (Days 0, 7, 14): Standard procedures were used to prepare samples for SEM.
Briefly, they were fixed in 0.5% glutaraldehyde in 0.1M sodium cacodylate buffer (pH 7.4) for
one hr and then for 48 hr in 0.1% osmium tetroxide. Samples were dehydrated in a series of ethanol
solutions (50-100%), and, following critical point drying, sputter coated with gold.
Photomicrographs were generated of SEM images (Quanta 200, FEI Company, Hillsboro, OR).
3.2.10. Statistical Analysis: All results are presented as least squares (LS) mean ± SEM. Statistical
analyses were performed with commercially available software (SAS 9.4, Institute, Cary, NC). A
3×3×3 factorial analysis of variance followed by pairwise tests of least-squares means was used to
compare gene expression and composition measures among time points, scaffolds and media (p <
0.05). Normality and homogeneity of variance were assessed with Shapiro-Wilk tests and residual
plots.
3.3. Results
3.3.1. Cell Viability (Days 0, 7, 14) Overall cell loading efficiency was 80.6 ± 3.4% and viability
was similar among scaffolds immediately after loading (Day 0, Fig. 12A). After 7 days of culture,
the percentage of live cells was not significantly different among constructs irrespective of medium
(Fig. 12B). After 14 days, the percentage of viable cells on CT constructs in S medium was
significantly lower than C constructs (Fig. 12C).
3.3.2. Gene Expression (Days 7, 14, 28)
In general ALP expression tended to decrease and OCN increase with culture time while Col1α1
increased with culture S medium (Fig. 16 & 17). The changes in ALP and OCN expression were
most pronounced in HT scaffolds cultured in O medium. Summarily, there was highest expression
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of ALP in HT constructs cultured in OS and O media after 7 days of culture. By 14 days of culture,
ALP expression was highest in HT and C constructs in O medium. After 28 days, the highest ALP
expression was in C constructs in O medium. The Col1α1 expression was highest in C and HT
constructs in O and OS media after 7 days and in S medium after 14 and 28 days of culture. By
day 28, C and HT constructs cultured in O media had the highest OCN expression.

Figure 15 Cell percentages (LS mean ± SEM) for type I bovine collagen (C), hydroxyapatite + β
tricalcium phosphate + type I bovine collagen (HT) and β tricalcium phosphate + type I bovine
collagen (CT) scaffold-ASC constructs after 0 (A), 7 (B), and 14 (C) days of culture in stromal (S),
osteogenic for 48 hours followed by stromal (OS) or osteogenic (O) medium. Significant
differences are indicated by different column superscripts within graphs (p<0.05).
With time, CB1 and OPG/RANKL expression tended to increase in constructs cultured in
O medium (Fig 16 & 18). The CB1 expression was highest in C constructs in O medium at all time
points. Expression of CB2 was highest in C and CT constructs after 14 days of culture in all media.
The OPG/RANKL expression ratio was highest in on HT constructs in all media after 14 and 28
days, though the greatest expression was reached after 28 days in O medium.
3.3.3. Compositional Analysis (Days7, 14, 28) (Fig 19 & 20)
Double stranded DNA (dsDNA) – PicoGreen): The dsDNA fold change tended to remain
the same or increase slightly with time. It was highest on HT constructs in O medium after 7 days,
in O and OS media after 14 days and in S and OS media after 28 days of culture.
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Figure 16. Fold change (2-ΔΔCt) in ALP, Col1α1, OCN, CB1, CB2, OPG/RANKL (mean ± SEM)
gene expression in C, HT, and CT ASC-scaffold constructs cultured in stromal (S), osteogenic for
48 hours followed by stromal (OS) or osteogenic (O) medium for 7, 14, and 28 days. Fold change
was calculated relative to the reference gene glyceraldehyde 3-phosphate dehydrogenase (GAPDH)
and target gene expression in constructs immediately after cell loading. Columns with different
superscripts within constructs and media are significantly different among time points.
Total Collagen – Hydroxyproline: Total collagen fold change also increased slightly or
remained static with time. Fold change was highest on C scaffolds for all time points and media.
Sulfated Glycosaminoglycan (sGAG) - Dimethylmethylene Blue (DMMB): The sGAG
fold change tended to increase with time in C and HT constructs cultured in O and OS media. It
was highest on HT constructs in OS and O medium after 7 days of culture and on C constructs
after 28 days of culture in the same media.
Total Protein – Lowry Assay: Total protein fold change was primarily evident in C
constructs, and it was highest on C constructs in S and O media after 14 days and in OS and O
media after 28.
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Figure 17 Alkaline phosphatase (ALP), collagen IαI (ColIαI) and osteocalcin (OCN) (LS mean ±
SEM) expression in type I bovine collagen (C), hydroxyapatite + β tricalcium phosphate + type I
bovine collagen (HT), and β tricalcium phosphate + type I bovine collagen (CT) scaffold-ASC
constructs cultured in stromal (S), osteogenic for 48 hours followed by stromal (OS) or osteogenic
(O) medium for 7, 14, or 28 days. The 2-ΔΔCt values are reported relative to the reference gene
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and target gene expression in constructs
immediately after cell loading. Columns with distinct superscripts are significantly different
among constructs within culture medium and those with different numbers of asterisks (*) are
significantly different among culture medium within constructs (p<0.05).
3.3.4. SEM
Following cell loading, collagen fibrils tended to fuse with each other or other scaffold
materials (Fig. 21). Amorphous matrix deposition was apparent in C constructs in S and O medium
after 7 and 14 days of culture. In HT constructs, there was considerably more loosely organized,
fibrous ECM following culture in S versus O medium and the amount increased with culture time.
Mineralized scaffold material tended to be most prevalent in CT constructs. The ECM was more
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fibrous in CT constructs cultured in S versus O medium after 7 and 14 days of culture, but
deposition was marginal compared to other constructs. Overall ECM deposition and organization
was greatest in CT constructs cultured in O medium for 14 days.

Figure 18. Cannabinoid receptors type I (CB1) and II (CB2), and the ratio of osteoprotegerin and
the receptor activator of nuclear factor kappa beta ligand (OPG/RANKL) (LS mean ± SEM)
expression in the same scaffolds under identical culture conditions as Figure 2. Columns with
distinct superscripts are significantly different among constructs within culture medium and those
with different numbers of asterisks (*) are significantly different among culture medium within
constructs (p<0.05).
3.4. Discussion
The results of this study indicate that HT and C scaffolds in O medium support more robust ASC
osteogenesis than CT scaffolds. This was evidenced by early increases in ALP expression, later
increases in OCN expression, and ECM deposition and ultrastructure. Similar genetic expression
and ECM deposition with higher collagen content on C scaffolds suggests comparable, though
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potentially slower osteogenesis and a strong propensity for a more fibrous matrix ultrastructure
compared to HT scaffolds. A notable distinction between the cell-scaffold constructs was
significantly higher CB1 expression on C scaffolds and OPG/RANKL expression on HT scaffolds
throughout the majority of the study. Together these results suggest that it is possible to customize
ASC osteogenic cell signaling for enhanced bone formation based on bone pathology.

Figure 19. Fold change (mean ± SEM) in dsDNA, total collagen, sGAG and protein in C, HT, and
CT ASC-scaffold constructs cultured in stromal (S), osteogenic for 48 hours followed by stromal
(OS) or osteogenic (O) medium for 7, 14, and 28 days. Individual values (unitless) were calculated
relative to Day 0 as Cf/Ci where Ci is content immediately after cell loading and Cf is content after
7, 14, or 28 days of culture. Columns with different superscripts within constructs and media are
significantly different among test time points.
The time course of ALP and OCN expression within HT constructs in O medium is
consistent with osteoblastic differentiation and maturation [249, 250]. Hydroxyapatite (HA) in the
HT scaffold may have been responsible for the initial enhanced ALP expression over the other
scaffolds since HA stimulates human ASC and bone marrow derived multipotent stromal cell
(BMSC) ALP expression [251, 252] and ASC osteogenic differentiation [253, 254]. The earliest
increase in ALP expression in this study was in O medium; however, the higher ALP in HT
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constructs cultured in OS medium for 7 days and S medium for 14 days further supports the effect
of the scaffold on the cells. Increased expression of ALP and OCN in C constructs also suggests
that collagen promotes osteoblastic ASC differentiation and maturation in O medium, though
potentially not as robustly as HA [118, 255]. This is further supported by lack of a decrease in
ALP expression in C constructs [245]. Genes for this study were selected to distinguish between
early osteoblastic differentiation (ALP), osteoblastic maturation (OCN), and osteoblastic activity
(COL1α1) for comparisons among treatments [256-258]. The focus of this study was on early ASC
direction and ECM production versus bone formation that is better described by later stage genes
[259].

Figure 20. Fold change in dsDNA, total collagen, sulfated glycosaminoglycan (sGAG) and protein
content (LS mean ± SEM) in the same constructs and media as Figure 2 after 7, 14 or 28 days of
culture. Columns with distinct superscripts are significantly different among constructs within
culture medium and those with different numbers of asterisks (*) are significantly different among
culture medium within constructs (p<0.05).
Lower osteogenic gene expression and ECM deposition within CT constructs may be due
tricalcium phosphate dissolution based on previous reports of lower proliferation and viability of
undifferentiated cells on comparable scaffolds [260]. Since lower cell viability was only detected
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in S medium after 14 days, cell loss may not be the strongest contributor to the observed differences.
Another possibility is that the high mineral content caused cell membrane damage or interfered
with cell attachment required for differentiation, maturation and ECM production [261-263].
Though surface roughness usually has a positive relationship with osteoblastic differentiation and
matrix production, it can be inhibitory beyond a certain point [264-266].

Figure 21. Scanning electron photomicrographs of human ASC-scaffold constructs composed of
bovine collagen type I (C), hydroxyapatite + β-tricalcium phosphate + bovine collagen type I (HT)
and β tricalcium phosphate + bovine collagen type 1 (CT) before (Pre-Cell Loading) and after
(Post Cell Loading) spinner flask cell loading and after 7 (Day 7) and 14 (Day 14) days of culture
in stromal (S) or osteogenic (O) medium. Black arrows: mineralized scaffold; yellow arrows:
collagen fibrils; two-stripe black arrows: extra-cellular matrix; three-stripe black arrows: scaffold.
Genetic expression is a standard mechanism to evaluate and compare cell characteristics
that is important to quantify changes induced by medium or scaffold as in this study [267]. Genetic
expression does not entirely reflect cell function in terms of matrix production [268], a central
point of directed osteogenesis [263]. Extracellular matrix production is central to the selfperpetuating cycle of ossification [269]. Determination of differences in ECM content provides a
mechanism to assess and quantify the process and provide a more comprehensive evaluation of
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treatment effects on cell behaviors than genetic analysis alone [270, 271]. Generally, increases in
dsDNA suggest cell proliferation associated with lack of differentiation [263]. Proteoglycan,
collagen and protein synthesis occurs throughout ossification primarily from osteoblastic ECM
production [269]. As such, the ECM content and ultrastructure helps to confirm tissue changes
suggested by gene expression.
While there was some evidence of osteogenic stimulation from culture in OS medium, it
did not support the same level as continuous O medium culture. The short term exposure in this
study may not have been sufficient to induce osteoblastic differentiation in the entire cell
population within the scaffolds since isolates may have contained cells at various stages of
differentiation.[244] Nonetheless there was a genetic effect of short term osteogenic medium
exposure as indicated by higher ALP expression at day 7 on HT scaffolds cultured in OS versus S
medium. Similarly, lower Col1α1 expression on C and HT scaffolds in the OS group that mirrored
that of scaffolds cultured in O medium after 14 and 28 days of culture suggest cell maturation.
Further support of the impact of OS medium included increased ECM protein, sGAG, collagen
and dsDNA over S medium at various points in the study. The variable increases in osteogenic
gene expression and ECM components are consistent with a cell population with variable maturity
[272]. Nonetheless, the observed genetic upregulation and increased ECM components confirm
that there is some benefit to short term exposure of ASC-scaffold constructs to osteogenic
medium.[271] Customization of medium and culture period will likely increase the effects.
Collagen upregulation and ECM deposition in C constructs in all culture media observed
in this study may be a result of collagen type I stimulation of extracellular signal-regulated protein
kinase (ERK) [273]. Coating cultureware with collagen increases ERK phosphorylation and
expression of ALP and OCN in human ASCs [274]. The results of this study are consistent with
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these earlier findings and may indicate that high collagen content scaffolds promote ASC
osteoblastic differentiation and ECM production, but slightly less than scaffolds with both collagen
and a mixture of inorganic minerals. The importance of this difference in patients with
compromised bone formation may not be relevant long term, so upregulation of the specific
signaling pathways discussed below may be the strongest mechanism for therapeutic
improvements.
Scaffold effects on CB1 and the OPG/RANKL ratio expression were the notable distinction
among C and HT constructs cultured in O medium. The importance of CB1 for MSC osteogenic
differentiation has been established. It increases with MSC osteoblastic differentiation [228, 275],
and BMSCs from CB1 knock outs have a reduced capacity for osteoblastic differentiation [227].
The role of CB1 role in bone homeostasis appears to be mediated primarily through adrenergic
signaling and separate from the Wnt signaling pathway [231, 276]. Of importance to clinical
translation is that lower CB1 expression is associated with age related bone loss and increased
marrow adiposity [227, 228].
The ratio of OPG/RANKL drives osteoblastic differentiation through increases in OPG or
decreases in RANKL, and OPG expression is mediated through Wnt/β-catenin pathways [98, 277281]. Disruption of the OPG/RANKL ratio is more closely aligned with bone pathology versus
bone aging associated with changes in CB1 expression [282, 283]. In contrast to the CB1 signaling
pathway apparent in C constructs discussed above, an increase in OPG/RANKL expression was
consistently apparent in HT constructs. The source of the difference may be that HA increases
low-density lipoprotein receptor-related protein 5 (LRP5) and β-catenin expression, and both
stimulate canonical Wnt [98, 278, 279, 284].
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Increased CB2 expression after 14 days of culture in all media and constructs suggests less
association with ASC osteogenesis than other genes. The role of CB2 in the regulation of bone
metabolism is not well defined, and existing information suggests both a supportive and an
inhibitory effect of CB2 on MSC osteogenesis [114, 228, 230, 285].
These results support the capability of human ASCs to be directed toward different
osteogenic pathways by scaffold substrate characteristics. This information may help guide
targeted research for distinct bone pathology. Local therapy based on predominant needs of the
recipient may be a safe and effective alternative to systemic activation of both cannabinoid and
Wnt signaling, which are both associated with serious side effects [229, 281, 286-288]. The
complexity of and overlap between signaling pathways, however, requires further work to confirm
distinct pathways at multiple levels between treatments.[277]
The parallel outcome measures in this study indicate that HT scaffolds in osteogenic
medium have the highest in vitro ASC osteogenesis followed by closely C. Further, osteogenesis
appears to be mediated through distinct cell signaling pathways by C and HT scaffolds. This may
indicate a significant value of considering patient characteristics when selecting bone grafts,
especially when combining them with exogenous ASCs. Since underlying bone pathology may
limit in vivo response to scaffolds with or without exogenous cells, the findings must be confirmed
in vivo prior to general application. Nonetheless, it is possible that native osteogenesis may benefit
more from some bone graft materials augmented by ASCs than others. Further, this information
creates a foundation for criteria to create autologous, viable bone grafts from adult ASCs to locally
treat deficient bone forming capacity.
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CHAPTER 4. POLYMER-MINERAL SCAFFOLD AUGMENTS IN VIVO EQUINE
MULTIPOTENT STROMAL CELL OSTEOGENESIS

4.1. Introduction
Viable graft composed of adult multipotent stromal cells (MSCs) and biocompatible scaffold is a
promising approach to enhance natural bone formation and augment current treatment strategies
for equine traumatic bone injury [221, 251, 289]. Autologous autograft promotes bone formation
by local cells, but harvest morbidity in addition to variable cell survival and graft quantity and
quality help fuel the search for regenerative medicine alternatives [219, 236, 290]. Osteogenic
capabilities of equine bone marrow- (BMSCs) and adipose-derived (ASCs) multipotent stromal
cells vary with culture conditions and scaffold carriers [184, 245, 291, 292]. Given the inherent
responsiveness of undifferentiated cells to surroundings [219, 221, 267], it is vital to confirm in
vitro MSC characteristics in vivo. This is especially true since cell-based therapies are designed to
enhance bone healing in potentially unfavorable conditions.
The natural bone fracture environment has over 200 noncollagenous matrix proteins and
collagen and hydroxyapatite (HA) nanostructure that guides native progenitor cell osteogenesis
[267]. Through structure and composition, functional scaffolds create a biomimetic environment
for endo- and exogenous cells [267, 293-297]. Mineral based scaffolds have good biomimetic
characteristics, but brittle mechanical properties complicate implant customization, surgical
stabilization and biological incorporation [298]. Scaffolds composed of both synthetic polymers
and minerals like HA and tricalcium phosphate (TCP) have biomimetic characteristics of inorganic
matrix but greater flexibility [298, 299]. A scaffold composition that supports consistent,
predictable tissue formation by MSCs from distinct tissues and donors is appealing for clinical
application.
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Poly-L-lactic acid (PLLA) and polyethylene glycol (PEG), biocompatible, nontoxic
polyester polymers, are often copolymerized for FDA-approved implants [300]. Distinct
PLLA:PEG ratios have predictable hydrolytic degradation [109, 301-305]. Addition of HA to
PLLA scaffolds neutralizes acid from PLLA hydrolysis [299] and enhances murine osteoblast cell
line survival, growth and osteogenic gene expression [306]. Composite PLLA/TCP scaffold
increases endogenous alkaline phosphatase activity in human ASCs over PLLA alone [297].
Information about equine MSC-scaffold osteogenesis is relatively limited [307], but this
contemporary knowledge supports potential for polymer-mineral scaffold carriers to support the
process [109, 302].
Homogenous distribution of viable MSCs throughout scaffold carriers is crucial for
organized tissue matrix production and organization [308]. Bioreactor dynamic cell loading under
optimal conditions limits cell loss and ensures distribution [124] important for neovascularization
and de novo tissue formation [223]. Spinner flask bioreactors limit cell cluster formation, facilitate
uniform cell seeding and support nutrient and waste exchange [309, 310]. Additionally, exposure
to fluid flow for as little as 15 minutes upregulates murine MSC osteogenic gene expression [311,
312]. Hence, spinner flasks provide an efficient mechanism for consistent construct loading that
may help drive osteoblastic differentiation and maturation.
Given the potential of equine ASCs and BMSCs to augment bone generation [313-315],
targeted work is necessary to identify polymer-mineral bioscaffold carriers [316-318] that reliably
promote equine MSC osteogenesis in vivo. This study was designed to quantify osteogenesis by
equine ASCs and BMSCs on scaffold carriers composed of TCP/HA (40:60, HT, ScaffdexTM, Ltd,
Tampere, Finland), PEG/PLLA (60:40, GA) and PEG/PLLA/TCP/HA (36:24:24:16, GT) in an
athymic mouse model. The tested hypothesis was that osteogenesis is comparable on GA and GT
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scaffolds with either ASCs or BMSCs and greater than on HT scaffolds with either cell type. It
was further hypothesized that the same scaffolds with MSCs have greater osteogenesis than those
without.
4.2. Materials and Methods
4.2.1. Ethics Statement
All animal procedures were approved by the Institutional Animal Care and Use Committee prior
to study initiation (protocols #13-050 and 07-049).
4.2.2. Study Design
Cell passage (P) 1 cryopreserved equine bone marrow (BMSC) and adipose-derived (ASC)
multipotent stromal cells were culture expanded to P3. Cells were loaded onto one commercially
available mineral (HT) and two novel polymer-mineral scaffolds (GA, GT) via a spinner flask
bioreactor. Passage (P) 3 immunophenotype and cell viability on scaffolds after 7 and 21 days of
static culture were determined. Scaffolds with and without cells were implanted subcutaneously in
athymic mice. Radiographs were performed immediately and then every three weeks up to 9 weeks.
Explants were evaluated for composition (double stranded DNA (dsDNA), total collagen, sulfated
proteoglycan, protein), osteogenic target gene mRNA expression (alkaline phosphatase (ALP),
bone sialoprotein (BSP), osteocalcin (OCN), osteoprotegerin (OPG)), calcium and phosphorus
content and ultra- and microstructure. All materials and reagents were from Sigma-Aldrich, St.
Louis, MO unless otherwise noted.
4.2.3. Scaffold Preparation (PEG/PLLA, GA; PEG/PLLA/TCP/HA, GT)
PEG/PLLA (60:40): Solutions of 10% PEG (molecular weight (MW) 1,900 – 2,200 g/mole) and
10% PLLA (MW 100,000 – 150,000 g/mole) in 1, 4-dioxane (AcroSealTM, ACROS Organics)
were combined at a ratio of 6:4 (v/v) with stirring at 85oC to create a homogenous mixture.
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PEG/PLLA/TCP/HA (36:24:24:16): TCP was added to 10% PEG at a ratio of 4:6 (TCP:PEG, w/w)
and HA to 10% PLLA at a ratio of 4:6 (HA:PLLA, w/w) under the same conditions as above.
Solutions were combined at a ratio of 6:4 (TCP-PEG:HA-PLLA) and then solidified in
polydimethylsiloxane tubes (inner diameter: 10 mm; depth: 10 mm) by cooling to -80oC overnight.
They were subsequently lyophilized for 48 hours. Tubular scaffolds were sliced into discs
(diameter: 10 mm; depth: 3 mm) that were individually packaged and sterilized with ethylene
oxide at 57oC for 2 hrs.
4.2.4. Tissue Harvest, Cell Expansion, Cryopreservation
Sternal bone marrow and subcutaneous adipose tissue were harvested from seven thoroughbred
geldings (6.3 ± 1.7 years; mean ± standard error of the mean (SEM)) as previously described [245].
Briefly, horses were sedated (detomidine HCl, 0.04 mg/kg intravenously (IV)), the sternebrae
aseptically prepared, and 6 ml of 2% lidocaine chloride infiltrated into the soft tissues. With 14 G
Jamshide needles, bone marrow was aspirated into heparinized syringes (1000 IU/60 ml bone
marrow aspirate). Next, skin and subcutaneous tissues dorsolateral to the base of the tail were
infiltrated with 2% lidocaine chloride. Skin was incised for 10 cm parallel to and approximately
15 cm lateral to the dorsal sacrum, and exposed subcutaneous adipose tissue (15-20 ml) was
sharply excised. The skin was apposed with #2 nylon.
Cells were isolated as published with minor modifications [245]. Bone marrow aspirate
combined with an equal volume of stromal medium (Dulbecco’s modified Eagle’s medium F-12
(DMEM/F-12, Hyclone, Logan, UT), 1% antibiotic/antimycotic solution (MP Biomedical, Irvine,
CA), 10% fetal bovine serum (FBS, Hyclone)) was separated via centrifugation (350 × g, 4oC, 30
min) with Ficoll-Paque® PLUS (Stem Cell Technologies, Vancouver, Canada). The cell layer was
removed and centrifuged (260 × g, 4oC, 5 min) to form a cell pellet that was seeded in T75 flasks
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(5×103 cells/cm2) for culture. Stromal medium was refreshed after 24 hours and then every 3 days.
In this study, P0 is the first cell passage of primary cells. Procedures performed at temperatures
other than room temperature are indicated.
Minced adipose tissue was combined with an equal volume of phosphate buffered saline
(PBS, Hyclone). After the mixture separated into two phases over 5 min, the infranatant was
digested in 1% bovine serum albumin (BSA, Fisher Bioreagents, Fair Lawn, NJ) and 0.1%
collagenase type I (Worthington Biochemical Corporation, Lakewood, NJ) in DMEM/F-12 for 2
hours at 37oC. After filtering (100 μm nylon cell strainers, BD Falcon, Bedford, MA) and
centrifugation (260 × g, 5 min), cells in DMEM with 1% BSA were added to an equal volume of
red

blood

cell

lysis

buffer

(0.16

mol/L

NH4Cl,

0.01

mol/L

KHCO3,

0.01%

ethylenediaminetetraacetic acid (EDTA)) for 5 min. The stromal vascular fraction (SVF) was
collected after centrifugation (260 × g, 5 min) and cultured like above.
At 70% confluence, cells were detached with 0.05% trypsin (Hyclone), suspended in
cryopreservation medium (80% FBS, 10% DMEM/F-12, 10% dimethylsulfoxide (DMSO, Fisher
Scientific, Fari Lawn, NJ)) at 1-1.5×106 cells/ml and aliquoted into 1.5 ml cryovials (Fisher
Scientific). Cells were cooled to -80oC (~-1oC/min, CoolCell®, BioCision, Larkspur, CA)
overnight and then transferred to liquid nitrogen for 33-45 days. To thaw, cryovials were placed
in a 37oC water bath for 1-2 min followed by centrifugation (380 × g, 5 min), a PBS wash, another
centrifugation (380 × g, 5 min) and then stromal medium culture as before.
4.2.5 Immunophenotype - Flow Cytometry
Passage 3 revitalized ASCs and BMSCs from 3 equine donors were combined in equal proportions
within cell type for immunophenotype detection. Aliquots of 1×105 cells in 150 µl PBS were
incubated for 30 minutes at room temperature with 200 µg/ml of labeled or unlabeled antibody
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(CD34-PE, CD29, CD73-FITC, CD44-FITC, CD90-PE, CD105-PE) specific or validated crossreactive for equine antigens (Table 9). Cells were rinsed with PBS, centrifuged (350×g, 5 min),
and fixed with 4% neutral buffered formalin. For CD29, cells were incubated with labeled antiimmunoglobulin (IgG-FITC) for 30 min, rinsed with PBS, centrifuged (350×g, 5 min), and fixed
with 4% neutral buffered formalin. Cell fluorescence was quantified using a FACSCalibur flow
cytometer and Cell Quest Pro software (BD Biosciences, San Jose, CA). Autofluorescence was
determined on antibody negative samples.
4.2.6. Construct Seeding and Culture
Passage 1 revitalized ASCs and BMSCs were culture expanded to P3 and then loaded onto
scaffolds (1×106 cells/scaffold) for 2 hours with 70 rpm stirring in spinner flask bioreactors (37o
C, 5% CO2). Spinner flasks consisted of 100 ml flasks (Bellco® Biotechnology, Newark, NJ)
containing 120 ml of serum-free stromal medium and three separate 4-inch-long, 22 gauge spinal
needles suspended from a rubber stopper at the top of each flask that each passed through the
center of one scaffold (Fig. 22). Individual loading processes for scaffolds without cells, pooled
aliquots identical to those used for immunophenotype, and for each cell tissue source and donor
included one scaffold of each composition situated at the middle of the fluid. After 2 hours, loading
efficiency was determined and cell-scaffold constructs divided into six equal pieces for immediate
evaluation, culture in stromal medium or implantation as described below.
4.2.7. Cell Number - 3-(4, 5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT)
Commercially available MTT (Cell Proliferation Kit I) was used to determine cell number
immediately after cell loading or following 7 or 21 days of stromal medium culture in 24 well
culture plates (n=3 replicates/cell tissue source/scaffold composition/time point). Briefly,
constructs were gently rinsed with PBS and placed into fresh plates followed by incubation with
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500 µl of a 5:1 mixture of stromal medium and MTT solution (5 mg/ml in PBS) for 2 hrs (37o C,
5% CO2). Subsequently, 500 µl of DMSO was added to each well, absorbance read at 540 nm
(Synergy HT, BioTek Instruments, Winooski, VT), and the cell number determined from equine
ASC or BMSC standard curves. Cell number fold change was calculated as Cf/Ci (Cf: cell number
after 7 or 21 days of culture; Ci: cell number immediately after scaffold loading).
Table 9. Antibodies for Flow Cytometry
Target
Antibody

Label

Marker expression

Manufacturer

Species

Diluent
species

BD
CD29

N/A

β1 integrin

Mouse

Canine

PBS

eBioscience

Mouse

Canine

PBS

eBioscience

Mouse

Human

PBS

eBioscience

Mouse

Canine

PBS

eBioscience

Mouse

Human

PBS

Mouse

Canine

PBS

Rabbit

Mouse

PBS

Biosciences
Cell-surface
CD44

FITC

Glycoprotein,
hyaluronic acid receptor

CD73

FITC

5’-Nucleotidase
Thy-1, fibroblasts,

CD90

PE

MSC, hematopoietic
progenitor (HSC)

CD105

PE

Type 1 Glycoprotein

BD
CD34

PE

HSC
Biosciences

Rabbit antiFITC

N/A

Sigma

mouse IgG
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Figure 22. Schematic of spinner flask bioreactor cell loading, scaffold division and implantation.
4.2.8. Scaffold Surgical Implantation
Six equal pieces of scaffolds containing ASCs, BMSCs or no cell (n=1/horse/cell tissue
source/scaffold composition) were surgically implanted in the dorsal subcutaneous tissues of male,
athymic mice (nu/nu, Charles River Laboratories, Wilmington, MA). Implants were harvested nine
weeks after surgery and evaluated for gene expression (n=2/mouse), composition (n=2/mouse),
ultra-structure, (n=1/mouse) and microstructure (n=1/mouse).
Mice were premedicated (glycopyrrolate, 0.02 mg/kg; butorphanol, 0.5 mg/kg, both
subcutaneously) and anesthetized with isoflurane on oxygen delivered via a Baine circuit and mask.
Following aseptic preparation, six 5 mm skin incisions were created equidistantly along the
dorsum extending from the scapula to the sacrum approximately 1 cm ventral to each side of the
spine. Following minimal blunt dissection, scaffolds were placed beneath the skin, subcutaneous
tissues closed with #3-0 nylon and skin apposed with tissue glue.
4.2.9. Radiographs – Mineral Deposition
Radiographs (Sound Technologies, Carlsbad, California) were performed immediately and 3, 6
and 9 weeks after surgery with mice in ventral recumbency and anesthetized as described above.
Mineral deposition was subjectively assessed based on changes in radiopacity.
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4.2.10. Microcomputed Tomography (μCT) – Porosity, Bone Volume/Total Volume
Two- and three dimensional images generated from a micro-computed tomography (μCT) scanner
(μCT 40; Scanco Medical AG, Bassersdorf, Switzerland) and graphics software were used to
quantify specimen percent porosity (Mimics®, Materialise, Ann Arbor, MI) and bone volume/total
volume (BV/TV, μCT Evaluation Program V6.6), respectively, 9 weeks after implantation.
Imaging technique (55kV, 145µA) and 2-dimensional 16-bit gray-scale threshold were identical
among samples. Percent porosity was measured on slices at 25, 50, and 75% of the total specimen
height. The mean of the 3 values was used as the measure for each specimen. To distinguish
between high contrast scaffold versus low contrast, newly deposited tissue, two thresholds were
used for 3-D image reconstructions of GT (170, 370 mgHA/ccm) and HT (380, 590 mgHA/ccm)
samples. The difference in the BV/TV at each threshold was considered a measure of new tissue
deposition. A single threshold (270 mgHA/ccm) was used for GA constructs which did not contain
high contrast material.
4.2.11. Compositional Analysis-DNA, Hydroxyproline, Sulfated Gyclosaminoglycan, Protein
Compositional analysis was performed identically to previous reports [135, 274, 319, 320]. Briefly,
constructs were lyophilized at -55oC and 0.2 mbar for 4-5 hours and then 20 mg of each sample
was digested (9 mM di-sodium ethylenediaminetetraacetic acid, 20 mM sodium acetate, 20 mM
L-cysteine (MP Biomedicals, Solon, OH), 2 mg papain (MP Biomedicals)/g lyophilized sample)
at 60oC for 10 hrs [77, 120]. Digested samples were vigorously vortexed and then centrifuged
(4000 ×g, 10 min). Supernatants were stored at -80oC until analysis. Double stranded DNA
(dsDNA) was determined with a commercially available kit (Quant-iTTM PicoGreen® Kit,
Invitrogen, Carlsbad, CA) [77]. Hydroxyproline content as a measure of total collagen was
quantified via Ehrlich’s colorimetric assay and absorbance at 550 nm based on trans-4-hydroxy-L
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proline (ACROS OrganicsTM, Morris Plains, NJ) standards [77, 321]. Sulfated glycosaminoglycan
(sGAG) was quantified with a dimethylmethylene blue (DMMB) assay, absorbance at 520 nm and
a chondroitin sulfate standard curve [77, 247]. Lowry’s total protein assay with Biuret’s and FolinCiocalteu’s reagents, absorbance at 650 nm, and bovine serum albumin standards was use to
quantify sample protein [322].
4.2.12. Scanning Electron Microscopy (SEM) - Ultrastructure, Phosphate, Calcium
Samples were fixed with 2.5% glutaradehyde in 0.1 M sodium carcodylate buffer (pH 7.4), post
fixed in 0.1% osmium tetroxide, and then dehydrated in a series of ethanol-distilled water solutions
[245]. After critical point drying, they were sputter coated with gold and imaged (FEI Quanta 200,
Netherlands). Surface calcium and phosphorus was measured in the center of each sample by
energy-dispersive X-ray spectroscopy (EDS, 20kV, 3% accuracy) [323].
4.2.13. RT-PCR - Gene Expression
Total RNA was isolated from harvested samples (RNeasy Plus Mini Kit, Qiagen, GmbH,
Germany), the concentration determined spectrophotometrically (NanoDrop ND-1000; NanoDrop
Technologies, Wilmington, DE, USA), and cDNA synthesized (QuantiTect Reverse Transcription
Kit, Qiagen). Equine and murine osteogenic target gene levels (alkaline phosphatase (ALP),
osteocalcin (OCN), bone sialoprotein (BSP) and osteoprotegerin (OPG)) (Table 10) were
quantified with real-time RT-PCR using SYBR Green (Qiagen) technology and an MJ Research
Chromo 4 Detector (Bio-Rad Laboratories, Hercules, CA). Primers were designed according to
species-specific genetic sequences. Each primer was tested with bone RNA to confirm lack of
cross reactivity. The ΔCt values were determined relative to the reference gene glyceraldehyde 3phosphate dehydrogenase (GAPDH).
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Table 10. Primer sequences
Species

Lineage

Primer

Housekeepi

Sequences

Accession No.

F: AAGAAGGTGGTGAAGCAGG
GAPDH

ng

NM_001163856.1
R: CTCAGTGTAGCCCAGGATG
F: GGAGTATGAGATGGACGAG

ALP

XM_005607380.2
R: GTAGTGAGAGTGCTTGTGCC
F: TGGCCCTGACTGCATTCTG

Equine

OCN

XM_005610022.1
R: CCCTCCTGCTTGGACATGAA

Osteogenic
F: CCCCCCTTGTCCTGACCACT
OPG

XM_001916099.4
R: CGCCCTTCCTCACATTCG
F: GAAGAATCGGACGCTGAG

BSP

XM_001496125.4
R: ATCGTAGACAGGGTGGTG
F:

Housekeepi
GAPDH ACCCAGAAGACTGTGGATGG

XM_017321385.1

ng
R:ACACATTGGGGGTAGGAACA
F: TGATGTGGAATACGAACTGG
ALP

XM_006538500.2
R: TGGGAATGCTTGTGTCTG

Murine

F: CCATCTTTCTGCTCACTCTG
OCN

NM_007541.3
R: TTATTGCCCTCCTGCTTG

Osteogenic
F: CACTCGAACCTCACCACAGA
OPG

NM_008764.3
R: GCTCGATTTGCAGGTCTTTC
F: CAGCCATGAGTCAAGTCAGC

BSP

NM_001204203.1
R: CTTGTGGCTCTGATGTTCCA
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4.2.14. Light Microscopy - Microstructure
Following fixation in 4% neutral buffered formalin, serial sections (5µm) of paraffin embedded
specimens were stained with hematoxylin & eosin (H&E) and Masson’s trichrome. Digital images
were generated of all specimens (Leica DM 4500B, Allendale, NJ).
4.2.15. Statistical Analysis
Statistical analyses were performed with the JMP statistical package (v13.0.0, SAS Institute, Cary,
NC). Mixed ANOVA models were used to evaluate cell number fold change, composition (dsDNA,
total collagen, sulfated proteoglycan, protein), gene expression, porosity and BV/TV among
scaffold compositions within cell tissue sources and between cell tissue sources within scaffold
compositions. Fixed effects included scaffold composition and cell tissue source. Equine donor
and mouse were random effects. Tukey’s post hoc tests were applied for multiple group
comparisons (p < 0.05).
4.3. Results
4.3.1. Immunophenotype - Flow Cytometry
The majority of P1 ASCs and BMSCs were CD29+, CD105+, CD34-, CD73- (Fig. 23). There
were higher percentages of C90+, CD105+, CD44+ ASCs (Table 11).

Figure 23. Immunophenotypes of P3 equine ASCs or BMSCs after culture expansion postcryopreservation. The black lines represent labeled cells and the green autofluorescence.
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4.3.2. Cell Number - 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium bromide (MTT)
The ASC and BMSC loading efficiencies were 81.2 ± 11.4% and 83.4 ± 4.4%, respectively. The
ASC and BMSC number increased significantly in HT constructs between 7 and 21 days of culture
and BMSCs increased similarly in GT constructs (Fig. 24). After 7 days, the increase in BMSC
number was greater in HT versus the other scaffolds, and after 21 days, the increase in GA was
lower than the other two.
Table 11. Percentages of CD29+, CD44+, CD90+, CD105+, CD34-, CD73- P3 equine ASCs or
BMSCs after culture expansion post-cryopreservation.
CD29+ CD34- CD44+ CD73- CD90+ CD105+
ASC

99

83.5

11.0

99.8

46.2

87.7

BMSC

90.3

97.9

1.5

99.9

28.2

58.8

Figure 24. Fold change in ASC (A) or BMSC (B) number after 7 or 21 days of static culture in
stromal medium on scaffolds composed of TCP/HA (40:60, HT), PEG/PLLA (60:40, GA) or
PEG/PLLA/TCP/HA (36:24:24:16, GT). Columns with distinct superscripts are significantly
different between culture times within scaffold composition and those with different asterisk (*)
numbers are significantly different among scaffold compositions within culture time (p<0.05).
4.3.3. Radiographs – Mineral Deposition
All GA scaffolds and GT scaffolds with ASCs or without cells remained radiolucent throughout
the study. Those GT scaffolds with BMSCs became radiopaque 6 weeks after implantation.
77

Scaffolds composed of HT were radiopaque throughout the study, and scaffold margins became
rounded with time (Fig. 25).

Figure 25. Radiographs of mice with carrier scaffolds composed of TCP/HA (HT), PEG/PLLA
(GA) or PEG/PLLA/TCP/HA (GT) with no cells or equine ASCs or BMSCs 0, 6, and 9 weeks
after surgical implantation. White circles surround radiopaque implants.
4.3.4. Microcomputed Tomography (μCT) – Porosity, Bone Volume/Total Volume
There were measurable differences between BV/TV of GT and HT constructs at low and high
thresholds, while BV/TV in GA constructs were only detectable at a high threshold (Fig. 26). The
HT constructs had the highest percent porosity (Fig. 27A). Within scaffold compositions, GA and
GT scaffolds with cells had higher porosity than those without, while HT scaffolds without cells
had higher porosity than HT-BMSC constructs. Direct comparisons among scaffold BV/TV is not
possible due to distinct thresholds used to create reconstructions. Within scaffold compositions,
GT- and HT-BMSC constructs had the highest BV/TV, and GT-ASC constructs had higher BV/TV
than those with no cells (Fig. 27B).
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Figure 26. Three-dimensional explant reconstructions demonstrating models generated with low
(left) and high (right) thresholds to distinguish between high contrast scaffold structure (left)
versus low contrast, newly deposited tissue (right). A single threshold was used for GA constructs
due to the limited presence of high contrast material in the specimens. See Fig. 20 for acronym
definitions.

Figure 27. Percent porosity (A) and BV/TV (B) (mean ± SEM) of equine ASC and BMSC
constructs 9 weeks after subcutaneous implantation in a murine model. Columns with distinct
superscripts are significantly different among cell tissue source within scaffolds and those with
different asterisk numbers (*) are significantly different among scaffolds within cell tissue source
(p<0.05). See Fig. 20 for acronym definitions
4.3.5. Compositional Analysis- DNA, Hydroxyproline, Sulfated Gyclosaminoglycan, Protein
Significant differences in extracellular matrix within scaffold composition included higher
hydroxyproline (collagen) in GT-ASC constructs versus those without cells (Fig. 28B), higher
protein in GT-ASC constructs versus no cells or BMSCs and higher protein in HT scaffolds
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without cells versus either ASC or BMSC constructs (Fig. 28D). Differences among scaffolds
within cell types included higher dsDNA in GT versus GA or HT scaffolds without cells, in GT
versus HT scaffolds with ASCs and in GA versus HT scaffolds with BMSCs (Fig. 28A).
Hydroxyproline was higher in HT versus GA scaffolds without cells and GT versus GA or HT
scaffold with ASCs (Fig. 28B). Both GA and GT scaffolds with ASCs or BMSCs had higher sGAG
than HT with the same cells (Fig. 28C). Protein was higher in HT versus GA scaffolds without
cells and GT versus GA or HT with ASCs (Fig. 28D).
4.3.6. Scanning Electron Microscopy (SEM) - Ultrastructure, Phosphate, Calcium
Collagen fibrils and amorphous matrix were apparent in all explants (Fig. 29). A notable
distinction was the presence of solid regions in various stages of mineralization and surrounded by
randomly oriented collagen fibrils in scaffolds with cells. The well delineated regions were distinct
from the more proteinaceous ECM of scaffolds without cells. Subjectively, BMSC construct ECM
was the most dense among explants.
Within HT-BMSC and GA and GT constructs, calcium and phosphorus percentages were
higher and lower, respectively, in scaffolds with versus without cells (Fig. 30), and ratios did not
change appreciably in HT-ASC constructs. The calcium phosphorus ratio was closest to that of
HA (1.6) in GA-BMSC and GT-BMSC constructs [324].
4.3.7. RT-PCR - Gene Expression
Equine – There was no detectable equine gene expression in scaffolds without cells. Osteogenic
gene expression tended to be highest in scaffolds with BMSCs and vary among scaffold
compositions. Within scaffold compositions, BMSC constructs had higher ALP and OCN than
ASC constructs (Fig. 31 A, B). The OPG and BSP expression was highest in GT- and HT-BMSC
constructs, respectively (Fig. 31 C, D). Within cell tissue source, ALP was higher in HT- versus
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GA-ASC constructs (Fig. 31A). Both ALP and OCN were lowest in HT-BMSC constructs (Fig.
31A, B). The OPG in GA-ASC constructs was higher and lower than GT- and HT-ASC constructs,
respectively. The BSP was lower in HT- versus GA- and GT-ASC constructs. Additionally, GTBMSC constructs had higher BSP than GA-BMSC constructs.

Figure 28. The dsDNA (A), hydroxyproline (collagen) (B), sulfated glycosaminoglycan (sGAG)
(C) and protein (D) content (LS mean ± SEM) equine ASC and BMSC constructs 9 weeks after
subcutaneous implantation in a murine model. Columns with distinct superscripts are significantly
different among cell types within scaffolds and those with different asterisk (*) numbers are
significantly different among scaffolds within cell types (p<0.05). See Fig. 20 for scaffold
composition.
Murine – Osteogenic gene expression tended to be highest in scaffolds with BMSCs
compared to those with no cells or ASCs. Differences among scaffold compositions varied and
tended to parallel the equine gene expression. Among cell tissue source within scaffold
composition, the highest expression levels included ALP in GA- and GT-BMSC constructs (Fig.
32A), OCN in all BMSC constructs (Fig. 32B), OPG in GT-BMSC constructs (Fig. 32C) and BSP
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in GT- and HT-BMSC constructs. Lowest expression levels included ALP expression in GT-ASC
constructs (Fig. 32A) and BSP in all scaffolds without cells (Fig. 32D). Among scaffold
compositions, ALP tended to be lower in GA and GT versus HT scaffolds with ASCs or without
cells and in HT versus GA and GT scaffolds with BMSCs (Fig. 32A). The OPG expression
followed the same general pattern with the exception that it was lower in GA- versus HT-BMSC
constructs (Fig. 32B). The BSP was highest in HT scaffolds without cells and lowest in GA-BMSC
constructs.

Figure 29. Scanning electron photomicrographs of scaffolds before cell loading (Preimplantation)
and 9 weeks after implantation without (No Cell) or combined with equine ASCs (ASC) or BMSCs
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(BMSC). Magnification = 3000x ; bar = 20 µm. Yellow arrows = collagen fibrils; Two-stripe black
arrow = solid (mineralizing) region. See Fig. 20 for acronym definitions.

Figure 30. Energy dispersive x-ray microanalysis of explants before (Preimplantation) cell loading
or combined with equine ASCs (ASC) or BMSCs (BMSC) 9 weeks after implantation. See Fig.
20 for acronym definitions.
4.3.8. Light Microscopy - Microstructure
Regardless of composition, scaffolds with cells had more ECM than those without, most ECM
deposition was on the implant periphery, and osteoid was apparent in all BMSC constructs.
Specific to constructs, there was more amorphous, proteinaceous ECM apparent on GT- versus
GA-ASC constructs, and GT-BMSC constructs had more osteoid ECM than GA-BMSC (Fig. 33).
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4.4. Discussion
The overarching conclusions from this study are that addition of mineral to polymer scaffolds
enhances equine MSC osteogenesis over polymer alone, but mineral (HT) scaffolds provide
superior support for equine MSC osteogenesis compared to either polymer composition. Parallel
outcomes disprove both parts of the first hypothesis since osteogenesis was best on HT scaffolds
regardless of cell tissue source and BMSCs showed more robust osteogenesis than ASCs. Further,
GT scaffolds supported better osteogenic differentiation and ECM deposition than GA. However,
the second hypothesis that the scaffolds with MSCs have greater osteogenesis than those without
is true.

Figure 31. Equine alkaline phosphatase (A; ALP), osteocalcin (B; OCN), osteoprotegerin (C;
OPG), and bone sialoprotein (D; BSP) levels (mean ± SEM) in equine MSC-scaffold constructs 9
weeks after implantation. Columns with distinct superscripts are significantly different between
cell tissue source among scaffolds and those with different asterisk numbers (*) are significantly
different among scaffolds between cell tissue source (p<0.05). See Fig. 20 for acronym definitions.
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This study also confirms the presence of exogenous mRNA in implants 9 weeks after
placement. Most previous work confirms persistence of implanted cells with inert cell labels or
plasmid gene expression that can be incorporated into endogenous cells following exogenous cell
senescence [325]. Few studies confirm the presence of exogenous mRNA to suggest, if not confirm,
viable cell osteogenic gene expression. Another major finding is the largely parallel equine and
murine genetic expression including higher osteogenic gene expression by murine cells in BMSC
constructs. Higher osteogenic potential of BMSCs compared to ASCs is consistent with
established information and largely attributed to epigenetic factors [291, 326]. Observed
upregulation of osteogenic gene expression by murine cells in equine BMSC constructs may be a
consequence of both growth factor production, ECM deposition, and direct and indirect signaling
by exogenous cells [9, 11, 245, 284, 327-334]. These findings are consistent with knowledge of
native cell recruitment and direction by MSC implants [267, 335, 336], and they further emphasize
the need to construct implants for optimum direction of both exo- and endogenous cell contributors
to osteogenesis.
Study findings and current knowledge show that polymer-mineral scaffold support of
equine MSC osteogenesis will be improved with further optimization. Previous reports indicate
that addition of mineral to polymer scaffolds enhances MSC osteogenesis in other species,
sometimes more than mineral alone [297, 323, 337]. A biomimetic environment is created, in part,
by composition, surface topography, microarchitecture and mechanical properties [267]. Flexible
polymer scaffolds with less structural organization in this study may have weaker osteogenic
signaling that the rigid, porous ceramic structure. Calcium ions released from calcium phosphate
based minerals play a major role in influencing osteoblastic differentiation [338], and the presence
of either HA or TCP enhances mRNA levels of BSP in human BMSCs without osteogenic medium
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[243]. Based on equine MSC osteogenic gene expression on scaffolds with calcium phosphate
(HA and TCP) in this study and on collagen in previous work, polymer scaffolds with threedimensional bone microstructure overlaid with minerals and collagen may better support
osteogenesis [238, 245]. Scaffolds specifically designed for ASC osteogenesis could also possibly
increase contributions to osteogenesis.

Figure 32. Murine alkaline phosphatase (A; ALP), osteocalcin (B; OCN), osteoprotegerin (C;
OPG), and bone sialoprotein (D; BSP) levels (mean ± SEM) in equine MSC-scaffold constructs 9
weeks after implantation. See Fig. 10 for acronym definitions.
Higher ECM and osteoid deposition on the scaffold periphery have resulted from cell
distribution and in vivo conditions. Cell distribution was not confirmed, so cells may have
concentrated on the scaffold periphery from spinner flask centrifugal forces and lack of continuous
scaffold pores [126, 140, 339, 340]. Better interstitial flow on the construct surface in vivo could
have promoted better cell survival that in the center despite small implant size [302, 309, 341].
While not directly translatable to in vivo, reduced in vitro MSC numbers at 7 and 21 days compared
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to initial number in half of the constructs may account for lower in vivo ECM deposition. The
cause of cell loss was not evaluated, but increased cell numbers in some scaffolds is inconsistent
with scaffold cytotoxicity. The MSC affinity for culture plastic in vitro or surrounding tissues in
vivo may have been equal or greater than that for scaffold components [265, 342]. Explant dsDNA
content does not suggest cell loss likely due to murine cells from the local environment in vivo.
Future studies to evaluate cell distribution and orthotopic ECM deposition will help resolve these
points.

Figure 33. Light photomicrographs of equine MSC-scaffold explants 9 weeks after surgery.
Masson’s trichrome stain; magnification, 10x; scale bar = 200 µm (A); Magnification 40x; scale
bar = 50 μm (B). Black arrow = osteoid, yellow arrow = collagen fibers; gray arrow =
proteinaceous ECM; Two-triple black arrow = scaffold. See Fig. 20 for acronym definitions.
Presence of equine MSCs significantly enhanced ECM deposition in scaffolds regardless
of composition, though SEM and light microscopy confirmed osteoid deposition was highest with
either BMSCs and/or high scaffold mineral content. Changes in EDS calcium and phosphate may
indicate early ion deposition for mineralization [343]. Compositional analysis confirmed
proteinaceous ECM in MSC constructs that was observed with light microscopy. Lower ECM
composition in HT constructs is likely from ECM deposition throughout GT and GA scaffolds
versus HT scaffold pore surfaces. The HT scaffold porosity may have decreased from ECM
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deposition within pores and polymer scaffold porosity increased from ECM deposition and
organization.
The results of this study are limited to ectopic versus orthotopic ossification that is more
representative of implant efficacy to support osteogenesis in native bone [344, 345]. Athymic mice
have diminished osteogenic capabilities compared to immunocompetent animals [346, 347], so
scaffolds and cell-scaffold constructs may behave differently in an equine fractures. Nonetheless,
subcutaneous implantation is an accepted approach with numerous intra-animal replicates to
compare in vivo ECM deposition and genetic expression among scaffolds and cell-scaffold
constructs [348, 349]. The study length exceeded the time for natural, early fracture stabilization
[350] to evaluate long term differences in cell-construct in vivo behaviors. Results that differ
between this and other studies can be attributable to study duration, distinct in vivo and in vitro
environments [351, 352], species [353, 354] and revitalized MSCs, a point that has been shown to
impact cell behavior [18, 23, 24] within immunophenotypes [6, 7, 355]. Nonetheless, the number
of sample replicates, duration, and parallel outcome measures in this study provide robust tests of
the stated hypotheses.
As a whole, these in vivo study results confirm that addition of mineral to polymer carrier
scaffold enhances strong osteogenic capabilities of equine MSCs without osteogenic
preconditioning prior to implantation and that BMSCs appear to have better osteogenic ECM
production and organization than ASCs Findings from these investigations confirm that
contributions of both exogenous cells and recruitment of host MSCs are vital to MSC construct
osteogenesis. The contributions in the present study may provide important information to help
overcome equine bone healing challenges. The novel scaffold carriers evaluated in this study are
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appropriate for continued development of synthetic graft materials and viable tissue implants to
augment equine fracture strategies.
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CHAPTER 5. THE EFFECTS OF COLLAGENASE CONCENTRATION ON EQUINE
ADIPOSE DERIVED-MULTIPOTENT STROMAL CELL ISOLATION

5.1. Introduction
The most common technique to isolate adipose derived multipotent stromal cells (ASCs) is based
on enzymatic digestion to separate the stromal vascular fraction (SVF) from the tissue. The cells
are subsequently cultured on plastic culture plate which selects for ASCs based on plastic
adherence [356]. Nevertheless, there is no standard protocol with uniform parameters for the
isolation [356]. Collagenase type I digests for ASC isolation are widely used, and the collagenase
concentrations are variable [96, 357]. This can result in irregularities between cell isolates even if
everything else is the same [356]. Commercial collagenase to dissociate tissues may leave foreign
protein residuals like collagenase type I, protease, polysaccharidases, and lipase [358]. In a
previous study in our laboratory, a 0.1% collagenase digest was used to isolate ASCs from equine
subcutaneous adipose tissue and the concentration could efficient yield nucleated cells and the
cells isolated exhibited in vitro proliferation and multipotent capabilities [291]. Reduction of
collagenase concentration used in the digest solution will reduce the foreign protein residuals.
In the horse, the adipose SVF and ASCs are used to treat joint related diseases and
tendon/ligament related injuries [359, 360]. However, common isolation and culture techniques
fail to ensure homogenous cell populations, and nonprogenitor cell contamination may impair
treatment efficacy and induce inflammation [359-361]. There are many cell subpopulations in the
SVF and cultured ASCs that include endothelial cells, erythrocytes, fibroblasts, lymphocytes,
monocyte/macrophages, preadipocytes, pericytes and hematopoietic stem and progenitor cells [75,
362, 363]. The identity of MSCs can be determined by immunophenotype based on surface protein
expression [364]. Fluorescence activated cell sorting (FACS) allows single cell selection so it is
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frequently used to isolate specific cell subpopulations [365]. In vitro, ASCs retain CD44 and
CD105 expression and lack the expression of major histocompatibility complex class II (MHCII)
[364], and they can be selected based on these characteristics. Cell sorting techniques to remove
nonprogenitor cells and purify cell isolates may result in more predictable cell behavior.
In published reports, the majority of equine reports utilize fresh cells [366]. However,
current knowledge supports that MSCs change with extensive culture including decreasing
expansion capacity and plasticity with increasing passage [367, 368], and the risk of microbe or
exogenous cell contamination also increases with culture time [41, 42]. As an alternative to
continuous culture, cryopreservation is often employed for cell preservation. Several studies
indicate that slow cooling and cryoprotectants (CPs) such as dimethyl sulfoxide (DMSO) and fetal
bovine serum (FBS) fully retain stem cell properties [25, 43, 77]. However, the actual impact of
slow cooling and freezing with CPs, particularly on the maintenance of multipotentiality in the cell
population after cryopreservation, is not clear [14].

Additionally, the chemical toxicity of

cryoprotectants should also be considered [43]. Several side effects of DMSO (e.g. nausea,
vomiting, flushing, fever, chills, dyspnea, cardiac symptoms, transient hypertension and
hypotension and anaphylaxis) are associated with the infusion of DMSO-cryopreserved
hematopoietic progenitor cell applications [54]. Conventional cryopreservation methods usually
result in some irreversible cell damage and mortality due to intracellular ice formation and CP
toxicity [14, 43]. Identification of an ideal medium for cryopreservation is the first step in using
cryopreserved MSCs in equine veterinary patients. To achieve this goal, reduction of the CP
toxicity and fully quantifying the effects of cryopreservation on short-term proliferation and
genetic profile of equine ASCs is necessary.
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The three-part tested hypothesis tested in this study was that 1) equine ASC yield, plasticity,
and expansion rate decreases with increasing collagenase in the tissue digest; 2) MHCII-, CD44+,
CD105+ ASCs have higher expansion and plasticity compared to MHCII+, CD44+, CD105+; and
unsorted cells; and 3) ASC expansion potential and plasticity decreases with increasing
cryopreservation medium DMSO concentration. The yield of nucleated cells, immunophenotype
profile, in vitro expansion capabilities, and plasticity of equine ASCs isolated from adipose tissue
digested with distinct collagenase concentrations were determined. The same was assessed after
FACS was employed to select MHCII-, CD44+, CD105+ and MHCII+, CD44+, CD105+ cells
from fresh and cryopreserved ASCs. Additionally, the in vitro expansion, immunophenotype
profile, and plasticity were evaluated in equine ASCs cryopreserved in media with 5% or 10%
dimethyl sulfoxide (DMSO).
5.2. Materials and Methods
5.2.1. Ethics Statement
All animal procedures were approved by the Institutional Animal Care and Use Committee
(Protocol #07-049).
5.2.2. Study Design
Subcutaneous adipose tissues from dorsolateral to the base of the tail were collected from 4 adult,
thoroughbred gelding horses (10.7±5.9 years of age, mean ±standard error of the mean (SEM)).
Different type I collagenase concentrations, 0.1%, 0.05%, and 0.025%, wt were used in adipose
tissue digests for ASC isolation. Stromal vascular fraction (SVF) cells from the series collagenase
digests were equally divided into two portions, fresh and cryopreserved. Identical cell aliquots
were cryopreserved in two different cryopreservation media: 1: 80% fetal bovine serum (FBS),
10% dimethyl sulfoxide (DMSO), and 10% Dulbecco’s Modified Eagle Medium: Nutrient
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Mixture F-12 (DMEM) (C1); or 95% FBS and 5% DMSO (C2) in liquid nitrogen for 30-60 days.
Two distinct cell subpopulations were sorted from fresh and cryopreserved cells via FACS, CD44+,
CD105+, the major histocompatibility complex class II (MHCII) - and CD44+, CD105+, MHCII+
cells. Cell doublings (CDs) and doubling times (DTs) were determined for all the cell groups.
Fibroblastic (CFU-F), osteoblastic (CFU-Ob), and adipocytic (CFU-Ad) colony-forming unit
frequency percentages and lineage-specific target gene mRNA expression levels were determined
(peroxisome proliferator-activated receptor γ (PPAR-γ), leptin – adipogenesis; alkaline
phosphatase (ALP), bone sialoprotein (BSP) – osteogenesis, sex determining region Y-box 2
(SOX2), Nanog - progenitor) after culture in lineage-specific induction or stromal media. The
oncogene mRNA expression levels were determined (β catenin, Notch 1, and FAS) after culture
in stromal media. Materials were from Sigma-Aldrich, St. Louis, MO unless otherwise noted.
5.2.3. Cell Isolation, Expansion and Cryopreservation
Subcutaneous adipose tissue was harvested from 4 adult euthanized thoroughbred gelding horses
(10.7±5.9 years of age, mean ±standard error of the mean (SEM)). Cells were isolated according
to published procedures with minor modifications [245]. Adipose tissue was weighed and rinsed
with phosphate buffered saline (PBS, Hyclone, Logan, UT) and minced. The minced tissues were
mixed with an equal volume of PBS for 3 minutes. The mixture was allowed to separate into two
phases and the upper phase was digested with one of three type I collagenase digestion
concentration digests: Group 1, 1% bovine serum albumin (BSA, Fisher Bioreagents, Fair Lawn,
NJ) and 0.1% collagenase type I (Worthington Biochemical Corporation, Lakewood, NJ) in
Dulbecco’s modified Eagle’s medium: F-12 (DMEM/F-12, Hyclone, Logan, UT); Group 2, 0.5%
BSA and 0.05% collagenase type I in DMEM/F-12; Group 3, 0.25% BSA and 0.025% collagenase
type I in DMEM/F-12). The commercial collagenase type I was from the same batch and contained
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no less than 125 activity units per mg. All digests were for 90 min with agitation at 37oC. The
digest was then filtered with 100 μm nylon cell strainers (BD Falcon, Bedford, MA) and then
centrifuged (260 × g, 5 min) to form the cell pellet. The cell pellet was suspended in 1% BSA in
DMEM and the mixture was centrifuged (260 × g, 5 min) and an equal volume of red blood cell
lysis buffer (0.16 mol/L NH4Cl, 0.01 mol/L KHCO3, 0.01% ethylenediaminetetraacetic acid
(EDTA)) was added. The mixture was maintained at room temperature for 5 min and centrifuged
(260 × g, 5 min) to remove red blood cells. The resulting stromal vascular fraction (SVF) pellet
was resuspended in stromal medium (10% FBS (Hyclone), 1% antibiotic/antimycotic solution in
DMEM) followed by culture (37 oC, 5% CO2) in T75 flasks (Fisher Scientific, Fair Lawn, NJ).
Medium was refreshed after 24 hours to remove unattached cells and then every 3 days [18]. The
cell yield was evaluated with 0.1% trypan blue staining by hemocytometer. Subsequent passages
were performed at 70-80% cell confluence. For purposes of this study, the primary cell isolated
was the SVF and the first cell passage of primary cells was P0. Aliquots (~ 1× 106 cells) of each
SVF were suspended in two freezing media, Cryo 1: 10% DMEM, 10% dimethyl sulfoxide
(DMSO, Fisher Scientific), 80% FBS; and Cryo 2: 5% DMSO and 95% FBS). CoolCell® was
employed to maintain the cooling rate at about -1°C/min and the container was kept at -80 oC
overnight when samples were moved to liquid nitrogen. The cryopreserved cells were kept in
liquid nitrogen for a minimum of 30 - 60 days and then moved to a 37oC water bath for 1-2 min
until the ice dissolved. The cryopreserved cells were seeded in T75 flasks as P0 after the
cryopreservation period.
5.2.4. Antibody Labeling
The Dylight 488 and Dylight 633 antibody labeling kits (Thermo Fisher Scientific, Somerset, NJ)
were used to label equine specific antibodies against CD44 and MHCII, respectively, according to
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the manufacturer’s instructions. Briefly, 100 μl antibody solution (1 mg/ml) was mixed with 8 μl
borate buffer and the mixture was incubated with DyLight Reagent for 60 min at room temperature
protected from light. The labeling reaction was mixed with the resin and then centrifuged (1000
× g, 1 min) to collect the purified antibody.
5.2.5. Fluorescence Activated Cell Sorting (FACS)
Fresh and cryopreserved P0 cells were equally divided to two cohorts: unsorted cells and sorted
cells. The sorted cells were incubated with antibodies that are equine specific or validated for
equine cross reactivity (CD44-488, CD105-PE, MHCII-633) for 30 min at room temperature. The
target cell populations (negative cells: CD44+, CD105+, MHCII-; positive cells: CD44+, CD105+,
MHCII-) were sorted and quantified by flow cytometry using a FACS Calibur flow cytometer and
Cell Quest Pro Software (BD Biosciences, San Jose, CA). Both cell populations were cultured in
stromal medium.
5.2.6. Cell Expansion
Cells were cultured in 12-well plates (Thermal Fisher Scientific) at an initial density of 5,000
cells/cm2. The cell number was evaluated after 2, 4, and 6 days of culture. Cell doublings (CDs)
and doubling times (DTs) were determined with duplicate cultures and calculated with the standard
formulae (CD= ln(Nf/Ni)/ln(2) and DT =CT/CD; Ni: initial cell number; Nf: final cell number;
CT: culture time) [18]. Cell counts were performed with the alamar blue metabolism assay.
Alamar blue (Thermo Fisher Scientific) was added to the culture medium for a final concentration
of 10%. The mixture was incubated about 4 hours at 37oC in darkness. Absorbance corresponding
to cell number was read at 570 nm and 600 nm. Day 2 and 4 cell numbers were used as the Ni for
Day 4 and 6, respectively.
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5.2.7. Multipotentiality – Limiting Dilution Assays
Limiting dilution assays were used to evaluate fibroblastic (CFU-F), osteoblastic (CFU-Ob), and
adipocytic (CFU-Ad) colony-forming unit frequencies [96]. For all cell populations, 8 replicates
of 5000, 2500, 1250, 625, 312 or 156 cells/well were seeded in 96-well plates and cultured in
stromal medium for 7 days. The CFU-F colonies were fixed with 4% paraformaldehyde and
stained with 0.1% toluidine blue. For CFU-Ob, cells were cultured in stromal medium for 7 days
followed by culture in osteogenic medium (DMEM/F-12, 10% FBS, 1% antibiotic/antimycotic
solution, 10 mmol/L β-glycerophosphate, 20 nmol/L dexamethasone, and 50 µg/ml sodium 2phosphate ascrobate) for another 4 days. Cells were rinsed 3 times with 150 mM NaCl and then
fixed with 70% ethanol and stored at 4 oC overnight. Cells were stained with a 2% alizarin red
solution for 10 min at room temperature and followed rinsed 5 times with distilled water. To
determine CFU-Ad, cells were cultured in stromal medium for 7 days followed by culture in
adipogenic

induction

medium

(DMEM/F-12,

3%

FBS,

5%

rabbit

serum,

1%

antibiotic/antimycotic solution, 33 µmol/L biotin, 17 µmol/L pantothenate, 100 nmol/L insulin, 1
µmol/L dexamethasone, 500 µmol/L isobutylmethylxanthine (IBMX), 5 µmol/L rosiglitazone
(TZD)) for 3 days. The same medium without IBMX and TZD was used as maintenance medium
to culture the ells for additional 3 days. The cells were fixed in 1% PFA at room temperature and
stained with 0.3% oil red O for 15 min. Wells were considered positive for fibroblastic, adipocytic
or osteoblastic when there were ≥ 10 toluidine blue stained, ≥ 10 oil red O-stained, or ≥ 1 alizarin
red stained colonies, respectively. The ratio of negative to total wells per row was used to compute
the CFU frequencies according to Poisson’s ratio (F=e-x; F: ratio of negative to total wells; e:
natural logarithm constant 2.71; x: CFU/well) [18, 96, 181].
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Table 11. Primer Sequences
Lineage

Primer

Housekeeping

GAPDH

Sequences

Accession No.

F: AAGAAGGTGGTGAAGCAGG
NM_001163856.1
R: CTCAGTGTAGCCCAGGATG
F: CTCTGGTAGTGCTGGGACATGTG
SOX2

XM_003363345.3
R: AGTACAACTCCATGACCAGCTC

Stromal
F: ACTGTCTCTCCTCTGCCTTC
Nanog

XM_014740545.1
R: TCTTCCTTCTTTGCCTCG
F: GGAGTATGAGATGGACGAG

ALP

XM_005607380.2
R: GTAGTGAGAGTGCTTGTGCC

Osteogenic
F: GAAGAATCGGACGCTGAG
BSP

XM_001496125.4
R: ATCGTAGACAGGGTGGTG
F: CCACTGACCAAAGCGAAG

PPAR-γ

XM_001492430.3
R: TGAGCGAAACTGACACCC

Adipogenic
F: GTTGAAGCTGTGCCAATCCG
Leptin

XM_014738998.1
R: CATCTTGGACAAACTCAGGAC
F: ACACAGACAAGCCACATC

FAS

XM_014733084.1
R: GCAATCAGTAACAGGAACAG
F: TTCGTGCTGCTCTTCTTC

Oncogenic

Notch1

XM_014736246.1
R: TGGTCTGTCTGGTCATCC
F: CAGGTGGTGGTGAATAAGG

β-catenin

NM_001122762.1
R: GTTGTGGAGAGTTGTAATGG
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5.2.8. Gene Expression – RT-PCR
Total RNA was extracted from cells (EZNATM Total RAN kit II, Omega bio-tek, Norcross, GA,
USA) and the concentration determined spectrophotometrically (NanoDrop ND-1000; NanoDrop
Technologies, Montchanin, DE). The RNA was transcribed to cDNA using Maxima First Strand
cDNA synthesis kit (Thermo Scientific) and target gene mRNA levels, glyceraldehyde 3phosphate dehydrogenase (GAPDH), PPAR-γ, Leptin, ALP, BSP, SOX2, Nanog, FAS, β-catenin,
and Notch1 (Table 11), were quantified with RT-PCR using SYBR Green (Absolute Blue qPCR
kit, Thermo Scientific) technology and HT7900 (Applied Biosystems, Darmstadt, Germany). The
ΔCt values were determined relative to the reference gene GAPDH.
5.2.9. Statistical Analysis
Statistical analyses were performed with the JMP statistical package (SAS Institute, Cary, NC).
Mixed ANOVA models were used to evaluate cell yield, cell immunophenotype percentages, CD,
DT, CFU frequency percentages and gene expression among cell types. Tukey’s post hoc tests
were applied for multiple group comparisons (p<0.05).
5.3. Results
5.3.1. ASC Isolation
Cell yields were 2.6 ± 0.5 × 105, 2.1 ± 0.5 × 105, and 1.2 ± 0.5 × 105 nucleated cells/g adipose
tissue for 0.1%, 0.05%, and 0.025% type I collagenase solution, respectively. The cell yield from
0.025% collagenase was significantly lower than for 0.1% (Fig. 34).
5.3.2. Immunophenotype
The percentages of negative (MHCII-, CD44+, CD105+) cells from the series of collagenase
digests were not significantly different (Fig. 35a).

Additionally, there were no significant

differences between percentages of negative cells among fresh cells, or those cryopreserved with
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either medium, Cryo 1 or Cryo2 (Fig. 35). A similar pattern was found in the percentages of
positive (MHCII+, CD44+, CD105+) cells (Fig. 35b).

Figure 34. Equine adipose tissue ASC yield (mean ± SEM, n=4) from three different type I
collagenase digest concentration (0.1%, 0.05%, 0.025%). Columns with different superscripts are
significantly different from each other (p<0.05)
5.3.3. Cell Expansion
Fresh cells isolated with distinct collagenase concentrations had similar CD and DT values.
Cryopreserved cells had similar CD and DT values for 5 and 10% DMSO cryopreservation
medium (Fig. 36). Since the percentages of positive and negative cells (Fig. 35) and in vitro
expansion rates (Fig. 36) from

different collagenase concentrations were similar,

immunophentoypes from different digests were combined within fresh and cryopreserved cells.
Following cell sorting after cryopreservation, there were very few MHCII+, CD44+,
CD105+ cells (7077 ± 8953 cells), and the cell isolates did not grow well. Therefore, CD and DT
values are not included in the results. The CDs of fresh, unsorted cells were significantly higher
compared to other cell populations (Fig. 37a), while the corresponding DT in fresh unsorted cells
was significantly lower than other cell populations (Fig. 37b). After cryopreservation, negative
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cells had similar growth parameters as the unsorted, cryopreserved cells. However, the fresh
positive and negative cell populations had significantly lower and higher CD and DT versus fresh,
unsorted cells, respectively.

Figure 35. Percentages (LS mean ± SEM) of fresh and cryopreserved cells isolated with digests
containing type I collagenase concentrations 0.1, 0.05, or 0.025% with immunophenotype CD44+,
CD105, and MHCII- (a), or MHCII+ (b). Cryo1: 80% FBS, 10% DMSO in DMEM/F-12; Cryo2:
95% FBS, 5% DMSO.
5.3.4. Multipotentiality- Limiting Dilution Assays
All cell populations maintained a fibroblastic-like morphology when cultured in stromal medium
(Fig. 38a). In osteogenic medium, calcium deposits in cell coloies stained with alizarin red (Fig.
38b). After adipogenic medium culture, robust lipid droplets stained with oil red O (Fig. 38c).
The CFU frequency percentage indicates the percentage of cells from a cell population that
have can form CFU-F, -Ob, or –Ad colonies.

Fresh MHCII-, CD44+, CD105+ cells had

significantly higher CFU-F than cryopreserved cells or cryopreserved cells (Fig. 39a). After
cryopreservation in medium with either 5 or 10% DMSO, unsorted cells had the significantly
lowest CFU-Ob frequency among all cell isolates (Fig. 39b).
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Figure 36. Cell doublings (CD) and doubling times (DT) (LS mean ± SEM) from fresh and
cryopreserved cells isolated with 0.1, 0.05, or 0.025% collagenase I digests. Cryo1: 80% FBS,
10% DMSO in DMEM/F-12; Cryo2: 95% FBS, 5% DMSO.

Figure 37. Cell doublings (CD) (a) and doubling times (DT) (b) (mean ± SEM) of fresh and
cryopreserved equine ASC isolates that were unsorted, MHCII+, CD44+, CD105+ (+) or MHCII-,
CD44+, CD105+ (-). Cryo1: 80% FBS, 10% DMSO in DMEM/F-12; Cryo2, 95% FBS, 5%
DMSO. Columns with distinct superscripts are significantly different (p<0.05).
5.3.5. Gene Expression
Lineage-specific Gene Expression
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When the cells were cultured in stromal medium, fresh MHCII-, CD44+, CD105+ cells had lower
SOX2 and Nanog (Fig. 40A and B) expression compared unsorted cells. The MHCII-, CD44+,
CD105+ cells had greater SOX2 expression (Fig. 40A), but lower Nanog expression (Fig. 40B)
after cryopreservation with 10% DMSO compared to unsorted cells with the same
cryopreservation medium. After cryopreservation in medium with 5% DMSO MHCII-, CD44+,
CD105+ Nanog expression was higher than unsorted cells (Fig. 40B). For the induced cells, fresh
MHCII-, CD44+, CD105+ cells had higher ALP expression (Fig. 40C) than unsorted and the same
immunophenotype had higher ALP (Fig. 40C) and BSP (Fig. 40D) expression versus unsorted
cells after cryopreservation with 5% DMSO. After culture in adipogenic medium, the PPAR-γ
and leptin expression (Fig. 40 E and F) in fresh and Cryo1 unsorted cells were significantly higher
than fresh MHCII-, CD44+, CD105+ and Cryo1 MHCII-, CD44+, CD105+cells, respectively.

Figure 38. Photomicrographs of equine ASCs after 7 days of culture in stromal medium with
toluidine blue staining a, 5 ×; with alizarin red staining of calcium deposition after 4 days of culture
in osteogenic medium b, 5 ×; with oil red O lipid staining after 3 days of culture in adipogenic
induction medium followed 3 days of adipogenic maintenance medium, c, 5 ×. Scale bar = 200
µm.
For the cells cultured in stromal medium, the significant differences among cell types
within cell subpopulations included Cryo2 negative cell subpopulation had the highest SOX2 and
Nanog expression than other negative cell subpopulations. Cryo1 negative cell subpopulation had
higher SOX2 expression than fresh negative cell subpopulation (Fig 40A). For unsorted cells,
fresh cells had higher and lower SOX2 expression versus Cryo1 and Cryo2 cells, respectively (Fig.
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40A and B). For the induced cells, the mRNA level of ALP in fresh negative cells was greater
versus cryopreserved negative cells regardless of cryopreservation methods (Fig. 40C) within cell
subpopulations. However, the Cryo2 negative cells had higher BSP expression versus other
negative cell subpopulations (Fig. 40D). On the other hand, after adipogenesis, the cryopreserved
negative cells had greater leptin expression versus fresh negative cells, while the fresh and Cryo1
unsorted cells had greater leptin expression versus Cryo2 unsorted cells (Fig. 40F).

Figure 39. Colony forming unit (CFU) frequencies (LS mean ± SEM) for the same cell populations
as Figure 32 following culture in stromal (CFU-F), osteoblastic (CFU-Ob), or adipogenic (CFUAd) medium. Columns with different superscripts are significantly different among cell
populations (p<0.05).
Oncogene expression
The mRNA levels of FAS and β-catenin in Cryo2 negative cells were significantly lower than
Cryo2 unsorted cells (Fig. 41A and C). The negative fresh cell subpopulation had lower β-catenin
expression than fresh unsorted cells (Fig. 41C). Significant differences within cell subpopulations
among treatments included higher FAS expression by Cryo1 negative cells versus Cryo2 negative
cells. Fresh, unsorted cells had higher Notch1 and β-catenin expression versus unsorted Cryo1
and Cryo2 cells, respectively (Fig. 41B and C).
5.4. Discussion
The findings of this in vitro study indicate that the collagenase concentrations used to digest equine
adipose tissue do significantly affect percentages of MHCII-, CD44+, CD105+ and MHCII+,
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CD44+, CD105+ isolated despite the fact that higher collagenase concentrations result in higher
nucleated cell numbers.

Post-isolate expansion rates are not impacted by collagenase

concentration, either. Additionally, MHCII+ and – cells have lower proliferation rates compared
to fresh, unsorted cells after cryopreservation with 5 or 10% DMSO. Perhaps of greatest
importance is that cryopreservation may reduce the oncogene expression (β-catenin, Notch1) and
enhance cell plasticity, especially when cells are cryopreserved in 5% DMSO.

Figure 40. The relative expression (LS mean ± SEM) of stromal (A, B), osteogenic (C, D), and
adipogenic (E, F) target gene mRNA levels in the same cell populations as Figure 32. The ΔCt
values are reported relative to the reference gene glyceraldehyde 3-phosphate dehydrogenase
(GAPDH). Columns within distinct superscripts are significantly different among cell
subpopulations within treatments and those with different numbers of asterisks (*) are significantly
different among treatments within cell subpopulations (p<0.05).

104

A collagenase digest of 0.1% collagenase type I and 1% BSA has been used to isolate equine ASCs
for several years [291]. MSCs are surrounded by a connective tissue matrix with several cell
subpopulations including adipocytes, nerve tissue, stromal vascular cells, and immune cells [369].
The commercial collagenase type I widely used in ASC isolation is made up of multiple enzymes
like collagenase, proteases, polysaccharidases, and lipase to dissociate the collagen fibers, proteins,
polysaccharides, and lipids to release the cells. Higher concentrations are thought to support better
tissue digestion, but they also run the risk of more foreign protein residues [358]. The results of
this study show comparable ASC isolation with the lower collagenase concentration under
identical conditions supporting use of less concentrated collagenase in the digest.

Figure 41. Fas cell surface death receptor (FAS) (A), Notch 1 (B), and β-catenin (C) (LS mean ±
SEM) expression in the same cell populations as Figure 33 after 7 days culture in stromal medium.
The ΔCt values are reported relative to the reference gene glyceraldehyde 3-phosphate
dehydrogenase (GAPDH). The ΔCt values are reported relative to the reference gene
glyceraldehyde 3-phosphate dehydrogenase (GAPDH). Columns within distinct superscripts are
significantly different among cell subpopulations within treatments and those with different
numbers of asterisks (*) are significantly different among treatments within cell subpopulations
(p<0.05). See Fig. 32 for acronym definitions.
An important findings of this work is the slower proliferation rates of CD44+, CD105+,
MHCII+ and MHCII- cells fresh and cryopreserved cells compared to paired, unsorted cells. CD44
and CD105, non-integrin receptors [370], are common stromal cell surface markers [371].
Preadipocyte and endothelial cell subpopulations isolated from human SVF cells have higher
proliferation rates compared to the unsorted cells [343, 372]. These cells were unlikely to be
present in the populations studies as they do not express CD44 and CD105 [371]. However, the
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presence of these cells in unsorted populations could explain the observed higher expansion rates.
Cryopreserved cells had lower proliferation rates than the fresh cells regardless of cryopreservation
medium similar to previous reports of human and canine ASC [6, 23, 24] while there was few
effect on the negative cells, suggesting the negative cells are more stable and predictable than other
cell subpopulations in unsorted cells during cryopreservation.
Lower CFU-F and CFU-Ob in cryopreserved cells is consistent with established
knowledge in many species including human [23], though results vary among studies from no
effect vitro [373]. Another interesting finding in this study is that the osteogenic differentiation in
equine unsorted ASCs was not impaired by the cryopreservation in vitro.

However, the

osteogenesis in negative cells was affected. Several studies demonstrated that the effects of
cryopreservation on osteogenesis were limited and the osteogenic capability is impaired in the late
passage [6, 25, 85].

However, some conflicting results showed the deleterious effects of

cryopreservation on osteogenic differentiation of human ASCs [23]. In the present study, the
effects of cryopreservation on negative cells were distinct between the early and late osteogenic
genes. ALP serves as the early marker of osteogenic differentiation whereas BSP is characteristic
of the terminally differentiated osteoblast [374]. Notably the lower ALP expression in negative
cells from Cryo2 treatment suggested the negative cells from cryopreserved cells were more
mature especially the cells were cryopreserved in the Cryo2 composed of 5% DMSO. Additionally,
the effects of cryopreservation on the negative cells from Cryo1 treatment are distinct to that from
Cryo2 treatment, which indicates the osteogenic differentiation was impaired due to higher DMSO
concentration in the cryopreservation medium. Overall the adipogenic capability in the negative
(MHCII-, CD44+, CD105+) cells was weaker than that in unsorted cells. Since several cell
subpopulations resident in the unsorted cells such as pre-adipocyte and hematopoietic
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stem/progenitor cells these cell subpopulations also had multipotent capabilities which may
contribute to the adipogenic differentiation [75, 371]. Additionally, the differentiation abilities in
human pericytes isolated from adipose tissue are greater than their MSC counterparts [375].
Generally, SOX2 was the stemness markers to evaluate the multipotency of MSCs [15, 16],
while in some studies SOX2 is involved in human tumor and cancer initiation [376]. We found
that cryopreserved cells showed enhanced SOX2 expression level.

The enhanced SOX2

expression after cryopreservation may indicate the oncogenic potential in equine ASCs was
initialed and enhanced. Some studies demonstrated that the overexpression of SOX2 in porcine
bone marrow stem cells (BMSCs) resulted in higher proliferation [9]. However, in another study,
the human cryopreserved ASCs showed increased expression of SOX2 after 3 month
cryopreservation in the cryopreservation medium (5% DMSO or 10% DMSO in DMEM/Ham F12 with or without FBS) compared to fresh cells, while their proliferation rate was not affected
[15]. In this study, the proliferation rate in the cryopreserved cells was impaired which indicated
the effects of SOX2 on ASCs are distinct with other studies may due to the species differences. In
fact, the proliferation and differentiation activity of MSCs is mainly affected by other factors,
including culture environment and oxygen tension level [15, 16]. Nanog is another transcription
factor used to regulate the maintenance of the pluripotent state in adult stem cells [377]. The
expression of Nanog is highly controlled in normal human cells while in different types of cancer
Nanog has high expression [378, 379]. The expression of Nanog was enhanced in negative cells
from cryopreserved cells kept at 5% DMSO may indicate the embryonic potential in the cell
subpopulation was enhanced. In short, cryopreserved equine cells maintained their SOX2 and
Nanog expression which are considered as the pluripotency genes [376], but the proliferation rate
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was hampered. More importantly, the enhanced oncogenic potential in cryopreserved cells also
needs to be considered.
In the whole study, the expression of Notch1 and β-catenin was lower in the cryopreserved
unsorted cells than that the fresh cells. Lower β-catenin expression in cryopreserved cells may
result from the present of DMSO.

DMSO as a permeable CP is widely used in MSC

cryopreservation [6, 43]. The hydrophobic interactions of DMSO can denature and deactivate
vital proteins as well as protect them [50]. β-catenin is an integral structural component of
cadherin-based adherens junctions and the imbalance in the structural [380]. The decreased
expression of β-catenin may result from the denaturation and deactivation. The Wnt/β-catenin and
Notch signaling pathways may contribute to the regulation of stem cell/progenitor cell self-renewal
in many tissues [381]. The dysregulation of β-catenin and Notch1 is associated with a number of
tumors, including epidermal tumors and T-cell leukaemias [381]. In adult organs, Wnt signaling
works as indispensable roles in tissue homeostasis, cell renewal, and regeneration and β-catenin
triggers the transcription of Wnt-specific genes responsible for the control of cell fate decisions
[380]. After cryopreservation the decreasing expression of β-catenin and Notch1 could result in
the fate of cryopreserved cell is out of control and enhance the oncogenic potential in these cells.
FAS (also called CD95 and APO-1) is regulated as the prototypical cell death receptor of
the tumor necrosis factor receptor (TNFR) superfamily and initiates apoptosis [382, 383]. The
down regulation of FAS has been demonstrated to promote tumor growth and cells are rendered
apoptosis resistant [101, 242, 384]. In the present study, the mRNA level of FAS in negative cells
from Cryo2 cells was lower than other negative cell subpopulations. In the previous study, FAS
ligand expression is rather restricted to the cells of T cell lineage [383] and the FAS-FAS ligand
interactions can trigger the cell death by apoptosis [385, 386]. Additionally, the FAS is required
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for MSCs therapy by recruitment of T cells [387]. The downregulation of FAS expression can
result in reduced multiple cytokines (e.g. monocyte chemoattractant protein-1 (MCP-1),
transforming growth factor-β (TGF-β)) secretion, and fail to upregulate the levels of Tregs and
induce T cell apoptosis in human bone marrow mesenchymal stem cells (BMMSCs) [387]. The
present results suggest the negative cells (MHCII-, CD44+, CD105+) from Cryo2 cells had the
relative low risk to be recognized by the immune system and low diminished apoptotic potential.
Overall, based on the results in the present study, we found that negative cells (MHCII-,
CD44+, CD105+) from the ASCs isolated from equine subcutaneous adipose tissue have more
predictable in vitro behaviors compared to the unsorted cells. As the current knowledge, ASCs
are composed of several cell populations, including endothelial cells, preadipocytes, pericytes and
other cells [75, 332, 363]. The percentages of these cell populations are variable due to individual
characteristics [75]. Therefore, selected negative cells from the heterogeneous population may
provide a predictable cell population and cryopreservation enhanced osteogenesis in the negative
cells.

Additionally, the embryonic potential may be enhanced in the negative cells after

cryopreservation and the risk of apoptosis is lower than other cell populations, especially 5%
DMSO was employed, which indicated 5% DMSO is recommended for the equine ASC
cryopreservation. The oncogene expression (Notch1 and β-catenin) in negative cells is more stable
than unsorted cells regardless of cryopreservation medium.
As a whole, the results from this in vitro study showed that lower collagenase concentration
(0.05%) is recommended for equine ASC isolation. More important findings in the present study
is the selected specific cell subpopulation from a heterogeneous population based on cell
immunophenotype profile can provide predictable and stable in vitro cell properties. To reduce
the cytotoxicity of cytoprotectants and retain embryonic potential, 5% DMSO for the
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cryopreservation of equine ASCs is recommended. Further, the relationship of tumor development
and cryopreserved cells in genetic levels must be confirmed before the cryopreserved cells are
used in clinical trials.
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CHAPTER 6. FELINE ADIPOSE DERIVED MULTIPOTENT STROMAL CELLS
HAVE TRANSDIFFERENTIATION ABILITY TO FORM FUNCTIONAL ISLET-LIKE
CELL CLUSTERS

6.1. Introduction
Diabetes mellitus is one of the most prevalent feline endocrinopathies, and about 15-20% of feline
diabetes cases are caused by decreased β-cell numbers or insulin resistance [308, 320, 388, 389].
The condition affects all breeds and sexes and is associated with reproductive sterilization [390,
391], obesity, physical inactivity [392], and advancing age [393] and drug side effects [308, 320,
388]. To date, no single cause or effective cure has been identified. Serious complications
associated with unregulated glucose levels include increased bone fractures [394], cardiovascular
disease [395], and neurological dysfunction [396], among others.

Contemporary treatment

consists of diet and weight management with exogenous insulin administration to replace that
normally produced by pancreatic β cells [397]. Available insulin formulations do not share the
feline amino acid sequence. Though insulin maintains biological activity across species, sequence
differences may affect activity and stimulate the immune system [398, 399]. Additionally, insulin
administration must be customized for individual patients, a challenging and time-consuming
process. The time and costs associated with establishing and revising insulin therapy and daily
injections can be a burden on the owners.
Due to their ability to differentiate into multiple tissues from the same embryonic layer [85,
400, 401], adult multipotent stromal cells (MSC) are increasing in popularity to restore issues lost
to trauma or disease.

Current knowledge also supports the additional ability of MSCs to

“transdifferentiate” into tissues that originate from other embryonic layers [402-404].

A

contemporary example of transdifferentiation is the differentiation of adipose-derived multipotent
stromal cells (ASCs) of mesodermal lineage into insulin producing cells (IPCs) of endodermal
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lineage. This has been accomplished in several species [106, 108, 404, 405], and creates an
opportunity to restore natural dynamic glucose regulation provided by β-cells without the
morbidity and potential complications of pancreatic tissue transplants [406, 407].
A mechanism to isolate specific ASC immunophenotypes from adipose tissues removed
with reproductive organs during routine feline sterilization procedures was recently developed in
our laboratory [85]. This study was designed to quantify the transdifferentiation capability of
feline ASCs isolated from the reproductive organs. The tested hypothesis was that fresh feline
ASCs cultured in pancreatic β cell induction medium had better insulin production and glucose
response compared to that cultured in stromal medium.
6.2. Materials and Methods
6.2.1. Study design
Feline ASCs were isolated by the method developed in our published study from adipose tissue
removed during routine sterilization of 8 male and 8 female adult cats [85]. For the purposes of
this study, the stromal vascular fraction was the primary cell isolate, and passage (P) 0 was the
first cell passage. Fresh cells were expanded to P3 and then paired samples were cultured in
stromal or three-step islet cell induction medium. The zinc concentration, insulin production, and
ultrastructure was compared between stromal cells and the induced cells from stage 3. Multipotent
capacity and lineage specific gene expression (insulin, NK6 homeobox 1 (NK6.1), proto-oncogene
tyrosine-protein kinase ROS1 (ROS1), somatostatin (STS), ISL LIM homeobox 1 (Isl1), glucagon
(GCG), paired box 6 (Pax6), AKT serine/threonine kinase 1 (AKT1), Ras-related protein Rab-2A
(RAB2A), hexokinase 1 (HK1), and glucose transporter 2 (Glut2)) was compared between culture
conditions in male and female donors. All materials and reagents were from Sigma-Aldrich, St.
Louis, MO unless otherwise noted.
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6.2.2. Cell Isolation
Adipose tissues were harvested from reproductive organs removed for elective sterilization and
cells were isolated as published with minor modifications [85]. Tissue was minced and digested
with 0.3% type I collagenase (Worthington Biochemical Corporation, Lakewood, NJ) in Kreb’s
Ringer buffer (KRB) for 30 minutes, 1,000 rpm stirring with a stir bar at 37oC. After filtering
(100 μm nylon cell strainers, BD Falcon, Bedford, MA) and centrifugation (260 × g, 5 min), the
resulting SVF pellets were resuspended in 5 ml red blood cell lysis buffer (0.16 mol/L NH4Cl,
0.01 mol/L KHCO3, 0.01% ethylenediaminetetraacetic acid (EDTA)) for 5 min. The SVF was
collected after centrifugation (260 × g, 5min) and seeded in 10-mm cell culture dishes in stromal
medium (Dulbecco’s modified Eagle’s medium F-12 (DMEM/F-12, Hyclone, Logan, UT), 1%
antibiotic/antimycotic solution (MP Biomedical, Irvine, CA), 10% fetal bovine serum (FBS,
Hyclone)). Stromal medium was refreshed after 24 hours and then every 3 days. After 70-80%
confluence, the SVF cells were detached with 0.05% trypsin (Hyclone) and cells were seeded in
T75 flasks with the density of 5 ×103 cells/cm2 for P0 and all subsequent passages. Procedures
performed at temperatures other than room temperature are indicated.
6.2.3. Multipotentiality
To confirm multipotentiality, P1 fibroblastic colony formation and adipogenic and osteogenic
differentiation tested cell isolates. For fibroblastic colony formation, P1 cells were cultured in
stromal medium for 7 days, fixed with 4% formalin, and stained with 0.1% toluidine blue. To
assess adipogenesis, cells were cultured in stromal medium to 70-80% confluence, washed with
phosphate buffered saline (PBS, Hyclone) and then cultured in adipogenic medium (Table 12) for
10 days. They were then fixed with 4% neutral paraformaldehyde (PFA) and stained with oil red
O. For osteogenesis, the cells were cultured in stromal medium as above the then in osteogenic
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preinduction medium for 10 days followed by osteogenic induction medium (Table 18) for another
10 days. Colonies were fixed with 70% ice cold ethanol and stained with 2% alizarin red.
6.2.4. Differentiation of feline ASCs into IPCs.
Cell isolates were culture expanded to P3. At 70-80% confluence, they were seeded in 6-well
ultralow attachment plates (Corning, Corning, NY) at 1 × 106 cells/well and cultured for 7 days in
stromal medium. A three-stage protocol was used to induce β-cell islet-like clusters (Table 12).
The cells in ultralow attachment plates were incubated in serum free medium (SFM) 1 for 2 days
as stage 1 and then in SFM 2 for another 6 days as stage 2. Cells were then manually transferred
to a standard 6-well plate (Thermo Fisher Scientific, Waltham, MA, USA) culture in stage 3
induction medium for another 4 days. All media were refreshed every 2 days. Paired cells were
cultured in stromal medium in standard 6 well plates throughout the induction process.
6.2.5. Dithizone Staining – Zinc Concentration
Following the induction process, cells were incubated with dithizone (DTZ, Fisher Scientific,
Fairlawn, NJ) solution (10 μl DTZ working solution (1 mg/ml in dimethyl sulfoxide (Fisher
Scientific)) in 1 ml of the culture medium) for 30 min at 37 oC. Cells were washed in PBS after
incubation and imaged with light microscope.
6.2.6. Immunohistochemistry – Intra-cellular Insulin
The Dylight 633 antibody labeling kit (Thermo Fisher Scientific, Somerset, NJ) was used to label
the antibody goat anti insulin according to the manufacturer’s induction. Briefly, 100 μl antibody
solution (1 mg/ml) was mixed with 8 μl supplied borate buffer and the mixture was incubated with
Dylight Reagent for 60 min protected from light. The labeling reaction was mixed with resin and
then centrifuged (1000 × g, 1 min) to collect the labeled antibody.
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Table 12. Composition of induction medium for differentiation
Medium

Composition
Minimum essential medium alpha (α-MEM), 10% rabbit serum, 10% FBS,

Adipogenic
10nM dexamethasone, 5 μg/ml insulin, 50 μM 5,8,11,14-eicosatetraynoic acid
medium
(ETYA, Cayman, Ann Arbor, MI), 100 μM indomethacin
Osteogeinc pre-induction: DMEM, 10% FBS, 100 nM dexamethasone, 0.25
Osteogenic
mM L-ascorbic acid;Osteogenic induction medium: osteogenic preinduction
medium
medium supplemented with 10 mM β-glycerophosphate
Stage 1: SFM 1 (2 days): DMEM, 17.5mM glucose, 1% BSA (bovine serum
albumin), 1× insulin-transferrin-selenium (ITS, Gibco BRL, Gaithersburg,
MD), 4nM activin A (R&D Systems Inc., Minneapolis), 1 mM sodium butyrate,
50 μM 2-mercapethanol, 1% N-2 supplement (R&D Systems Inc.), 1% B-27
supplement (Gibco), 5 μg/ml laminin (Corning), 50 ng/ml recombinant human
hepatocyte growth factor (HGF, EMD Millipore, Temecula, CA), 20ng/ml
β-cell

basic fibroblast growth factor (bFGF, Gibco); Stage 2: SFM 2 (2 days): DMEM,

induction

17.5mM glucose, 1% BSA, 1 × ITS, 0.3mM taurine (ACROS Organics, Morris

medium

Plains, NJ), 5 μg/ml laminin, 20 ng/ml bFGF, 1% N-2 supplement, 1% B-27
supplement, 50 ng/ml HGF; Stage 3: SFM 3 (2 days): DMEM, 17.5 mM
glucose, 1.5% BSA, 1.5 × ITS, 3 mM taurine, 100 nM glucagon-like peptide 1
(GLP-1, TOCRIS bioscience, Ellisville, MO), 1 mM nicotinamide (ACROS
Organics), 1 × non-essential amino acids (NEAA, Gibco), 10 nM pentagastrin
(TOCRIS bioscience), 1% N-2 supplement, 1% B-27 supplement, 50ng/ml
HGF, 20ng/ml bFGF, 5 μg/ml laminin, 10 ng/ml betacellulin (R&D Systems)
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Cells were washed with PBS and fixed overnight in 4% neutral PFA.

They were

permeabilized with 0.5% Triton X-100 in PBS and then incubated with the labeled antibody goat
anti insulin (1:200 in PBS, Santa Cruz Technologies, CA) for 30 min. After incubation, the cells
were washed with PBS and then cytoskeletal actins was stained with β actin-FITC for 30 min (1:
500 in PBS, Neomarkers, Fremont, CA). Photomicrographs were obtained for all labeled cells
with confocal laser scanning microscopy (CLSM, Leica TCS SP2, Leica, Wetzlar, Germany).
6.2.7. Glucose Challenge Assay – Glucose Sensitivity
The induced islet-like cell clusters were collected and washed twice with PBS. The islet-like cell
clusters were incubated with KRB buffer for 1 hour at 37oC,followed by incubation with KRB
buffer supplemented with different glucose concentrations (25 and 55 mM) for 30 min at 37oC.
Following incubation, the medium was collected and stored at -80oC until further use. The stored
medium was analyzed for insulin content using a feline specific enzyme-linked immunosorbent
assay (ELISA) kit (Mybiosource, San Diego, CA). The cells cultured in stromal medium were
used as a control.
6.2.8. Transmission Electron Microscopy – Ultrastructure
Following a PBS rinse, cells were fixed in 2% PFA and 2.5% glutaraldehyde in 0.1 M PBS for 10
min. The samples were centrifuged (350 × g, 5 min) and then fixed with fresh fixative with gentle
agitation for 2 hours. They were mixed with equal amounts of 3% agarose and the mixture was
placed to a glass slide. When the mixture solidified, it was sliced into cubes. The cubes were
washed with 0.1 M PBS and 0.08M glycine 5 times (15 min/time) followed by incubation with 2%
osmium tetroxide in 0.1 M PBS in the darkness for 1 hour to fix the cells. The samples were
washed with H2O and dehydrated in a series of ethanol-distilled water solutions. The dehydrated
samples were infiltrated with 1:1 ethanol and LR white resin for 2 hours, and then infiltrated with
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100% LR white resin for another 2 hours. Embedded samples were placed into the bottom of a
beem capsule and incubated in an 18 oC oven for 24 hours. Ultra-thin sections (90 nm) were cut
and stained with 2% uranyl acetate and lead citrate. Some sections were directly evaluated with
transmission electron microscopy (JEOL JEM-1400, Japan). The other sections were blocked in
5% BSA in PBS for 30 min and then incubated with goat anti insulin in 0.1% BSA in PBS (1:20)
for another 90 min. After incubation, the sections were washed in 0.1% BSA in PBS 6 times (5
min/time) and then incubated in secondary antibody (rabbit anti goat IgG-Gold, Sigma-Aldrich)
in 0.1% BSA in PBS for another 90 min. After incubation, the sections were washed with 0.1%
BSA buffer and PBS, respectively. The sections were then fixed in 2% glutaraldehyde in PBS for
5 min and contrasted with 2% uranyl acetate and lead citrate after being thoroughly washed in
distilled water. Gold labeled sections were observed with TEM
6.2.9. Scanning Electron Microscopy – Surface Ultrastructure
Cells were collected by filtration and fixed in 2% PFA and 2% glutaraldehyde in 0.1 M PBS for
15 min. The solution was extracted into a 10 ml syringe with a Swinney filter holder fitted with a
2 μm pore polycarbonate with 13 mm diameter. Entrapped cells on the filtered were fixed as
before another 15 min and then rinsed with 0.1 M PBS and distilled water. The filter was removed
from the syringe and dried with hexamethyldisilazane (HMDS, Electron Microscopy Sciences,
Fort Washington, PA) for 30 min, 1:1 100% ethanol and HDMS, and 2 changes for 30 min each
with 100% HDMS. Finally the HDMS was removed and the samples were placed in a hood
overnight to air-dry. The dried samples were mounted onto aluminum SEM stubs, coated with
platinum in an EMS 550X sputter coater and imaged with JSM-6610 High vacuum mode SEM
(JEOL Ltd., Japan).
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6.2.10. RT-PCR – Gene Expression
Total RNA was isolated from cells harvested from each induction stage (EZNA® MicroElute Total
RNA kit, Omega, Bio-Tek, Norcross, GA). The quality and concentration was determined
spectrophotometrically (NanoDrop ND-1000; NanoDrop Technologies, Wilmington, DE), and
cDNA synthesized (Maxima First-Strand cDNA synthesis kit, Thermo Scientific, Waltham, MA).
Feline pancreatic target gene levels (insulin, Isl1, HK1, Glut-2, NK6.1, ROS1, STS, GCG, Pax6,
AKT1, and RAB2A) (Table 13 &14) were quantified with real-time RT-PCR using the Thermo
Fisher AbsoluteTM Blue QPCR Rox Mix technology and an ABI Prism 7900 HT Sequence
Detection System (Applied Biosystems, Foster City, CA) using feline-specific primers. The ΔCt
values were determined relative to the reference gene β-actin.
6.2.11. Statistical Analysis
All results are presented as least squares (LS) mean ± SEM. Statistical analyses were performed
with the JMP statistical package (v 13.0.0, SAS Institute Cary, NC). Mixed ANOVA models were
used to evaluate insulin levels between glucose concentrations within genders and between
genders within glucose concentrations. The same models were used to evaluate target gene
expression among induction stages within genders and between genders within induction stages.
Tukey’s post hoc tests were applied for multiple group comparisons (p<0.05).
6.3. Results
6.3.1. Multipotentiality
All cell isolates displayed osteogenic and adipogenic differentiation based on histochemical
staining. Cells had a fibroblastic shape when cultured in stromal medium (Fig. 42A). Colony
calcium stained with alizarin red following culture in osteogenic medium (Fig. 42B), and lipid
droplets stained with oil red O after adipogenic medium culture (Fig. 42C).
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Table 13. Insulin specific primer sequences
Lineage

Primer

Housekeeping

β-actin

Sequences

Accession No.

F: AGCCTTCCTTCCTGGGTATG
XM_006941899.3
R:ACAGCACCGTGTTAGCGTAG
F: AACGAAATACTTGGCGG
Nkx 6.1

XM_019829291.1
R:CCAGAGGCTTGTTGTAGTCG
F: GGCAATCGGTGGTAGTAA

Pax6

XM_019812231.1
R: CTTGGTATGTTATCGTTGG

Transcription

F: CAAGGACAAGAAGCGGAG

Factor
Isl 1

XM_003981424.3
R: CTGGGTTTGCCTGTAAGC
F: TTGGCTTGGATGAGTTACG

Glut 2

XM_003991916.3
R: GACTTTCCTTTGGTTTCCG
F: CTTCGTCAACCAGCACC

Insulin

XM_019811180.1
R: ACAGCATTGCTCCACGA
F: TGAACACCAAGAGGAACAA

Protein

Glucagon

XM_006935320.2
R: ACCAGCCAAGCAATGAAT
F: CCAGACAGAGAACGATGCC

Somatostatin

XM_003991805.4
R: CAGGGTTTGAGTTAGTGGA

6.3.2. Cell Morphology
All cells cultured in ultralow attachment plates formed cell clusters. Following transfer to a
standard six well culture plate, cells cultured in stromal medium attached to the plate in colony
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formation within 24 hours (Fig. 43A). The vast majority of those cultured in induction medium
did not attach at any point and remained as detached cell clusters (Fig. 43 B and C).
Table 14. Insulinoma primer sequences
Lineage

Primer

Sequences

Accession No.

F:AACAACAGCCTCTACTACAG
ROS1

XM_019831130.1
R: TATCCTCCGACCGAATCC
F: CCAACACCTTCATCATCCG

Akt1

NM_001322435.1
R: CCATCATTTCCTCCTCCTG

Oncogene
F: ACAGACAAGAGGTTTCAGC
RAB2A

XM_019822712.1
R: TATGACCGTGTGATGGAAC
F: TGAGAAGATGGTGAGTGGC

HK1

XM_006937834.3
R: GGCAGAGCGAAATGAGAC

6.2.3. Dithizone Staining – Zinc Concentration
The cells cultured in induction medium formed clusters that stained DTZ, confirming zinc
accumulation (Fig. 44B, C), and those cultured in stromal medium did not stain (Fig. 44A). As
before, cells cultured in stromal medium attached to standard culture ware while those cultured in
induction medium did not (Fig. 44A).
6.2.4. Immunohistochemistry
The cells cultured in stromal medium lacked insulin expression, while the cells cultured in
induction medium had strong insulin expression (Fig. 45).
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Figure 42. Photomicrographs of feline ASCs following culture in stromal medium A, 5 ×, scale
bar = 500 μm; with alizarin red staining of calcium deposition after cultured in osteogenic medium
B, 5×, scale bar=500μm; with oil red O lipid staining after culture in adipogenic medium C 40×,
scale bar = 50 μm.

Figure 43. Light photomicrographs of fresh feline P3 ASCs from male (A, B) and female (C) after
culture in stromal (A), pancreatic β-cell induction (B, C) medium and transferred to the normal
culture plate. 5× magnification. Scale bar=500 μm.

Figure 44. Light photomicrographs of fresh P3 feline ASCs from males (A, B) and females (C)
after culture in stromal (A) or pancreatic β-cell induction (B, C) medium. Dithizone staining of
zinc. 20 × magnification, scale bar = 100 μm (A, B); 40× magnification, scale bar = 50 μm.
6.2.5. Glucose Challenge Assay
Male and female ASCs cultured in induction medium released insulin in response to glucose (Fig.
46). Insulin secretion was slightly higher (55.7 versus 62.7) at the higher glucose concentration.
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6.2.6. Transmission Electron Microscopy – Ultrastructure
Cell ultrastructure was distinct between cells cultured in stromal versus induction medium.
Notable differences were the presence abundant perinuclear mitochondria in the cells cultured in
stromal medium (Fig. 47A) and secretory granules in the induced cells (Fig. 47B).

Figure 45. Fluorescent photomicrographs of cells cultured in stromal or induction medium and
labeled with antibodies against insulin (red) and actin (blue).
6.2.7. Electroimmunohistochemistry – Insulin Localization
Insulin labeling was localized to the cytoplasm of cells cultured in induction medium, while there
was no labeling in those cultured in stromal medium (Fig. 48).
6.2.8. Scanning Electron Microscopy – Surface Ultrastructure
Cells cultured in stromal medium tended to form loose, spherical clusters while those in β cell
induction medium formed larger, highly organized clusters with an irregular shape (Fig. 49).
Proteinaceous material was apparent on the surface of differentiated cell clusters (Fig. 49B).
6.2.9. Gene Expression
Transcription factor expression: The mRNA levels of transcription factors (Nkx 6.1, Pax6, Isl1,
and Glut-2) at Stage 1 tended to be lower than other induction stages (Fig. 50). The mRNA levels
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of Pax6 and Glut2 in female samples had lower expression than male at induction stages 1 and 2
and induction stage 1, respectively (Fig. 50B and D).

Figure 46. Glucose challenge assay. The insulin secretion from differentiated islet-like cell
clusters at stimulated (25 and 55 mM) concentrations of glucose are illustrated.

Figure 47. Transmission electron photomicrographs of feline ASCs culture in stromal (A) or
induction (B) medium. Legend: M – mitochondria, G – secretory granules. Scale bar = 2 μm.
Pancreatic β-cell target gene expression: Insulin expression detectable only after stage 2
and 3 induction (Fig. 51 A). Glucagon expression was higher after stage 3 induction versus the
other stages (Fig. 51 B). Somatostatin levels were lower after stage 1 induction compared to the
others (Fig 51 C).
Oncogene expression: There was no difference in ROS1, AKT1, RAB2A, or HK1
expression among induction stages (Fig. 51).
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Figure 48. Transmission electron photomicrographs demonstrating insulin labeled with antiinsulin antibodies (arrows) in feline ASCs cultured in stromal (A) or induction (B) medium. Scale
bar = 0.5 μm.

Figure 49. Scanning electron photomicrographs feline ASCs cultured in stromal (A) or β cell
induction (B) displaying cell cluster morphology (white arrows) and proteinaceous material on the
surface of clusters cultured in induction medium (black arrows). Scale bar = 5 μm.
6.3. Discussion
The overarching conclusions from the present study are that feline ASCs isolated from the
reproductive organs have endodermal transdifferentiation capability, but cells from male donors
have distinct morphology compared to female donors. Induced cells appear to form functional
clusters based on zinc accumulation secretion of insulin in response to glucose stimulation, the
presence of intracellular insulin, and the pancreatic β-cell specific gene expression [408]. This
promising achievement significantly advances the potential to produce custom feline insulin for
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exogenous administrations as well as a cell-based therapy for temporary or long term restoration
of feline pancreatic β cell function.

Figure 50. Feline NK6 homeobox 1 (A; NK6.1), paired box 6 (B; Pax6), ISL LIM homeobox 1
(C; Isl1), and glucose transporter 2 (D; Glut2) levels (LS mean ± SEM) in feline ASCs following
three induction stages of pancreatic β cell culture induction. Columns with distinct superscripts
are significantly different between sex within stages. Different asterisk numbers (*) are
significantly different among stages within gender.
The culture protocols used in this study were customized for feline cells and designed to
replicate in vivo pancreatic formation and development. Giving species differences, culture
methods are most effective when designed for the target species [104, 403, 405, 409]. In the
developed three-stage induction system, N-2 and B-27 were intended to enhance proliferation and
apoptosis and protect against reactive oxygen species in the absence of FBS [404, 410, 411]. FBS
is the common supply in culture medium and it can provide growth factors, nutrients and hormones
for cell proliferation and adhesion [47, 315]. Additionally, there are several extrinsic factors used
in the system that have beneficial effects on differentiation of MSCs into insulin producing cells
[123].
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Figure 51. Feline insulin (A), glucagon (B), and somatostatin (C) levels (LS mean ± SEM) in
feline ASCs following three stages of pancreatic β cell culture induction. Columns with different
asterisk numbers (*) are significantly different among stages within gender.
In detail, at Stage 1 using activin A and sodium butyrate to direct ASCs to undergo
endoderm differentiation [409]. ITS, 2-mercaptoethanol, and the supplements can protect ASCs
and reduce the risk of apoptosis [409, 412]. The ultra-attachment culture plate used in the present
study can enhance cells to form three-dimensional aggregates. The aim of Stage 2 was to induce
the endoderm cell clusters formed at Stage 1 into pancreatic endodermal lineage. Taurine was
induced into the induction medium and is essential for the development of functional β cells [409].
In the induction process, we found the induced cell clusters performed similar morphology of
induced β-cell cluster morphology from other species [411] and lose the capacity to attach to the
plastic culture ware which is widely used as one of criteria to define MSC [413]. Cells cultured in
stromal medium retain their plastic affinity after culture on ultralow normal culture plates while
those in induction medium did not, further confirming differentiation and maturation.
At the final stage, the cell clusters were converted into functional pancreatic hormoneexpressing islet-like cell aggregates with the help of GLP-1, nicotinamide, taurine, and β-cellulin.
Nicotinamide was reported that it can promote the maturation of precursor cells into insulinproducing cells and increase the rate of proinsulin biosynthesis [414]. Addition of β-cellulin and
nicotinamide to the Stage 3 induction medium was to promote β cell maturation and generate cells
expressing endocrine hormones including insulin and glucagon [123]. At the final stage, the
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induced cell clusters were specifically labeled with the zinc-chelating dye DTZ, which could stain
β-cells due to the presence of zinc in insulin-containing secretory granules [408].
Immunofluorescence, DTZ staining, and immune electron microscopy results further confirmed
that the induced cells had insulin expression. The RT-PCR studies showed that the induced cells
coexpressed insulin, glucagon, and somatostatin. These results are in accordance with normal
pancreatic development, in which immature islets are known to coexpress pancreatic hormones
[409, 415].

Figure 52. Feline proto-oncogene tyrosine-protein kinase ROS1 (A; ROS1), AKT serine/threonine
kinase 1 (B; AKT1), Ras-related protein Rab-2A (C; RAB2A), and hexokinase 1 (D; HK1) levels
(LS mean ± SEM) in feline ASCs following three stages of pancreatic β cell culture induction.
Another interesting finding in this study is the mRNA levels of Pax6 and Glut2 differences
between male and female ASCs at the early induction stage, suggesting that the cells from male
cats may have higher sensitivity than that from female cats. Based on the current reports, human
male ASCs have greater osteogenic potential than that female ASCs [416]. Pax6 is the necessary
transcription factor that can transactivate the insulin promoters [417]. The higher expression of
Pax6 in male ASCs at the early induction stages may indicate that the male ASCs are easier to
initiate pancreatic β cell differentiation.
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As a whole, from the results obtained, male and female ASCs were proven to have
endodermal transdifferentiation capability. The induced cell clusters can secrete insulin under the
glucose stimulation. In the clinical context, our present study demonstrated the potential for stem
cell-based therapy to treat feline diabetes. Although the mechanisms of the transdifferentiation in
feline ASCs are not clear and the pancreatic specific transcription factor expression is still need
more evaluation, the current induction can provide a powerful base for future evaluation. The
results presented in this study can provide direct evidence supporting the notion that
transdifferentiation of feline ASCs to functional insulin-producing cells may represent a viable
therapeutic option for feline diabetes.
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CHAPTER 7. CONCLUSIONS AND FURTHER STUDIES
This dissertation is focused on the evaluation of the effects of cryopreservation, and physical and
chemical environments on adult adipose derived mesenchymal stromal cells (ASCs) from different
species. Overall, the therapeutic applications of ASCs in veterinary medicine are in the early stage
of development. Even though there are many commercial ASC-based products for dogs, cats, and
horses around the world, these applications are not approved by the U.S Food and Drug
Administration (FDA). Numerous studies have focused on the characterization of cryopreserved
ASCs from several species, while the conflicting results are also reported or the published results
are variable. Therefore, more investigations are necessary in the field of ASCs before they are
applied in clinical trials. Major contributions of the studies described in this dissertation are the
evaluation of cryopreservation effects on ASCs from different species in genetic, protein and
ultrastructure levels. Additionally, it is the first time we demonstrated that feline ASCs also have
transdifferentiation capability to form functional islet-cell clusters.
The first and third parts in this dissertation, the cryopreservation effects on ASCs isolated
from canine and equine adipose tissues were evaluated in ultrastructure, genetic and protein levels.
Based on our findings, we found that even though the same cryopreservation technique and
cryopreservation medium were employed, cryopreserved ASCs had distinct in vitro properties due
to various species different. These findings suggest that the cryopreservation medium designing
should be considered the individual characteristics. In the fifth chapter in this dissertation, the
cells were selected from the heterogeneous cell population isolated from equine adipose tissue
based on the common ASC immunoprofile expression. In this chapter, we found that the selected
cell subpopulation was more stable and predictable compared to the unsorted heterogeneous cell
population and the embryonic gene expression was enhanced in the selected cell subpopulation
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after cryopreservation. Results of the study showed that the heterogeneous cell population isolated
from the equine adipose tissue has unpredictable cell properties. Therefore, to purify and select
desired cell subpopulation via the immunoprofile expression is necessary for the predictable
outcomes. Nevertheless, we also found that the selected cell subpopulation had lower proliferation
rate, suggesting the other cell subpopulations in the heterogeneous cell population may make the
contribution to the in vitro proliferation.

Therefore, the contributions from the other cell

subpopulations and environments to the selected cell subpopulation proliferation need to be
studied in the future.
Cryopreserved human ASCs were loaded into three commercial bone scaffolds via a
spinner flask bioreactor system and then cultured in stromal, osteogenic, or osteogenic for 48 hours
followed by stromal culture medium up to 28 days. The results from in vitro human ASC
osteogenic study showed that continuous culture in osteogenic medium supports the best human
ASC osteogenesis on bone-graft scaffolds. The results from the study demonstrated that the
distinct bone graft components may direct human ASCs toward different osteogenic pathways.
This work confirms the need to consider individual patient characteristics during the bone graft
selection for the greatest treatment outcomes.
In the third part of the dissertation cryopreserved equine ASC and bone marrow
mesenchymal stromal cells (BMSCs) were used for equine bone tissue regeneration. It is possible
that scaffold component modification can promote bone augment. For the study, custom scaffolds
were synthesized, and cryopreserved equine ASCs and BMSCs were loaded onto the scaffolds via
the spinner flask bioreactor and then implanted subcutaneously in athymic mice in the absence of
osteogenic supplements for up to 9 weeks. De novo bone formation was confirmed and the
contributions of exogenous and host MSCs were demonstrated. Also, the mineral containing
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scaffolds showed superior osteogenic support versus polymer alone. This work emphasizes the
necessity of mineral components in customized osteogenic scaffold designing and further confirms
the contribution of exo- and endogenous MSCs for the de novo tissue formation in vivo.
The last part of this dissertation describes using of feline ASCs from reproductive organs
to regenerate functional pancreatic β cells. An efficient three-step pancreatic β cell induction
system was developed for the feline study. Feline-specific pancreatic induction medium was
designed and tested to confirm feline pancreatic differentiation capability. Results of the study
showed that feline ASCs have endodermal transdifferentiation capability to form functional isletlike cell clusters in vitro. The system developed in the study can be used for feline ASC-based
diabetes mellitus studies to benefit research and clinical applications.
Our research provides critical information to translate ASCs from research to clinical trials
in veterinary medicine. These studies investigated the impact of cryopreservation on ASCs
isolated from various species and proved for the first time the feline ASCs have endodermal
transdifferentiation capability as other species. Further studies may include optimization of
cryopreservation medium to minimize the impact on ASC properties based on the species
differences, crystallization of secreted feline insulin and three-dimensional structure evaluation,
and characterization and functional analysis of induced islet-like cell cluster in vivo.
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